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Abstract
Previous work demonstrated that fibronectin is expressed in embryonic 
mouse detrusor smooth muscle cells (DSMC). Integrins are cell surface 
receptors for extracellular matrix (ECM) molecules, including fibronectin. The 
general hypothesis explored here is that ECM/integrin interactions are 
important in normal and pathological DSMC differentiation.
The first specific hypotheses tested were that the candidate fibronectin 
receptor integrin a5pi and the laminin 1/2 candidate receptor integrin a7p1 
are expressed by developing DSMC, Using immunohistochemistry, Western 
blots, and flow cytometry, these proteins were found to be expressed during 
murine bladder differentiation.
This led to the second specific hypothesis, namely that embryonic nascent 
DSMC adhere to fibronectin, a process mediated by integrin a5|31. Fibronectin 
substrate was shown to enhance the adhesion of disaggregated embryonic 
mouse bladder cells. Blocking integrin receptors using RGD oligopeptides 
modestly but significantly decreased adherent cells expressing desmin, and 
reduced cell spreading.
To explore roles for fibronectin in whole bladders, rather than isolated cells, 
embryonic mouse organ cultures were established which recapitulated some 
in vivo differentiation features. However, no specific effects on growth or 
differentiation could be demonstrated using presumed Tibronectin-blocking' 
antibodies. Time did not allow testing of RGD oligopeptides.
Last, the following hypotheses were explored: that fibronectin is expressed 
during normal human fetal DSMC differentiation, and that this pattern is
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altered in bladders from fetuses with presumed bladder outflow obstruction. 
Fibronectin was indeed found to be expressed during normal human detrusor 
differentiation and its expression was sometimes reduced in malformed 
human fetal bladders.
These studies provide further descriptive, and hence circumstantial, evidence 
that ECM/integrin interactions may be important in normal DSMC 
development. Further studies are warranted to resolve the apparently 
conflicting/ambiguous organ and cell culture data regarding possible roles for 
fibronectin and its receptors. The studies also provide preliminary evidence of 
abnormal fibronectin expression in human congenital bladder anomalies.
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Abbreviations
aSMA a  smooth muscle actin
|jg microgram
pi microlitre
|jM micromolar
6Wks 6 weeks of postnatal age
ANOVA analysis of variance
ARK animal research kit
ATP adenosine triphosphate
BCA bicinchoninic acid
BOO bladder outflow obstruction
bp base pairs (DNA)
BrdU 5-bromo-2-deoxyuridine
BSA bovine serum albumin
CD31 platelet endothelial cell adhesion molecule (PECAM)
ODD collagen, dispase, DNase
CO2 carbon dioxide
CT connective tissue
D1 post natal day 1
DAB diaminobenzidene
DMEM Dulbecco’s modified Eagle’s medium
DNA deoxyribosenucleic acid
DNase deoxyribosenuclease
DPX distyrene (polystyrene), a plasticizer (dibutylphthalate), and
xylene
DSM detrusor smooth muscle
DSMC detrusor smooth muscle cell
E12 embryonic day 12
E14 embryonic day 14
E16 embryonic day 16
E18 embryonic day 18
ECM extracellular matrix
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ELISA enzyme linked immunosorbent assay
Fab the part of an antibody containing the antigen binding site
FACS fluorescence activated cell sorter
FCS fetal calf serum
FITC fluorescein isothyocyanate
H20 2 hydrogen peroxide
HRP horseradish peroxidase
igG immunoglobulin G
IHC immunohistochemistry
ILK integrin linked kinase
ITS insulin transferrin and selenium
kDa kilodalton
LDH lactate dehydrogenase
mg milligram
ml millilitre
mM millimolar
mm2 square millimetre
mm3 cubic millimetre
NaCI sodium chloride
ng nanogram
nm nanometres
NP40 nonidet P40
°C degrees centigrade
OCT optimum cutting temperature
PAGE polyacrylamide gels
PBS phosphate buffered saline
PBS Prune Belly syndrome
PBSABC PBS with magnesium and calcium chloride to 1mM
PCD programmed cell death
PCNA proliferating cell nuclear antigen
PMSF phenoxymethyl sulfoxide
POD peroxidase
PS1 Drosophila laminin receptor integrin a  subunit
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PS2 Drosophila RGD receptor integrin a  subunit
PUV posterior urethral valves
RAD arginine-alanine-aspartate
RBC red blood cell
RGD arginine-glycine-aspartate
rTDT terminal deoxynucleotidyl transferase
SDS sodiumdodecylsulphate
SEM standard error of the mean
SMC smooth muscle cells
TEMED tetramethylethylenediamine
TNF tumour necrosis factor
TRITC tetramethylrhodamine isothiocyanate
TUNEL terminal rTDT-mediated UTP nick end labelling
UGS urogenital sinus
UK United Kingdom
VSMC vascular smooth muscle cell
WB Western blot
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Preface. Hypothesis, aims and overview
Overall hypothesis
Extracellular matrix (ECM)/integrin interactions may be important in the early 
steps of normal bladder muscle growth and differentiation. Specifically, 
fibronectin acting through a candidate integrin receptor (integrin a5p i) may be 
important during bladder smooth muscle development in that it may maintain 
fetal smooth muscle cells (SMC) in a proliferative phenotype. Laminins acting 
through a candidate muscle laminin receptor integrin a7p1, may induce a 
maturation response, and might help maintain adult SMC in the differentiated 
form. These ECM/integrin interactions may also be important in pathological 
bladder morphogenesis as occurs in human fetal obstructive uropathy.
Overview
The results section of this thesis is arranged into four chapters as follows:
Study 1 (Chapter 5): Analysis of expression of adhesion molecules fibronectin 
and laminin-1/2 and their candidate receptors during fetal mouse bladder 
development
Hypothesis: During murine bladder development, the candidate fibronectin 
receptor integrin a5p i may be expressed by detrusor smooth muscle cells 
(DSMC), and that laminin 1/2 candidate receptor integrin a7 may be 
expressed by DSMC.
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Aims: 1) To examine if expression of candidate fibronectin receptor integrin 
a5p1 and laminin 1/2 receptor integrin a7p1 occurs in mouse bladders during 
fetal development and postnatal maturation by immunohistochemistry; 2 ) to 
further quantify this protein expression by using Western blots, or flow 
cytometry.
Study 2 (Chapter 6): Functional interaction between DSMC and fibronectin 
matrix in cell culture.
Hypothesis: In Vitro DSMC may adhere to fibronectin, possibly modifying cell 
behaviour, and that this adherence may be mediated by the candidate 
fibronectin receptor integrin a5p1.
Aims: 1) to examine adhesion of disaggregated bladder cells from fetal and 
mature murine bladders to a fibronectin substrate; 2 ) characterise these 
adherent cells; 3) Examine any proliferative effect that fibronectin adhesion 
may have on fetal bladder cells; 4) Examine any effect blockade of 
fibronectin/integrin interaction may have on adhesion of cells from whole 
bladder suspensions.
Study 3 (Chapter 7): Mouse fetal bladder explant fibronectin blocking 
experiment.
Hypothesis: Fibronectin-integrin interactions in ex vivo bladders may be 
important in modulating DSMC development.
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Aims: 1) Generate a fetal bladder explant model; 2) use this model to 
investigate the effect of disrupting fibronectin-integrin interactions on fetal 
bladder DSMC development.
Study 4 (Chapter 8): Fibronectin expression in normal and pathological 
development of human fetal bladders
Hypothesis: Fibronectin may be expressed in the basal lamina during normal 
human fetal DSMC development, furthermore altered fibronectin expression 
might be implicated in detrusor smooth muscle pathology in human bladder 
outflow obstruction (BOO).
Aims: 1) Demonstrate the normal pattern of fibronectin expression in human 
fetal bladders, and to correlate this with gestational age, and measures of cell 
turnover. 2) Describe the abnormal pattern of muscle, and fibronectin 
expression in presumed fetal BOO and to compare this with normal 
development.
Long-term Significance
An understanding of the role on matrix-integrin interactions in normal and 
pathological bladder development may contribute to a better understanding of 
the processes involved in normal development and in congenital uropathy. 
This may in the future provide an idea as to how the disease process may be 
modified and ultimately could lead to information useful in constructing a 
tissue-engineered neobladder.
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Chapter 1. Introduction
The urinary bladder is a unique organ. It is the most distensible organ in the 
body, able, under normal circumstances in an adult human, to store 400- 
500mls of urine at low pressure, and then to expel this completely, several 
times a day (Chang et al 1998). This compliance is determined in part by the 
structural properties of the extracellular matrix (ECM) and cells that make up 
the bladder wall (Ewalt et al 1992). In congenital uropathies, such as posterior 
urethral valves (PUV), fetal urinary obstruction may be associated with a 
derangement of normal development, leading to a fibrotic, poorly compliant, 
high pressure reservoir and renal impairment. In man, posterior urethral 
valves are the commonest single cause of end-stage renal failure in childhood 
(Woolf and Thiruchelvam 2001) and PUV-associated bladder dysfunction may 
further damage the kidneys postnatally (Parkhouse et al 1988). Renal 
functional and structural outcome is therefore intimately linked to bladder 
function and hence bladder development.
An understanding of the molecular processes that influence bladder growth 
during development, and the role that ECM plays in this, is beginning to 
emerge. That fibronectin is an instructive molecule in fetal development can 
be seen by the severe mesodermal defects, and peri-implantation lethality of 
homozygous fibronectin null mutant mice. Two further lines of evidence 
demonstrate a role for ECM in normal bladder organogenesis: first, 
expression of the ECM components fibronectin and laminin are
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developmentally regulated in the developing murine bladder (Smeulders et al 
2002, 2003); second, smooth muscle cells grown on fibronectin are synthetic 
and proliferative (Morla and Mogford 2000), whereas these cells grown on 
laminins are more contractile (Thyberg and Hultgardh-Nilsson 1994). An 
important class of cell surface receptors for ECM are integrins. These 
heterodimers are formed from a  and p subunits. So far more than 20 subtypes 
of integrin have been described in man, with different, but overlapping ligand 
affinities. These integrins have a structural role connecting ECM to the cell 
cytoskeleton, but also have important signalling roles in determining cell fate. 
Integrin sub-types have been reviewed by (Hynes 2002).
This thesis focuses on detrusor smooth muscle (DSM) cell development and 
on the accompanying changes in extracellular matrix, as described in the 
preface. The hypothesis for this thesis is that specific ECM proteins 
(fibronectin and laminins) interact with their integrin receptors (integrin a5pi 
as a candidate fibronectin receptor, integrin a7pi as a candidate laminin 
receptor) and that this may be important not only in the early steps of detrusor 
smooth muscle cell differentiation, but also in the pathological response to 
bladder outflow obstruction.
Described below are normal bladder embryology, and the changes in cell 
phenotype during organogenesis. The components of ECM are described, as 
is the hierarchical structure of connective tissue. Specifically the reasons for 
choosing the candidate matrix molecules are highlighted. Integrin structure, 
classification and function are reviewed, and the choice of integrin subtype to 
be examined in this thesis is justified.
35
The role of mechanical factors are in normal bladder development will be 
discussed both at the level of the whole organ, and at a cellular level. The role 
that integrins play in mechanotransduction -  communicating physical forces 
from outside cells to the cytoskeleton - will be highlighted.
Finally, pathological bladder outflow obstruction (BOO) will be discussed.
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Embryology of bladder development
Embryology of the mammalian urinary bladder involves the patterning of the 
tissues by gastrulation, then three dimensional body folding to create the 
cloaca. In placental mammals the cloaca is then divided, the anterior part 
becoming the urogenital sinus (UGS). The bladder forms from the cranial part 
of the UGS, and its surrounding mesenchyme, but also by incorporation of the 
distal mesonephric ducts to form the trigone (Larsen 2001).
Tissues formed by gastrulation. By day 14 post conception the human embryo 
consists of 2 layers: the epiblast and hypoblast. (These were previously 
termed ectoderm and endoderm.(Larsen 2001)) On day 15 the primitive 
streak appears on the dorsum. It is at this point that the fundamental axes of 
the body are established: cranial/caudal, left/right, ventral/dorsal. The 
definitive endoderm and intra-embryonic mesoderm form by gastrulation 
through the primitive streak (figure 1.1). Thus the epiblast gives rise to the 
ectoderm, mesoderm and endoderm. During the third week 2 depressions 
appear in the ectoderm, which fuse tightly with the endoderm, preventing 
ingrowth of the mesoderm: these are the buccopharyngeal membrane and the 
cloacal membrane. The allantois is a diverticulum of the endoderm that 
extends into the body stalk (Larsen 2001).
Cloaca created by 3D body folding. Embryonic folding occurs during the fourth 
week of human development converting the flat trilaminar germ disc into a 
three dimensional structure. This occurs because of rapid growth of the 
embryonic disc compared to the yolk sac. The endoderm at the lateral edge of
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the embryonic disc is attached to the yolk sac, so the expanding disc bulges 
into a convex shape. As a result of this folding the cephalic, lateral and caudal 
folds meet in the mid-line. The endoderm now forms cranial and caudal blind- 
ending tubes (foregut and hindgut respectively), with the future midgut 
between them, widely connected to the yolk sac. The foregut ends in the 
buccopharyngeal membrane and the hind-gut at the cloaca, which abuts the 
cloacal membrane. The buccopharyngeal and the cloacal membranes have 
moved onto the ventral surface of the embryo, as has the body stalk (figure 
1.1). The ectoderm that was immediately caudal to the cloacal membrane in 
the bilaminar disc has now been rotated to lie adjacent to the body stalk, 
cranial to the cloacal membrane. The cloaca has a ventral diverticulum which 
is formed by the allantois, which in turn passes through the umbilical ring, into 
the body stalk (Larsen 2001).
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Figure 1.1:Embryology of the bladder -  Gastrulation and body folding (A) 
Gastrulation is the process by which patterning of the embryonic tissues 
occurs, and cell and determined. (B) The tissues are then arranged in their 
correct anatomical relationship by the process of three dimensional body 
folding. Modified from Larsen 2001.
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Division of cloaca into anterior urogenital sinus and posterior rectum. The 
wedge of mesoderm between the allantois and the yolk sac elongates and 
forms the Tourneux fold. Rathke’s folds in the lateral wall of the cloaca fuse 
with the Tourneux fold growing down from cranially to produce the urorectal 
septum that separates the cloaca into an anterior urogenital sinus and a 
posterior hind-gut (figure 1.2). Eventually the bilaminar buccopharyngeal 
membrane and the cloacal membrane, which are not supported by 
mesoderm, break-down. This anterior urogenital sinus has a cranial 
component which will form the bladder, a pelvic component which will form 
the urethra in the female and posterior urethra in the male, and an external 
part which forms the introitus in the female and the urethra in the male 
(Larsen 2001; Thomas et al 2002).
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Formation of the bladder. The human urinary bladder develops from the 
cranial part of the urogenital sinus: the inner, endoderm gives rise to the 
bladder epithelium and its surrounding mesenchyme to the middle lamina 
propria and the outer smooth muscle layer. The exception is the base of the 
bladder, the trigone, where the caudal ends of the mesonephric ducts (the 
common excretory ducts) and their ureteric buds were thought to be gradually 
incorporated into the bladder wall, explaining the ureteric position in duplex 
renal anomalies (Mackie and Stephens 1975). More recently, it has been 
shown that in the mouse the common excretory duct undergoes apoptosis 
(Batourina et al 2005). By seven weeks the human bladder has a primitive 
urothelium, surrounded by undifferentiated mesenchyme. The mature bladder 
therefore has an inner urothelium, subjacent to this is the lamina propria, rich 
in interstitial collagens and blood vessels, surrounded by the detrusor layer of 
smooth muscle, covered by serosa (figures 1.3 and 1.4B).
Time-table for embryogenesis of the mouse bladder
The mouse provides an easily accessible, accurately timed source of 
embryonic bladder tissue, so this is the model studied. The cranial part of the 
urogenital sinus can be detected in the mouse at embryonic day 12 (E12). 
Incorporation of the distal mesonephric ducts occurs over days 12 and 13, so 
the bladder is a recognizable entity by embryonic day 14 (E14). This is 
equivalent to Carnegie stage 20 in the human (Kaufman 2003), or seven 
weeks gestational age (Hunter et al 2003). Bladder development has
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therefore been studied in this thesis from embryonic day 14 onwards. 
Subsequent time-points include E16, E18 and neonatal dayl mouse bladders. 
Mice reach maturity by 6  weeks of postnatal age, so this was the final 
developmental time-point examined.
Changes in cell phenotype during detrusor development
In the mouse, the mesenchymal cells of the primitive bladder are initially 
highly proliferative (Smeulders et al 2002). Differentiation of these 
mesenchymal cells into smooth muscle cells requires mesenchymal-epithelial 
interaction (Baskin et al 1996b) (figure 1.3). Paradoxically, this smooth muscle 
differentiation first occurs at the periphery of the bladder, with the expression 
of smooth muscle markers such as a-smooth muscle actin (a-SMA), desmin, 
and smooth muscle myosin, expressed by fetal smooth muscle cells (Baskin 
et al 1996c;Wu et al 1999a). This is associated with a peak in expression of 
fibronectin in the ECM neonatally (Smeulders et al 2003). As bladder 
development progresses these fetal smooth muscle cells (SMC) become 
increasingly differentiated and decreasingly proliferative culminating in the 
mature adult SMC which in normal circumstances is non-proliferative 
(figure1.4A) (Smeulders et al 2002). Simultaneously, in the basal lamina 
surrounding these cells, fibronectin is replaced by laminin (Smeulders et al 
2003). Ultrastructural examination, allows the synthetic fetal cells to be 
differentiated from the purely contractile adult cells (Wu et al 1999a): Fetal 
smooth muscle cells have prominent Golgi apparatus, a prominent 
‘fibronexus’ (fibronectin fibrils in association with focal adhesions -  please see
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section on integrins), and prominent caveolae, yet still have a contractile 
apparatus; adult smooth muscle cells no longer have the synthetic apparatus, 
or the ‘fibronexus’, but do have more contractile machinery (Wu et al 1999a).
Urothelial development
In human bladders at 7 weeks, there is an initial primitive epithelium that is 
bilayered, with cuboidal glycogen rich epithelium. By 13-17 weeks of gestation 
this has developed a third layer and by 17-21 weeks, has become a 3-4 cell 
thick epithelium with the ultrastructural characteristics of urothelium (Newman 
and Antonakopoulos 1989). These 3 layers have been called basal, 
intermediate and superficial or umbrella cell layer, and are capable of sliding 
movement one over the other (De La et al 2002).
Epithelia can be classified according to their expression of cytokeratin 
intermediate fibres. There are approximately 20 sub-types described. In 
columnar epithelium simple cytokeratins are expressed -  which include 8 , 18, 
19 and 20. Squamous epithelia elaborate instead cytokeratins 4 and 13 in 
non-keratinizing epithelia and 4 and 13 in keratinizing epithelia. Transitional 
epithelium (urothelium) contains both simple cytokeratins 8  and 18, but also 
squamous cytokeratins 4 and 13 (De La et al 2002).
Baskin et al have demonstrated that in rat bladders the urothelium initially 
expresses cytokeratins 7,8,18 and 19 at 15 days gestation (equivalent to 
embryonic day 14 in the fetal mouse), with the addition of cytokeratin 5 at 17 
days gestation, and upregulation of cytokeratin 14 in the newborn bladder
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(Baskin et al 1996c). De La Rosette et al have further shown that these 
cytokeratins are expressed in human epithelium also, but that there are 
specific layers of epithelium that particularly express some of these 
cytokeratins: cytokeratin 18 is predominantly expressed in the superficial, 
umbrella cell layer antenatally, whereas it is more generally expressed in all 
layers apart from the basal layer in postnatal bladders; cytokeratin 2 0  is 
expressed in intermediate and umbrella cell layers antenatally, but only in 
umbrella cells post natally; finally cytokeratin 5 is a marker of basal cells (De 
La et al 2002). This stratified expression of cytokeratins has been used by 
(Scriven et al 1997) to demonstrate reconstitution of transitional epithelium 
from monolayer culture.
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Figure 1.3. Reciprocal induction gives rise to the layers of the bladder. 
Embryonic day 14 (E14) mouse urinary bladder and 6 week, adult 
bladder, showing immunostaining for cytokeratin 18 (epithelial marker). 
These bladders are shown to the same scale (bar 1mm). The bladder at 
E14 is composed of only 2 layers: mesenchyme and epithelium. 
Reciprocal induction (red lines) between epithelium and mesenchyme is 
necessary for differentiation of smooth muscle cells, and for maturation of 
the epithelium to urothelium. The mature bladder has three layers to its 
wall: detrusor, lamina propria, and urothelium.
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The hierarchical structure of connective tissue
That extracellular matrix is composed of two regions, the basal lamina 
(basement membrane) and interstitial matrix, can be seen on electron 
microscopy (Bosman and Stamenkovic 2003). The basal lamina is a 
condensed matrix that underlies epithelia, and completely surrounds 
connective tissue cells such as SMCs, connecting these cells to the interstitial 
matrix.
Interstitial matrix
Figure 1.4B is a diagrammatic representation of the histology of the mature 
bladder. The structural collagens (I and III) and elastin largely determine the 
mechanical properties of the bladder wall (Ewalt et al 1992). Most of the work 
that has been done on the changes in ECM during bladder development has 
therefore concentrated on these. The structural collagens are present 
predominantly in the lamina propria, underlying the urothelium, subserosally, 
and between the muscle fibres in the detrusor (Smeulders et al 2003). These 
collagens connect to the basal lamina which in turn adheres to the cells, via 
cell surface receptors, the most important of which are integrins, forming a 
hierarchical structure (figure 1.4C).
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Components of basal lamina
The basal lamina is a specialised subset of the ECM that underlies epithelia 
and endothelia, and surrounds ‘connective tissue cells’ such as fibroblasts 
and smooth muscle cells. It is highly conserved, with the same four basic 
components being present in worms, fruit flies and man (Hynes and Zhao 
2000) and reviewed by (Hutter et al 2000). These are laminins, collagen IV, 
nidogen (also known as entactin) and perlecan. The laminins are adhesive 
and bind cell surface receptors including integrins. These then bind to 
collagen IV, the cross-links being stabilised by nidogen and perlecan.
Collagen IV is linked to the structural collagens (I and III) by adhesive 
collagens such as collagen VII and IX. Fibronectin in contrast is a later 
evolutionary innovation only present in the basal lamina of vertebrates (Hynes 
and Zhao 2000), not being present in Caenorhabditis elegans (Hutter et al
2000).
Collagen IV is secreted by connective tissue cells, including fetal SMCs 
(Baskin et al 1993b). Purified collagen IV will spontaneously polymerize 
forming a branching network (Yurchenco and Furthmayr 1984), similar to that 
seen in vivo (Yurchenco and Ruben 1987). This collagen network will bind to 
cell surface receptors (e.g. integrins a ip i ,  and a2(31) and to nidogen. 
Collagen IV null mutant mice survive until late gestation, coincident with the 
onset of muscle contractions, suggestive that there may be a role for collagen 
IV in resisting mechanical stress (Guo et al 1991).
Nidogen exists as two sub-types, nidogen-1 and nidogen-2, with similar 
structures. It is widely expressed in basal laminae. Nidogen-1 (entactin-1) is
48
150 kDa sulphated glycoprotein that consists of three globular domains 
connected by rod domains (Fox et al 1991). Nidogen-1 binds laminin, collagen 
IV perlecan and fibulins, forming a ternary structure. Blocking antibodies to 
integrin a3(31 and a 6 pi have been shown to inhibit cell adhesion to nidogen-2 
in cell culture, including A431 human epidermal cell line and HBL-100 human 
cell line (Salmivirta et al 2002). Cell culture studies demonstrated that 
antibodies to nidogen-G3 domain (laminin binding site) inhibited basement 
membrane formation (Aumailley et al 1993), but nidogen null mutant C 
Elegans (Kang and Kramer 2000) and nidogen-1 null mutant mice were able 
to from basal lamina, although the phenotypes were not normal (Murshed et 
al 2000). ‘Compensation’ appears to take place when nidogen-1 or -2 are 
knocked out.
Perlecan is a proteoglcan, consisting of a core protein of 400 kDa, with 
heparan sulphate or chondroitin sulfate attached. It is capable of binding 
nidogen, dystroglycan, and to immobilize fibroblastic growth factor (FGF) 
amongst other growth factors (Hopf et al 1999;Hopf et al 2001 ;Mongiat et al
2001). It is also widely expressed in basal lamina and cartilage (Handler et al 
1997). Integrins have been shown to bind to perlecan, through an RGD 
independent mechanism (Hayashi et al 1992). Dystroglycan has recently 
been shown to be important for binding of perlecan to laminin (Kanagawa et al 
2005). In homozygous perlecan null mice basal lamina failure occurred in 
myocardial basement membranes and also in basal lamina separating 
developing neuroectoderm from underlying mesenchyme (Costell et al 1999). 
These results suggest that there is a role for perlecan in basement membrane 
assembly and also in cell adhesion, making these membranes more resistant
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to mechanical stress. In human disease mutant perlecans have been found in 
chondrodysplasia associated with myotonia (Stum et al 2005).
Taken together these observations have lead to Yurchenco et al (2004a) to 
suggest a hypothetical model of basal lamina formation in which cell surface 
receptors (integrins, dystroglycans and syndecans) bind to laminin G regions, 
leading to polymerization of laminin. This initial basal lamina subsequently has 
incorporation of nidogen and perlecan, which allow linkage with collagen IV to 
form a stable basement membrane (Yurchenco et al 2004a).
Other components of basal lamina include SPARC, fibulins, tenascins and 
fibronectin. Fibronectin is discussed below.
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Figure 1.4 Hierarchical structure of connective tissue. (A) Mesenchymal cell 
differentiation pathways. Mesenchymal cells can differentiate into a fetal 
SMC phenotype stabilised by fibronectin (red box), which can in turn mature 
into an adult SMC phenotype maintained by laminins (green box), or can 
become fibroblasts. Dotted arrows with question marks show possible 
dedifferentiation/transdifferentiation pathways. Figure 1.4B: Histology of 
bladder wall: Collagen I and III, blue, predominates in lamina propria, inter­
fascicular spaces of the detrusor, and sub-serosally. Lamina propria, pink, 
underlies urothelium, but completely surrounds SMCs in smooth muscle 
fibres. Figure 1.4C: Hierarchical structure of extracellular matrix. The 
structural collagens I and III, blue lines, link to basal lamina, pink. Cells 
adhere and interact with basal lamina through integrins, shown in green. 
Modified from McCarthy et al 2003.
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Laminins
Twelve different sub-types of laminin have been described in the human 
(Colognato and Yurchenco 2000). Laminins are cross shaped trimers 
consisting of a, p and 7 subunits. These are secreted into the basal lamina by 
connective tissue cells, where spontaneous polymerization can take place, 
although at physiological concentrations receptor mediated polymerization is 
important (Colognato et al 1999;Colognato and Yurchenco 2000). These 
receptors include dystroglycans and laminin integrins (integrin a7p1 is 
especially important in skeletal muscle). The laminins provide a ‘glue’ to link 
cells together, but also influence cell fate (differentiation, proliferation, 
migration and phenotype) as reviewed by (Colognato and Yurchenco 2000).
Structure of laminins
Laminins are eccentric cross-shaped trimers consisting of a, p and y subunits. 
Heterotrimers are large proteins with a molecular mass ranging from 500 kDa 
to 1000 kDa. Each laminin subunit (a,p or y chain) consists of: first an N 
terminal short arm of the laminin subunit laminin domain VI, and a globular 
laminin domain IV connected by multiple repeats of EGF domains; second, a 
coiled-coil-forming domain which forms the long arm. Ionic interactions 
between repeated heptad motifs on the coiled coil domain allow formation of 
the triple helix of the long arm (Beck et al 1993). It is the short arm domains 
that are involved in calcium dependent, spontaneous, reversible 
polymerization (Paulsson et al 1988;Cheng et al 1997).
52
VI V  IVb 11 lb IVallla II I
“> g lM lgmTITTITIlgmi Coiled Coil (0(G2)(0@(S
VI V IV III II I
Coiled Coil
VI V IV III II I
Coiled Coil
Figure 1.5: Laminin a,p,y subunits form a laminin hetero trimer. Schemata for 
laminin a l,p l and y l subunits. T o ge the r these  fo rm  th e  laminin-1 
he te ro trim er. Modified from Colognato et al 1999
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Laminin a  subunits have 5 additional globular carboxy terminal domains, (G I­
GS). The carboxy terminal globular (LG regions) proteins are involved in cell 
receptor binding (integrin a7(31 and a-dystroglycan-dystrophin in skeletal 
muscle cells) (Colognato et al 1999). Collagen IV binds to laminins and is also 
cross-linked by entactin (Mann et al 1988).
Classification of laminin sub-types
Laminin was first described as a matrix product of murine sarcoma cells, 
Engelbroth-Holm-Swarm (EHS) cells (Chung et al 1979; Brauer and Keller 
1989). The molecule was initially described as a trimer of A, B1 and B2 
subunits, but the now accepted terminology was revised in 1994 (Burgeson et 
al 1994). Twelve different laminin sub-types have been described in 
mammals, of the theoretical possible 45 combinations of 5 different a, 3 p and 
3 y chains. These laminin subtypes can be separated into different classes 
according to their short arm length: laminins 1-4,12 have full length short 
arms; laminins 6-9 have truncated a  subunit short-arms, but complete p and y 
short arms; laminin 5 has truncation of all the short arms; laminins 10 and 11 
have elongated a5 long chains, reviewed by (Colognato and Yurchenco 
2000).
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Table 1.1: Laminin subtype classification by subunit composition
Laminin Subunits
Laminin-1 a ip iy1
Laminin-2 a2piy2
Laminin-3 aip2y2
Laminin-4 a2p2y1
Laminin-5 a3p3y2
Laminin-6 a3piy1
Laminin-7 a3p2y1
Laminin-8 a4piy1
Laminin-9 a4p2y1
Laminin-10 a5piy1
Laminin-11 a5p2y1
Laminin-12 a2piy3
The distribution of different subunits (and hence different laminins) has been 
described. For example Laminin a1 is expressed in the developing embryo as 
part of the initial basal lamina in the developing embryo (Smyth et al 1999;Li 
et al 2002). Laminin a2  is expressed in skeletal and cardiac muscle, and in 
peripheral nerves and brain (Sunada et al 1995a;Sunada et al 1995b).
Laminin a3 however is predominantly present in laminins in the basal lamina 
of skin and other epithelia -  as demonstrated by the abnormalities of the
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homozygous LAMA3 knockout mouse (Ryan et al 1999). Similarly whilst pi 
subunit expression is widespread (Sasaki et al 1987), p2 expression is limited 
to the kidney (Noakes et al 1995) and neuromuscular junction (Hunter et al 
1989) and p3 expression is present in epithelia (Pulkkinen et al 1995).
Laminin y1 is widely expressed, but y2 is predominantly expressed in epithelia 
(Pulkkinen et al 1994), whereas y3 is expressed in skin, heart, lung and 
reproductive tracts (Koch et al 1999).
Laminin production and polymerization
Laminins are produced by connective tissue cells, and epithelial cells. 
Specifically fetal SMCs have been shown to be produce laminin in culture 
(Baskin et al 1993b). The laminin a1, pi and y1 subunits are synthesized and 
secreted as laminin trimers. These laminin monomers then interact with cell 
surface receptors (integrins, dystroglycan and syndecan) through their G 
modules, allowing these trimers to become anchored. Polymerization 
spontaneously through their short arms then follows. This receptor-mediated 
polymerization has been specifically described in skeletal muscle myotubes 
by Colognato et al (1999), and in murine embryoid bodies (a model of 
gastrulation) by Li et al (2002). Once receptor mediated polymerization has 
occurred on skeletal cell myotube, a further reorganization of the cell surface 
receptors (dystroglycans, and integrins) occurs together with a conformational 
change in the attached cytoskeleton, producing a polygonal network of 
laminin extracellularly, and receptors and actin cytoskeleton intracellularly 
(Colognato et al 1999). There may well be signalling activated by this two-
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stage process of receptor mediated laminin self-assembly, followed by cortical 
cytoskeleton rearrangement.
The amount of laminin expressed in basal lamina represents a balance 
between synthesis and breakdown. Matrix metalloproteinases are most 
probably important in the breakdown of ECM, and ultimately maintaining this 
balance.
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Figure 1.6: Receptor mediated laminin polymerization. Laminin-1 heterotrimers bind 
membrane bound receptors (e.g. integrins), and amino terminal short arms polymerize. 
The cell surface receptors become organized in turn, leading to cytoskeleton 
rearrangement. Modified from Colognato et al 1999.
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Figure 1.7: digestion products of laminin-1. Modified from Colognato et al (2000).
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Figure 1.8: binding sites of laminin-1. a lp l, a2pl, a6pl, a6p4, a7pl are integrin 
receptors. aDG is a-dystroglycan. Modified from Colognato et al (2000).
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Laminin receptors
Receptors for laminin can ligate binding sites on the short arms, long arm, or 
G domain of laminin. Proteolysis fragments of laminins have been used to 
investigate these interactions: E1 fragment containing short arms of laminin a  
and y chains, E8 containing the carboxy terminal of the long arms of a, |3, and 
Y subunits, as well as the G domains G1 to G3 of the laminin a  chain. The E3 
fragment includes laminin a  G domains G4 and G5.
Laminin short arms: The amino terminal of laminin a  subunits have specific 
binding sites for integrins a1|31 and a 2 p i.  This has been demonstrated by 
expressing domains IVb to VI of laminin a1 and a 2  subunits. Blocking with 
integrin specific antibodies has shown that these domains have specific 
binding sites for integrins a1(31 and a2p1 (Colognato et al 1997). The 
significance of this is unclear as integrin a i  null mutant mice do not have an 
obvious phenotype, although fibroblast migration is not normal (Gardner et al
1996). Nidogen has been shown to bind laminin IV domains of the laminin y1 
subunit (Salmivirta et al 2002). This may well be important in allowing cross- 
linking between laminins and collagen IV networks in the basal lamina.
Laminin long arms:
Agrin is a multidomain proteoglycan produced by motor neurons that localizes 
to motor end plates. Agrin is crucial for the development of neuromuscular 
junctions. It has been shown to bind to a region on the long arm of laminins 1, 
2 and 4 (specifically to a 20 AA section of laminin y1) (Kammerer et al 1999).
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Laminin G domains:
E8 fragment (domains G1-G3): Integrin a6p1 and a6|34 bind specific regions 
of the G1-3 domains (fragment E8) (Aumailley et al 1990). Knockout mouse 
mutants of integrin a6 and (34 are neonatally lethal due to severe skin 
blistering as occurs in human junctional epidermolysis bullosa (Georges- 
Labouesse et al 1996).
Similarly integrin a7p i binds the E8 fragment of laminins -  which contains the 
G1-3 domains (Kramer et al 1991). This integrin binds laminin-2 and 4 more 
strongly than laminin 5 (Yao et al 1996b). Integrin a l  is reported to be 
expressed in skeletal muscle, cardiac muscle and smooth muscle (Yao et al 
1996a;Yao eta l 1997).
Integrin a3(31 also binds the E8 fragment of laminins, (G1-G3 domains). 
Recombinant soluble a3pi has been shown to adhere to laminin 5, 10 and 
11, but not laminin 1 or 2 (Eble et al 1998).
E3 fragment (domains G4, G5): The G4 domain contains a binding site for a- 
moiety of a-dystroglycan (Andac et al 1999; Hohenester and Engel 2002). 
Homozygous a-dystroglycan mouse mutants are lethal at peri-implantation at 
embryonic day 6.5 (Williamson et al 1997). Chaemeric mice for a-dystriglycan 
knockouts survive longer and develop a muscular dystrophy-like phenotype 
(Cote et al 1999).
The E3 fragment (domains G4 and G5) are also capable of binding heparin, 
heparan sulphates and sulfatides (Roberts et al 1985; Sung et al 1997). There 
is also a heparan binding site on the L4 domain of the short arm of the laminin 
a chain (Colognato-Pyke et al 1995).
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Laminin function
Laminins are functionally important in two main ways.
1) Structurally, laminins are important in maintaining the mechanical 
properties of basal lamina acting. The interaction with nidogen, perlecan and 
collagen IV allows a ‘ternary’ structure to develop from the laminin and 
collagen IV networks. They are therefore important in maintaining the 
hierarchical structure of connective tissue.
2) Laminins are capable of acting as signals. A number of different examples 
exist including cell culture experiments, murine models of organogenesis and 
human diseases.
Determining cell differentiation in cell culture: Vascular SMC grown on 
fibronectin become synthetic and proliferative, whereas when similar cells are 
grown on laminins, they become differentiated, non-proliferative and 
contractile (Morla and Mogford 2000).
An intriguing possible role for laminin signalling has been described by 
Schuger et al (1997) in myogenesis in the lung bud: in this system 
mesenchymal-epithelial interaction results in laminin-1 expression only at the 
interface between the primitive epithelium and the lung-bud mesenchyme. 
The effect of this expression is to cause elongation of the mesenchymal cells 
and subsequent differentiation to a smooth muscle phenotype. Associated 
with this is upregulation of laminin-2 expression which further promotes 
smooth muscle differentiation (Schuger et al 1997;Relan et al 1999).
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Basal lamina of skeletal muscle is rich in laminins, especially laminin 2 and 4. 
Defects in these laminins (especially laminin a2 subunit) and in their integrin 
(integrin a7|31) and dystroglycan receptors result in congenital muscular 
dystrophy, (Mayer et al 1997; Burkin et al 2001; Yurchenco et al 2004b).
The signalling function of laminins may occur in two ways. Firstly, the receptor 
facilitated laminin self-assembly can induce laminin cortical rearrangement 
mediated through the cell surface receptors (integrins and dystroglycans) in 
skeletal muscle (Colognato et al 1999). Cell shape can influence 
differentiation and survival, as will be discussed below in the section on 
geometric control of cell fate (Relan et al 1999). Secondly, once the ternary 
structure of basal lamina (collagen IV and laminin networks stabilise by 
nidogen and perlecan), then the cell surface receptors for laminin, particularly 
integrins) can transmit signals either by mechanotransduction or by activating 
signalling pathways. This will be discussed further below.
Laminin expression in the mammalian urinary tract
Urinary bladder detrusor expression: Generic laminin expression 
progressively, as assessed by immunohistochemistry and Western blot, 
increases during murine detrusor smooth muscle (DSM) development 
(Smeulders et al 2003), and is strongly expressed, as assessed by 
immunohistochemistry, in the basal lamina of DSMC in adult human bladders 
(Wilson et al 1996). No published sub-typing of laminins has been described 
in the DSMC basal lamina. Fetal DSMC have been shown to produce laminin 
in culture (Baskin et al 1993b), but no sub-typing of laminins is described.
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Urothelial basement membrane expression: The literature on urothelial 
basement membrane laminin production is more extensive. In murine 
bladders laminin is expressed in the urothelial basement membrane during 
development, however these laminins were not sub-typed (Baskin et al 
1996a; Smeulders et al 2003). Wilson et al show that laminin is strongly 
expressed in the urothelium of human adult bladders, but again is not sub­
typed (Wilson et al 1996). The prognostic significance of loss of decreased 
laminin 5 (as assessed by laminin y2 subunit immunostaining) from the 
basement membrane and increased stromal and intracellular immunostaining 
has been described with progression of urothelial carcinoma (Hindermann et 
al 2003; Kiyoshima et al 2005).
Expression in ureters: Hattori et al (2003) have demonstrated the pattern of 
expression of laminin subunits by real time polymerase chain reaction (RT 
PCR) of mRNA from cultured cells from adult human ureters (These were 
obtained from three radical nephrectomies performed for renal cell carcinoma. 
Adjacent ureteral tissue was examined histologically to confirm that cultured 
tissue was benign). Urothelial cells and stroma were cultured separately. 
Immunofluorescence of frozen sections of whole ureter probed with anti- 
laminin a  chain antibodies was performed. This demonstrated that urothelial 
cells synthesized laminin a1 , a 3  (strongest signal on western blotting), and 
a5  chains, and that laminin 5 (a3(33y1) was only present in the urothelial 
basement membrane, not elsewhere within the ureter. Stromal cells 
synthesized laminin a1 , a2 , a 4  (most strongly staining on Western blot), (31, 
(32 and y1 subunits. The predominant laminins present in the stroma were
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laminins 8 and 9 -  although laminin a 2  subunit was also present in this 
compartment (constituent of laminin 2, 4 and 12) (Hattori et al 2003).
Candidate laminin integrin receptor in detrusor
From preliminary results reported in Chapter 5 and the review of laminin 
subunits described above, receptors for laminin 1 (a1 (31 y1) G domains (ie 
integrins a 6 p i and a 7 p i)  and laminin 2 and 4 (a2p1y1 and a2(32y1) G 
domains (i.e. integrin a3p1, a 6 p i and a7p 1) would be appropriate choices as 
candidate laminin receptors. In the Appendix preliminary 
immunohistochemistry results for integrin a 6  immunostaining are described. 
No immunostaining was found in the developing murine detrusor layer. 
Integrin a 7 p i was therefore chosen as the candidate integrin laminin receptor 
for this thesis.
66
Fibronectin
Fibronectin was first described by Hynes in 1973. It was identified by surface 
iodination as a 250 kDa protein present on the surface of normal tissue 
cultured cells, and easily removed by proteolytic digestion. Viral 
transformation inhibited its expression. Initially termed large external 
transformation sensitive (LETS) protein (Hynes 1973), LETS had a major 
effect on cell adhesion and morphology (Ali et al 1977), and was found on 
immunostaining to have a fibrillar pattern (Vaheri et al 1976). Mosher and 
Vaheri together with Ruoislahti coined the name ‘fibronectin’ for LETS. It was 
found to exist in two forms: as an ECM protein, and as a plasma protein. This 
plasma form binds fibrinogen and precipitates at 4°C which had lead Edsall in 
1947 to name it ‘cold insoluble globulin’ (Edsall et al 1947). Fibronectin was 
subsequently found to not just adhere to fibrinogen, but also to denatured 
collagen (gelatin) allowing gelatin affinity chromatography to be used to purify 
it (Engvall and Ruoslahti 1977). Using an adhesion blocking antibody, and 
digestion fragments of the molecule, a 108 amino acid sequence was 
identified that promoted cell adhesion (Pierschbacher et al 1982). 
Subsequently the site of cell adhesion was isolated to a 4 amino acid moiety 
RGDS (Pierschbacher and Ruoslahti 1984). Using the RGD peptide coupled 
to sepharose allowed the identification of an RGD receptor that bound 
vitronectin, not fibronectin (and was subsequently found to be integrin cxv(33) 
(Pytela et al 1985a). Using the active cell-binding domain of fibronectin as the
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ligand instead allowed isolation of the fibronectin receptor (Pytela et al 
1985b).
Fibronectin fibrils extracellularly parallel the actin cytoskeleton intracellularly, 
and connect to them (Heggeness et al 1978). These transmembrane 
connecting proteins were initially identified as ‘fibronectin’ receptors and 
named integrins (Tamkun et al 1986).
Fibronectin structure
Fibronectin normally exists as a dimer composed of 230-270 kDa subunits. 
Cellular fibronectin is produced by many cell types and is a component of 
basal lamina, whereas plasma fibronectin is a soluble molecule present at 300 
ng/ml. Plasma fibronectin may be involved in wound healing and 
haemostasis.
Kornblihtt et al described the primary structure in 1985. Each monomer is 
composed of a mosaic of three fibronectin sub-types (termed fibronectin 
modules or repeats type I, II and III, 40, 60 and 90 residues long respectively). 
These are arranged as follows: amino- terminal of molecule 20 residues long; 
five type I repeats; a connecting strand; type I repeat; two type II repeats; 
three type I repeats; one type III repeat (in more recent literature this is 
termed fibronectin 111-1); a connecting strand; 14 units of type III repeats 
(fibronectin III-2 to15); one connecting strand IIICS (also termed the variable 
region); one type III repeat; one connecting strand; three type I repeats; 
terminal carboxy- segment (Kornblihtt et al 1985).
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Fibronectin monomers are covalently linked to form dimers by 2 disulphide 
bonds in the COOH terminal.
Alternative splicing can occur at three sites: EIIIA (Extradomain (ED)-A), EIIIB 
(ED-B), and the variable region V (IIICS) (Schwarzbauer et al 1989). This 
alternative splicing of the mRNA transcript has been reviewed by Ffrench- 
Constant (1995). The EIIIA domain is an extra type III repeat between the 11th 
and 12th type III repeats that can be included or excluded by exon skipping 
(Kornblihtt et al 1985). Similarly the EIIIB repeat, between fibronectin type III 7 
and 8 repeats, can be included or excluded (Schwarzbauer et al 1987). The 
V-region can be alternatively spliced, with 5 different transcripts described in 
the human (VO -  no connecting AA residues in the variable region, V64 -  64 
amino acid residues, V89, V95 and V120); three are described in the rat (VO, 
V95, V120); two are described in the chicken (V76 and V120) as reviewed by 
(ffrench-Constant 1995). Overall twenty different fibronectin isoforms have 
been described in the human, with 12 murine variants as reviewed by 
(ffrench-Constant 1995).
Plasma fibronectin produced by liver hepatocytes almost completely lacks 
EDA and EDB (Schwarzbauer et al 1987). Conversely, cellular fibronectin is 
detected by immunostaining with antibodies for EDA and EDB (Paul et al 
1986). The expression of these EDA and EDB regions is developmentally 
regulated. EDA and EDB being present in fetal fibronectin, but is variably 
downregulated in post natal fibronectin in different tissues in frogs (DeSimone 
et al 1992) and chickens (Ffrench-Constant and Hynes 1989).
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In skin wound healing in adult rats in situ hybridization data shows up- 
regulation of EDA and EDB in fibronectin mRNA (Ffrench-Constant et al
1989). Similarly RT-PCR has shown an upregulation of EDA in regenerating 
rat liver (Caputi et al 1995). This suggests a role in developmental regulation 
and wound healing for these splice variants of fibronectin. However, Muro et 
al have generated mouse mutants that constitutively expressed fibronectin 
containing EDA, or were homozygous for EDA absent fibronectin. These mice 
were all viable, and developed normally. Both mutants had shortened 
lifespans, but the EDA absent mice also had poor wound healing of their skin 
(Muro et al 2003). Similarly, the in vivo role of the EDB exon in mice has been 
investigated by producing EDB negative mice. These mice were normal and 
fertile, although fibroblasts from these mice did produce less fibronectin in 
vitro (Fukuda et al 2002).
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Figurel. 9: Structure of fibronectin, with integrin binding sites. Fn 1, 
fibronectin type 1 repeat, Fn 2 , fibronectin type 2 repeat; Fn 3, 
fibronectin type 3 repeat. RGD -  arginine-glycine-aspartate recognition 
site. SS, synergy sequence. Modified from Pankov et al (2002).
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Fibronectin receptors
Fibronectin molecules are capable of binding multiple ligands. ECM ligand 
sites, sites of fibronectin to fibronectin adhesion and integrin binding sites are 
discussed below.
1) ECM ligands: By using the strategy of protease digestion, and selective 
absorption onto ligands bound to agarose beads, several functional domains 
of fibronectin were identified.
The amino-terminal fibronectin I 1st - 5th (FNI 1-5) repeats are important for 
cellular fibronectin binding and polymerization as demonstrated by mutation 
analysis of fibronectin, in which truncated fibronectin was produced lacking 
one or all of these units, and failure of mutant truncated fibronectin to adhere 
either to fibroblasts, or Staphylococcus aureus (Sottile et al 1991). The 
fibronectin I 4th and 5th repeats are both required for fibrin adhesion to occur 
(Matsuka et al 1994). These 4th and 5th repeats are also part of the functional 
domain also binds Staphylococcus aureus (Huff et al 1994). Tissue 
plasminogen activator (factor Xllla ) binds to the amino terminal domain of 
fibronectin (Mosher et al 1980). Heparin also adheres to the n-terminal 
fibronectin I 1st -5th repeats (Hayashi et al 1980).
A second carboxy terminal heparin binding site has also been described 
(Richter et al 1981), which resides on 13th fibronectin III repeat (FNIII 13). The 
binding site is formed from a ‘cationic cradle’ of 4 arginine residues and with 
interaction from a 2 further arginine and a lysine residue (Busby et al 1995).
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Another glycosaminoglycan binding site has been described in the V region of 
fibronectin (Mostafavi-Pour et al 2001).
The collagen-binding domain of fibronectin was found by protease digestion of 
the intact molecule using trypsin (Ruoslahti et al 1979). This has been shown 
to be a functional domain containing FNI 6, FNII 1-2, FNI 7-9 (Skorstengaard 
et al 1994). It is a separate domain to the ‘cell-binding’ domain of fibronectin.
The ‘cell-binding’ domain of fibronectin was found to be an arginine-glycine 
aspartate (RGD) moiety on the 10th fibronectin type III repeat (FNI11-10)
(Pytela et al 1985b), that acts as an integrin binding site. Analysis of the 
crystal structure shows that the RGD moiety is on a ‘stalk’ projecting away 
from a molecule (approximately 10 angstroms (A)), composed form FNIII 7-10 
(Leahy et al 1996). Adhesion to this site is greatly increased by the presence 
of the ‘synergistic’ binding sites on FNIII 8 and 9 (Aota et al 1991). These 
domains are found to be ‘facing’ the RGD moiety on FNIII 10 on analysis of 
the crystal structure (Leahy et al 1996).
2) Fibronectin binding sites: Five fibronectin-fibronectin binding sites have 
been identified. These are: 1) the assembly domain, FNI 1-5 (Sottile et al 
1991), 2) two binding partners for the assembly domain, FNIII 1-2 (Aguirre et 
al 1994) and FNIII 12-14 (Bultmann et al 1998); 3) FNIII 2-3 binding FNIII 12- 
14 (Johnson et al 1999) and FNIII 1 binds FNIII 7 (Ingham et al 1997). The 
assembly site (FNI 1-5) and the assembly partners are important in the 
polymerization of fibronectin dimmers to form fibrils (discussed below). The 
intramolecular interactions are important in maintaining plasma fibronectin in 
its compact form, preventing fibril formation (Cheng et al 1997).
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3) Integrin binding sites on fibronectin:
EDA and V region: Integrin a4p1 has been shown to recognize the Heparin II 
binding region of fibronectin, FNIII12-14, and the ‘V ’ region (Wayner et al
1989), allowing cell adhesion and migration of cultured melanoma cells (This 
integrin can also recognize vascular cell adhesion molecule-1 (VCAM-1). A 
specific amino acid sequence I DAPS is recognized in the heparin II binding 
region, on FNIII14 (Mould and Humphries 1991). Similarly the EDA region is a 
ligand for integrin a 9 p i, which is widely expressed in murine smooth muscle 
(Palmer et al 1993;Liao et al 2002). This integrin is upregulated transiently in 
cutaneous wound healing (Singh et al 2004).
FNIII 5: A similar short amino acid sequence on fibronectin type III repeat to 
that on FNIII 14 is recognized by integrin a4pi and a4p7 (Moyano et al 1997). 
The functional significance of this is unclear.
N-Terminal FN 11-9, FN I11-2: The amino-terminal region when digested from 
intact fibronectin yields a 70 kDa fragment that contains the fibronectin 
assembly region and is recognised by a complex formed from the cell binding 
region of fibronectin and integrin a5pi (Dzamba et al 1994).
FNIII10 RGD moiety: Integrin a5p i, avp3 (avpl ,avp5,avp6), a8p i and allbp3 
recognize this binding site. The ‘vitronectin receptor’ integrin avp3 was the 
original integrin identified using RGD in an affinity column (Pytela et al 1985a), 
with integrin a5p1 requiring the synergy site in FNIII 8-9 to also be included in 
the affinity column in order to adhere (Pytela et al 1985b). Integrin a8pi has 
been shown to be a fibronectin, vitronectin and tenascin mediated by the RGD
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moiety (Schnapp et al 1995a). This integrin is expressed in murine smooth 
muscle cells (Schnapp et al 1995b). The RGD sequence is also recognized by 
integrin allb|33 expressed by platelets, but inclusion of the synergy binding 
site present in the central cell binding domain improves adhesion (Ginsberg et 
al 1985).
The evidence for integrin a3pibeing an RGD receptor is conflicting. Integrin 
a3|31 (originally described as extra-cellular matrix receptor I (ECMR1) and 
VLA3) was described as being a receptor for collagen, laminin and fibronectin 
(Wayner and Carter 1987;Takada et al 1988). However at physiological salt 
concentrations human integrin a3|31 does not bind to fibronectin affinity 
columns (Hynes et al 1989). In contrast Elices et al have shown that integrin 
a3pi may act as an RGD receptor (Elices et al 1991).
Fibronectin polymerization
Fibronectin matrix can be deposited by two mechanisms: firstly, deposition of 
a cellular fibronectin matrix which requires active cellular intervention; 
secondly, tissue injury results in the extravasation of plasma proteins and the 
formation of an ‘injury associated’ matrix in which fibronectin becomes bound.
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Fibronectin matrix assembly
The process of fibronectin fibril assembly requires fibronectin-integrin 
interaction, fibronectin conformational change, and then polymerization.
Fibronectin-integrin adhesion: 1) Initially integrin-bound fibronectin is diffusely 
localized at the cell surface. 2) Receptor clustering associated with this 
dimeric FN cause the formation of complexes of integrin a5|31, the 
cytoplasmic tails of which become associated with intracellular adapter 
proteins and actin cytoskeleton, forming fibrillar adhesions (Ohashi et al 
2002). These fibrillar adhesions are composed of integrin a5(31, focal 
adhesion kinase (FAK), vinculin and paxillin (Sechler and Schwarzbauer
1997), and are enriched with tensin in comparison to focal adhesions. Focal 
adhesions are fixed and contain integrin av|33, paxillin and vinculin. It is from 
these fixed points that fibrils grow (in a centripetal direction towards the cell 
nucleus), ‘pulled’ by the fibrillar adhesions containing integrin a5b1, along 
actin stress fibres (Ohashi et al 2002). Cytochalasin B inhibits actin 
cytoskeleton and prevents further fibronectin fibrillogenesis, with some fibrils 
contracting (Ohashi et al 2002); similarly division of a growing fibronectin fibril 
using a laser causes the fibril to retract (Ohashi et al 1999). 3) The stretching 
of fibronectin fibrils may expose cryptogenic binding sites, and promote further 
polymerization.
Other cell-surface receptors can bind fibronectin and participate in 
fibrillogenesis. These include syndecan-4 (a transmembrane heparan 
sulphate proteoglycan) can bind FN. This stimulates RHO GTPases and FAK, 
enhancing fibrillogenesis (Saoncella et al 1999). The urokinase plasminogen
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activator receptor (uPAR) has been shown on binding its P-25 ligand to 
promote integrin a5|31 mediated fibronectin fibrillogenesis (Monaghan et al 
2004).
Fibronectin conformation changes during fibriilogenesis: Soluble, plasma 
fibronectin has a compact conformation (Johnson et al 1999), held in this form 
by intramolecular interactions between FNIII2-3 and FNII112-14. Recombinant 
fibronectin lacking FNII11-7 rapidly assembles on the cell surface into 
detergent insoluble fibronectin aggregates (Sechler et al 1996). Fluorescence 
resonance energy transfer (FRET) has also been used to examine changes in 
fibronectin folding during fibrillogenesis. Random labelling using donor and 
acceptor fluorophores allows changes in FRET to identify alternative 
fibronectin conformations (Baneyx et al 2001). Fibronectin is compact in 
solution and on initial cell adhesion, but during initial clustering becomes more 
extended, with fibronectin dimmers in fibronectin fibrils being highly extended 
(Baneyx et al 2001, 2002). The highly extended conformation could allow 
further exposure of cryptic fibronectin binding sites (Baneyx et al 2002). 
Different alignments are possible because of the multiple fibronectin binding 
sites available on each molecule.
Fibronectin polymerization: Initially fibronectin is incorporated into short fibrils 
at the cell periphery. Subsequently the fibrils become thicker and longer 
(Ohashi et al 1999, 2002). Fibronectin dimers are incorporated into the 
growing fibrils by two processes: firstly by integrin binding (Fogerty et al
1990), secondly by fibronectin-fibronectin interactions independent of the 
RGD binding site (Sechler et al 1996). Initially these fibrils are deoxycholate
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(DOC) soluble, but over a period of 2-3 hours become irreversibly insoluble 
(McKeown-Longo and Mosher 1983). This mechanism could be by covalent 
disulphide bridge formation between dimers, however biochemical analysis 
fails to support this. DOC insolubility may be due to the formation of stable 
non-covalent intermolecular interactions (Chen and Mosher 1996).
Initial fibronectin fibrillogenesis requires an activated integrin fibronectin 
receptor (often integrin a5p1 (Pankov et al 2000)), fibronectin adhesion, and 
an intact cytoskeleton to generate tension (Wu et al 1995). Tensin dependent 
movement of the integrin a5pi complexes, along actin cytoskeleton, relative 
to fixed focal adhesions (containing integrin avp3) could be important in 
inducing conformational change in bound fibronectin dimers, exposing further 
binding sites (Pankov et al 2000).
Fibronectin fibril matrix maintenance is dynamic: In fibroblast culture, 
fibronectin matrix turnover is slow (McKeown-Longo and Mosher 1983), but 
continual, mediated by a caveolin-1 dependent endocytosis (Sottile and 
Chandler 2005). Continual fibronectin polymerization is necessary for 
maintenance of the fibronectin fibril network, which is in turn necessary for 
collagen I and thrombospondin deposition (Sottile and Hocking 2002).
Provisional matrix in wound healing: Tissue injury results in the extravasation 
of plasma proteins and the formation of an ‘injury associated’ matrix, the 
principle components of which are fibrin, which by the action of activated 
factor XIII, is cross-linked by plasma-derived fibronectin (Okada et al 1985). 
This fibronectin in concert with growth factors such as platelet derived growth 
factor and transforming growth factor p result in migration of fibroblasts, and
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their transformation into myofibroblasts (Lariviere et al 2003). This results in 
wound contraction, ECM synthesis, including locally produced cellular 
fibronectin, and wound healing (Gabbiani 2003).
Fibronectin Function
Evidence for a functional relevance of fibronectin expression comes from 
several lines of research including cell culture work, and knockout mouse 
mutants. Smooth muscle function can depend on ECM, as vascular smooth 
muscle cells can be switched from a contractile phenotype when cultured on 
laminin, to a synthetic type on fibronectin (Thyberg and Hultgardh-Nilsson 
1994). Similarly on fibronectin VSMC are more proliferative than when 
cultured on laminin (Morla and Mogford 2000). It has been shown that a 
fibronectin matrix is necessary for the polymerization of collagen I and III 
(Veiling et al 2002).
Homozygous fibronectin null mouse mutants are lethal, suffering severe 
mesodermal defects including impaired angiogenesis (George et al 1993). 
These homozygous mutants implant, gastrulation starts, but have no 
notochord, or somites, with variable degrees of deformity of the heart, intra 
and extra-embryonic vasculature and amnion. This reinforces the general 
requirement for this ECM protein during development, but unfortunately these 
mouse mutants die at embryonic day 8, before bladder development has 
started. These mutants are therefore uninformative with regards bladder 
development (George et al 1993).
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The composition of the ECM surrounding a connective tissue cell is a balance 
between synthesis of the ECM components and their breakdown (for example 
by matrix metalloproteinases). The ECM in turn influences the behaviour of 
the cells. This has been demonstrated by (Hedin et al 1997) who found that 
VSMCs cultured on laminin whilst initially non-proliferative, became so after a 
number of hours with the production of their own fibronectin matrix. This 
required the expression of the fibronectin receptor integrin a5(31 (see below).
Fibronectin expression in the bladder
The descriptive murine urinary bladder studies of Smeulders et al have 
demonstrated that detrusor fibronectin expression rises form embryonic day 
14 (E14) to a peak at the end of gestation, neonatal day 1(D1), by western 
blot, with a fall in levels postnatally with maturation at 6weeks, in parallel to 
the expression of the fetal smooth muscle cell phenotype (Smeulders et al 
2002, 2003). E14 is the first day in the fetal mouse that the bladder can be 
easily isolated as a discrete organ. Smeulders et al used Chemicon AB2033, 
as used in this thesis. In a study of adult human bladders fibronectin is shown 
to be expressed in the detrusor SMC basal lamina (Wilson et al 1996). In 
ultrastructural studies of the developing rat bladder (from E14, E18 newborn 
and adults), fetal SMCs are shown to have a fibronexus (Wu et al 1999a).
This fibronexus has previously been shown to consist in part of fibronectin 
fibrils, actin cytoskeleton and connecting proteins in both SV40 transformed, 
cultured hamster fibroblasts, and cultured human fibroblasts (Singer 1979).
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Candidate fibronectin integrin receptor
Possible candidates include integrins a4p1, a5 p i, av|33, a8p i. Integrin allbp3 
is predominantly a platelet expressed integrin although ectopic expression 
has been described in tumours. Integrin a5pi is the archetypal fibronectin 
receptor and important not just in ligation of fibronectin, but also in 
fibrillogenesis; for these reasons it was the candidate fibronectin receptor 
studied in this thesis.
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Integrins
As described above in the introductory section to fibronectin, the first ‘integrin’ 
identified was the vitronectin receptor, followed by the fibronectin receptor. It 
rapidly became apparent that there was a family of heterodimeric receptors 
that had similar structure and function. These receptors connected ECM and 
the intracellular cytoskeleton -  ‘integrating’ the inside and outside of the cell, 
influencing cell migration and adhesion. (Hynes 1987) coined the term integrin 
in a review article, and labelled the subunits as a  or p.
Eighteen a  subunits, and eight p subunits have been described, forming by 
noncovalent interaction 24 different integrin subtypes, as reviewed by (Hynes 
2002). Further complexity is achieved by post-translational modification, 
modulation of integrin ligand affinity and interactions with ECM, cell surface 
and intracellular molecules. Integrins can adopt a low affinity state for their 
ECM ligands, which on activation (which may be an ‘outside-in’ or ‘inside-out’ 
signal), clump together to form focal adhesions, reinforcing ECM cell 
cytoskeleton interactions and recruiting many other cell surface molecules 
that can act as receptors, as well as proteins many with dual structural and 
signalling function.
Integrin receptors are ‘polygamous’, capable of recognizing many different 
ECM ligands, often via common minimal recognition sequences. Ligand 
binding is, however, greatly modified by the context of these sequences: firstly 
ligand conformation regulates availability of the recognition site, e.g. RGD 
binding site of fibronectin is more readily available than the cryptic RGD site 
on collagen which only becomes available on damaging the collagen 
molecule; secondly, neighbouring sequences on the ligand modify integrin
82
receptor binding, e.g. the fibronectin synergy binding site composed of FNIII 
repeats 8-9 modifies integrin a 5 p i ligation of fibronectin (Aota et al 1991). 
Integrin-ligand binding has been reviewed by (Plow et al 2000). Loss of one 
subtype of integrin receptor can be compensated by another integrin subtype 
as reviewed by (De Arcangelis and Georges-Labouesse 2000).
Below will be reviewed integrin structure, classification, integrin ‘binding sites’, 
activation, focal adhesion formation and function, interaction between cell 
shape and integrin function, and mechanotransduction.
Integrin structure
Integrins are heterodimers of one a  subunit, and one p subunit, noncovalently 
associated. Each subunit is composed of a large extracellular component 
formed from multiple structural domains composed of several hundred amino 
acid residues, a transmembrane domain, and a small cytoplasmic domain of 
between 20 and 70 residues.
a-subunit basic structure. Extracellular domain 1) The amino terminal has a 7- 
fold p propeller head (which complexes with the p subunit l-like domain), 2) 
connects to a thigh domain (1st p sheet domain), a linker domain which can 
act as a ‘genu’ or knee and connects to 3) calf-1 domain (2nd p sheet domain), 
and 4) calf-2 domain (3rd p sheet domain). This connects to a transmembrane 
domain, which in turn connects to the cytoplasmic domain. The membrane 
proximal cytoplasmic domain has a highly conserved GFFKR amino acid 
sequence involved in binding the cytoplasmic tail of the p subunit, and control 
of integrin activation (O'Toole et al 1991 ;0'Toole et al 1994).
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I/A Domain: a  subunits can be classified by the presence or absence of an 
extra I/A domain, a  subunits lacking the I/A domain include a3 , a6 , a7 , a5, av  
and a8. a  subunits including the I/A domain include a1 ,a2, a10 , a11 , a 4  and 
a9.
/3-subunit basic structure. The head of the p subunit is formed from a loop 
formed by the disulphide bonding of the N-terminal PSI-like domain to the 
distal end of the p subunit leg. The most distal end of the loop is therefore 
formed from the p I/A domain. The ‘leg’ of the p subunit is formed from 4 I- 
EGF domains (numbered 1-4) connected to the p tail domain that connects to 
the transmembrane domain, and then the cytoplasmic domain. This 
cytoplasmic domain varies between the p subunits, but all have a proximal 
cytoplasmic domain that is highly conserved and interacts with the membrane 
proximal domain of the a  subunit forming a ‘clasp’ (O'Toole et al 1991; 
O'Toole et al 1994).
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Figure 1.10: Integrin subunit structure. Modified from Hynes 2002.
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Inactivated integrin structure. The crystal structure of the integrin av|33 has 
been described which reveals that this integrin is bent over at 135°, with a 
‘genu’ or knee between the thigh and calf of the a  subunit and a similar bend 
between l-EGF 2 and 3 of the p subunit. The I/A domain of the p domain is in 
close proximity to the p propeller of the a  subunit (Xiong et al 2001), forming 
the ligand binding head of the integrin. This is thought to represent the low 
affinity or inactivated conformation of the integrin heterodimer. When RGD 
oligopeptides are added, there is no change in conformation (Xiong et al 
2002), but the RGD oligopeptides bind at the a  and p subunit interface.
In the inactive state there is a salt bridge between the a  and p proximal 
cytoplasmic domains that maintains the integrin in an inactive state. Deletion 
of either of these regions results in a constitutively active integrin receptor 
(O'Toole et al 1991;0'Toole et al 1994).
Activated integrin structure. By using molecular electron microscopy, 
unligated integrin a 5 p i head-piece has been shown to adopt a ‘closed’ 
conformation similar to the ‘closed’ conformation of integrin avp3 when 
unligated, but when fibronectin fragments are allowed to ligate, this integrin 
straightens-out (Takagi et al 2003). This ‘opening-out’ does not appear to 
happen when a similar experiment is repeated with fibronectin fragments and 
integrin avp3 (Adair et al 2005). The evidence is therefore conflicting about 
the straightening and ‘opening-out’ of the whole integrin receptor on 
activation, but other studies support at least the opening of the interface 
between the a  subunit p propeller and the p subunit I/A domain: Mould et al 
(1997) has shown using monoclonal antibodies to the binding sites of integrin 
a5  and p i and competitive inhibition of binding using RGD or fibronectin
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central cell binding region peptide, that the RGD sequence of fibronectin binds 
P-I/A domain, whereas it is the synergy site which interacts with the propeller 
(Mould et al 1997); similarly both the synergy site and the RGD site of 
fibronectin are necessary for maximum activation of integrin a5p1 (Garcia et 
al 2002); also in the ‘closed model’ of integrin avp3 described by Xiong (Xiong 
et al 2002), several residues on the a  subunit propeller are covered by the p 
I/A domain which are the binding sites of function blocking antibodies for 
several integrins, as reviewed by (Humphries 2002).
Activated integrins do have a loss of association between a  and p subunits 
(Luo et al 2004). This is capable of putting the integrin into its activated form 
as demonstrated on NMR studies of the cytoplasmic domains of allb and p3 
subunits (Vinogradova et al 2002; Vinogradova et al 2004). Talin has been 
shown to also inactivate the ‘clasp’ between these subunits (Vinogradova et al 
2002). Activated, ligated integrins may then further cluster due to interaction 
of their transmembrane domains (Li et al 2003).
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ECM ligand
Salt bridge
Figure 1.11: Integrin activation. Talin binding to the cytoplasmic tail of p subunit 
results in ‘unclasping’ of the membrane proximal salt bridge between the integrin 
a and p subunits - leading to a conformational change that exposes the ligand 
binding site, and may or may not be associated with straightening of the whole 
integrin dimer. Modified from Hynes 2002.
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Integrin subunit cytoplasmic binding sites
The cytoplasmic tails of both the a and p subunits have both been shown to 
possess ligand-binding sites, although the p subunits have a much larger 
range of potential ligands and are perhaps most functionally important.
Cytoplasmic binding sites of integrin a  subunits
a2 integrin has been shown to bind F-actin (Kieffer et al 1995). Calreticulin 
has been shown to ligate a2 subunits (Coppolino et al 1995). Caveolin-1 
binds integrin a  subunits and mediates adapter protein she (Src Homology 
adapter proteins) recruitment and subsequent control of the cell cycle (Wary 
et al 1998). She adapter proteins consist of one Src type 2 homology 
sequence (Sh), and one domain with homology to collagen a1 chain (CH) 
(Pelicci et al 1992), and act as an adapter protein in signal transduction from 
protein kinases (Pelicci et al 1992). The integrin aLp2 integrin is necessary 
for modulation of LFA-1 adhesion to intercellular adhesion molecule (ICAM), 
and this is mediated through the cytoplasmic domain of the aL subunit 
(Tohyama et al 2003).
Cytoplasmic binding sites of integrin (3 subunits
Integrin p cytoplasmic tails are central to many integrin functions. Loss of the 
cytoplasmic domains in p i, p2 and p3 integrins causes failure to localize to 
focal adhesions (Solowska et al 1989), reduced ligand binding (Hayashi et al
1990), and decreased activation of downstream signalling activity (O'Toole et
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al 1994). Many different proteins bind the p-integrin cytoplasmic tails including 
actin binding proteins and signalling proteins.
Actin binding proteins
In order for cells to change shape and migrate and assemble fibronectin 
matrix, connection to the actin cytoskeleton is necessary. Adapter proteins 
include talin, paxillin, a-actinin, and filamin.
Talin is an antiparallel homodimer of 270 kDa units, each consisting of a 
50kDa head (which binds p integrin subunits) and a 220 kDa tail. It binds piA, 
p1D, p2, p3 and p5, with weak p7 adhesion (Pfaff et al 1998; Sampath et al 
1998; Calderwood et al 1999). The head region contains a FERM domain 
(four-point-one, ezrin, radixin, moesin), which are known to bind the 
cytoplasmic tails of transmembrane proteins (Calderwood et al 2002). Talin 
binding of integrin p cytoplasmic tails can cause integrin activation, e.g. 
platelet integrin allbp3 (Calderwood et al 2002). Inhibition of talin using small 
interfering RNA (RNAi) prevents conformational change of integrins, 
preventing activation on the cell surface, and cannot be overcome by over­
expressing other putative integrin binding proteins (Tadokoro et al 2003).
Talin is necessary for the normal development of mice, flies and worms: talin 
null mutant mice die at E8.5 having failed to undergo gastrulation (Monkley et 
al 2000); D. melanogaster talin null mutants show failure to form focal 
adhesions on the cell surface, and failure of integrin-cytoskeleton interaction) 
(Brown et al 2002); in C. elegans talin deficiency resulted in loss of normal 
cytoskeletal organization and adhesion in contractile cells as well as deficient
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migration) (Cram et al 2003). Integrin activation due to talin binding occurs as 
a result of disruption of the ‘clasp’ formed by a salt bridge between the 
membrane proximal regions of the integrin a and p subunits (Patil et al 1999; 
Vinogradova et al 2002; Garcia-Alvarez et al 2003; Ulmer et al 2003). Integrin 
dimers assume an activated conformation as described above. Once bound 
to the p integrin subunit, talin provides an initial link between integrin clusters 
and the cytoskeleton (as described on initial integrin avp3 clustering in the 
presence of fibronectin) (Jiang et al 2003). Application of mechanical force to 
these clusters results in further cytoskeleton recruitment mediated by talin 
(Giannone et al 2003). Talin is also necessary for subsequent paxillin and 
filamin binding into these focal complexes (Giannone et al 2003). Inhibition of 
talin binding can occur as a result of phosphorylation of the NPXY motif of p 
subunit cytoplasmic tails by Src (Garcia-Alvarez et al 2003).
Paxillin is an adapter protein that binds p1 integrin cytoplasmic tails. It was 
first described by (Glenney and Zokas 1989), and described as a focal 
adhesion and vinculin binding protein by (Turner et al 1990). It consists of 4 
carboxy terminal LIM domains that bind to focal adhesions (Dawid et al 1998), 
5 leucine rich ‘LD’ domains that bind proteins such as FAK and vinculin 
through conserved paxillin-binding sub-domains (Brown et al 1998). Several 
proline-rich SH3 binding motifs are present in the amino terminus (Weng et al 
1993) as are several serine/threonine and tyrosine phosphorylation sites. 
Paxillin can bind syndecans, integrins, serpentine receptors, growth factor 
receptors, and link these to integrin-linked kinase (ILK), FAK, vinculin, 
actopaxin amongst others. An important function of paxillin is to integrate 
signals from integrins and growth factors, as reviewed by (Brown and Turner
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2004). Paxillin is one of the first proteins to be localised to focal complexes in 
areas of cell protrusion (Laukaitis et al 2001). Homozygous paxillin knockout 
mice are embryonically lethal (Hagel et al 2002), with a phenotype similar to 
fibronectin knockout mice (Hagel et al 2002). Paxillin expression is regulated 
during development, expression of paxillin occurring after mid-gastrulation, 
with strong expression in the dorsal aorta, endocardium and notochord (Hagel 
et al 2002). Paxillin is expressed in the dense plaques of smooth muscle 
(Turner et al 1991).
Filamins: Three filamin isoforms have been described. They are actin filament 
cross-linking proteins formed from 2 parallel 250 kDa subunits (Turner et al 
1990). Each subunit has an actin binding amino terminal, with a repeated 100- 
residue rod domain containing repeated 6-9 amino acid sequences, 
alternating with 3-4 amino-acid sequences (Gorlin et al 1990). Filamins cross­
link actin filaments and bind transmembrane proteins including integrins (31 A, 
P1D, (32, (33, and (37 (Sharma et al 1995; Loo et al 1998). The type of actin 
network that filamin cross-linking produces in part depends on the ratio of 
filamin to actin present: a high molar ratio of 1:10-50 produces parallel actin 
‘stress fibres’, whilst a lower ration 1: 150-740 produces a loose, orthogonal 
network (Brotschi et al 1978; Dabrowska et al 1985). Filamin can also act as a 
scaffold for the binding of signalling proteins such as GTPases, including Rho, 
Rac and Ras, which can then lead on to filopodia formation (see below) (Ohta 
et al 1999). Filamin c is expressed in the dense plaques and dense bodies of 
mature smooth muscle (Tachikawa et al 1997).
a-actinin is a member of the spectrin family and consists of anti-parallel 
homodimers of 100kDa. The amino terminal contains two calponin homology
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domains that bind actin, the central part of the molecule is formed from 4 
spectrin-like repeats, and the carboxy terminal contains two EF hands which 
can bind divalent cations such as calcium (Baron et al 1987). a-actinin can 
bind the cytoplasmic tails of p integrins to actin stress fibres (Pavalko et al
1998), and is recruited to focal adhesions (Cattelino et al 1999). a-actinin also 
serves as a scaffold binding signalling molecules at focal adhesions, for 
example MEKK1 which is an activator of other kinases including p38 and ERK 
(Christerson et al 1999). Activity of a-actinin has been shown to be modulated 
by four mechanisms: firstly by calpain, which promotes focal adhesion 
disassembly by inhibiting a-actinin recruitment to focal adhesions (Bhatt et al
2002); secondly, binding of phophatidyl inositol products (of phosphatidyl 
inositol 3-kinase activity) reduces a-actinin binding of p-integrin cytoplasmic 
tails and actin and promotes dissipation of focal adhesions (Greenwood et al
2000); thirdly, phosphorylation of a-actinin can modify its activity, with 
increased phosphorylation in activated platelets (Izaguirre et al 1999), but 
when phosphorylated by FAK, reduced binding to actin fibres (Izaguirre et al
2001); fourthly, for the non-muscle isoforms of a-actinin, increased Ca2+ 
binding reduces actin ligation (Burridge and Feramisco 1981).
Skelemin has been shown to bind the membrane proximal region of the 
cytoplasmic tails of pi and p3 integrins, and is a member of a superfamily that 
modulate the binding of myosin to actin (Reddy et al 1998).
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Signalling molecules that bind /3-integrin cytoplasmic tails
Two kinases have been reported to bind integrin cytoplasmic tails, focal 
adhesion kinase (FAK) and integrin-linked kinase (ILK). These are implicated 
in inside-out and outside-in signalling.
Focal adhesion kinase is a 119kDa protease that is rapidly phosphorylated 
and associated with focal adhesions when cells are plated onto ECM such as 
fibronectin (Hanks et al 1992). It consists of an amino-terminal FERM domain, 
(four-point-one, ezrin, radixin, moesin domain), which binds p-integrin 
cytoplasmic tails (Schaller et al 1995), a central catalytic domain, and a 
carboxy-terminal ‘focal adhesion targeting’ domain (FAT), which leads to 
binding at focal adhesions (Martin et al 2002). Clustering of integrins leads to 
rapid phosphorylation of FAK at tyrosine 397 (tyr397), amongst others, 
maximising activation of FAK signalling pathways (Calalb et al 1995). This 
creates a high affinity binding site for the SH2 domain of Src kinases (Schaller 
et al 1994), which in turn causes further phosphorylation of FAK (Owen et al
1999). This stimulates the recruitment of phosphoinositol 3-kinase (PI3 
kinase) (Akagi et al 2002), phospholipase c (PLC) and the adapter protein 
Grb7 (Han and Guan 1999). The c-terminal domain FAT contains a binding 
site for paxillin, and 2 SH3 proline rich binding sites that can ligate Cas (Harte 
et al 1996) and regulators of small GTPases (GRAF and GAP which modulate 
Rho, and ASAP which modulates Arf1 and Arf6) (Liu et al 2002). These small 
GTPases are important in cytoskeletal reorganization (see bellow). FAK, via 
Cas binding to Crk stimulates cell migration (Cary et al 1998;Klemke et al 
1998), which in turn may involve DOCK180 activating Rac (Kiyokawa et al 
1998;Brugnera et al 2002). Cell adhesion mediated via integrins is synergistic
for the proliferation that growth factors cause via MAP kinase pathway. ECM 
adhesion stimulates MAP kinase activity in the absence of growth factors 
(Moro et al 1998), conversely growth factors cannot efficiently activate the 
Raf-MEK-Erk pathway when cells are in suspension and the integrin signal 
blocked (Renshaw et al 1997). This integrin signal is mediated by FAK 
activation (Renshaw et al 1999). Integrins via FAK modulate small GTPase 
activity (Rac and Rho) which determine cell shape, and motility, and via FAK 
modulate MAPK/MEK/ERK pathway and influence cell proliferation.
Integrin linked kinase (ILK) is a 59kDa protein originally identified by its 
interaction with pi integrin cytoplasmic tail (Hannigan et al 1996). It consists 
of monomers containing four ankyrin-like repeats at the amino terminal, a 
pleckstrin homology domain, and a kinase at the carboxy terminal (Hannigan 
et al 1996). It has binding sites for a number of other proteins including 
integrin p i ,  PINCH (Tu et al 1999) and the adapter protein families a  and p 
parvin, which are actin binding proteins (Olski et al 2001;Tu et al 2001). ILK 
localises to focal adhesions (Hannigan et al 1996), and to fibrillar adhesions, 
associated with fibronectin fibrillogenesis in diabetic nephropathy (Guo et al 
2001). Homozygous ILK null mutant D. melanogaster are embryonically lethal, 
with loss of actin binding at muscle attachment sites (Zervas et al 2001). ILK 
can phosphorylate PKB/AKT, suppressing caspase-3 and inhibiting apoptosis 
and anoikosis (Persad et al 2000;Persad et al 2001). It is also capable of 
upregulating cyclin D1 in murine mammary cells -  promoting cell cycle 
progression (D'Amico et al 2000). ILK can also increase AP1 activity resulting 
in increased matrix metalloproteinase 9 expression, and the potential for 
increased ECM remodelling or invasiveness (Troussard et al 2000).
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(34 integrins are a component of hemidesmosomes
Integrin a6|34 is an integrin with a specificity for laminins that is associated 
with formation of hemidesmosomes in epithelia. Specifically the |34 
cytoplasmic tails contains fibronectin type III repeats that are involved with 
attachment to hemidesmosomes (Spinardi et al 1993). Loss of this integrin 
can result in epidermolysis bullosa and neonatal lethality (Georges- 
Labouesse et al 1996).
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Figure 1.12: Integrin activation and actin binding: (A) ‘inside-out’ signalling: 
talin binding to the p-integrin cytoplasmic tail activates the integrin dimer 
allowing ligation of ECM protein e.g. fibronectin. (B) ’outside-in’ fibronectin 
ligation by integrin dimer leads to (C) adapter protein binding eg talin. These 
adapter proteins then link to actin. Talin (and a-actinin) can in turn bind 
vinculin which can bind actin filaments, with Arp 2/3 acting as a nucleation 
site for further actin polymerization (D). ILK, integrin linked kinase, which 
acts as an adapter protein, but also as a kinase. Modified from Brakebusch 
et al (2003)
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Figure 1.13: Integrins can activate multiple signalling pathways. Integrin 
ligation and activation leads to activation of multiple signalling pathways, 
including small GTPases (red) e.g. Rac, Rho, Ras, Cdc42; protein 
kinases (green) including FAK, Akt, Raf, Mek, ERK, in turn leading to 
alterations in cell shape, cell motility, survival and proliferation. FAK, 
focal-adhesion kinase; PI3K, phosphoinositide 3-kinase. Modified from 
Flynes 1999.
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Integrin activation
Integrin activation can proceed from outside-in, or inside-out.
Inside-out signalling involves talin binding to the p-cytoplasmic tail, and 
‘unclasping’ of the salt bridge between the a and p subunit membrane 
proximal domains. A conformation change can occur, allowing increased 
binding of ligand externally, leading to integrin clustering. Outside-in signalling 
occurs when increased ligand availability promotes integrin binding and 
conformation change, again leading to integrin clustering.
Clustering of integrins and focal complex formation
The clustering of integrins results in recruitment of FAK, and stimulates 
phosphorylation of FAK and further recruitment and phosphorylation of other 
signalling proteins such as Src and Cas. These small focal adhesions have 
been called focal complexes and are present at the periphery of cells. These 
focal complexes are regulated by Rac and CDC42 (small GTPases) (Nobes 
and Hall 1995). CDC42 promotes filopodia formation, whereas Rac promotes 
lamellopodia formation, stabilised by these initial focal complexes into which 
paxillin and a-actinin are recruited (Laukaitis et al 2001). Src recruitment can 
lead to phosphorylation of the integrin p-subunits, which can lead to focal 
complex disassembly, or the focal complexes can persist. The formation of 
these focal complexes involves further recruitment of ligated integrins (initially 
these are integrin avp3 in the model used by Zaidel-Barr et al (2003)), and
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has been shown to be hierarchical with talin and paxillin incorporated next, 
followed by vinculin and FAK (Zaidel-Bar et al 2003).
Focal adhesions form from focal complexes
Remodelling occurs with an increase in FAK and vinculin, with zyxin and 
tensin recruited for the first time, associated with an increase in (31 integrins - 
leading to formation of focal adhesions (Zaidel-Bar et al 2003). The formation 
of these focal adhesions is under the control of the small GTPase Rho (Ridley 
and Hall 1992;Chrzanowska-Wodnicka and Burridge 1996), and is associated 
with force generation and actin stress fibre formation.
Force acting on cells modifies the type of focal adhesion formed. The force 
may have an extracellular origin, or may be intracellularly generated.
‘Intracellular force’ is generated by actin-myosin contraction driven by myosin 
ATPase activity. This activity is modulated by myosin light chain 
phosphorylation, which occurs as a result of the action of the Rho effector, 
Rho Kinase (ROCK) (Amano et al 1996;Kimura et al 1996;Kureishi et al 
1997).
‘External force’ when applied to adherent cells has been shown to result in 
cell stiffening and new focal adhesion formation, mediated by integrins (Wang 
and Ingber 1995). Similarly, using optical tweezers to increasingly ‘pull’ on a 
fibronectin coated bead has been shown to increase strength and rigidity of 
the cytoskeleton (Choquet et al 1997). Mechanical force can increase focal 
adhesion formation (Balaban et al 2001), and can cause maturation of focal 
adhesions (Galbraith et al 2002).
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Fibrillar adhesions
Fibrillar adhesions are formed from focal adhesions, and contain integrin a5|31 
and tensin. These adhesions are associated with fibronectin fibrillogenesis, as 
described above (Pankov et al 2000).
Three-dimensional focal adhesions
Fibroblasts seeded into floating collagen gel become quiescent and assume a 
three-dimensional ‘dendritic’ shape typical of fibroblasts in resting connective 
tissue (Grinnell et al 2003). Mammary epithelial cells seeded onto EHS 
derived matrix form three dimensional structures after 8 days in culture, 
becoming differentiated, assuming an acinar conformation, and producing 
milk (Barcellos-Hoff et al 1989). ‘Three-dimensional’ focal adhesions formed in 
vivo or in three-dimensional culture are different to those formed by cells on a 
two-dimensional substrate (Cukierman et al 2001). Specifically fibroblasts 
produced three-dimensional focal adhesions that had no (33 integrin, instead 
contained a5|31 integrin unlike focal adhesions; and included FAK, paxillin and 
vinculin unlike fibrillar adhesions. Three-dimensional matrices also had 
enhanced biological activity (adhesion, movement, cell morphology, and 
proliferation), blocked by a function blocking antibody to integrin a5|31 
(Cukierman et al 2001).
Phytogeny of integrins
The single sponge integrin has homology with both the C. elegans a-integrin 
subunits and the RGD, and laminin integrins expressed in D. melanogaster. 
RGD and laminin binding receptors are present in all vertebrates and 
invertebrates studied so far. These RGD integrins are C. elegans a1, D.
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melanogaster PS2, and human integrins a5, a8 and aV. The laminin binding 
integrins include C. elegans a2, Drosophila PS1 and human a3, a6 and a7. D. 
melanogaster include a group of receptors not present in vertebrates (PS3 
group), and vertebrates include 2 further groups not present in C. elegans, or 
D. melanogaster. These are the I/A domain integrins (so-called because of an 
extra domain in the a subunit that is thought to be associated with collagen 
binding), and a second group comprised of two members, integrin a4 and a9 
(Hughes 2001).
Hughes (2001) reported a possible mechanism for the growth in numbers of 
the members of the integrin families. The original laminin and RGD integrins 
present in Drosophila and vertebrates may have undergone a series of linked 
duplications: One ancestral pair of laminin (PS1) and RGD (PS2) integrins 
could have both been duplicated onto another chromosome (chromosome 17 
in the human) -  giving rise to integrins a3 and allb. The original pair could 
then have been duplicated once more giving rise to chromosome 2 integrins 
a6 and aV, and to chromosome 12 integrins a7 and a5 (Hughes 2001).
The family trees of the integrin a and (3 subunits has been described (Hughes
2001). A simplified version showing only the human a integrins (figure 1.14), 
and p integrins (figure 1.15) is shown here.
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Figurel .14: Phylogenetic relationship of human integrin a  subunits 
is. Adapted from Hughes et al 2001. WBC, white blood cell.
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Figure 1.15 : Phylogenetic relationship of human integrin p subunits. 
Adapted from Hughes et al 2001.
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Integrins expressed in the bladder
DSMC integrins
Integrins expression in the human bladder detrusor has been described by 
(Wilson et al 1996). This was a descriptive study only using 
immunohistochemistry (IHC), using samples of tissue obtained from an adult 
human cystectomy, and a normal post-mortem bladder. These specimens 
were probed using antibodies to integrin a3, a5, av, av|33, (31, (33 and |34.
Fibronectin was expressed in the basal lamina of DSMC, with immunostaining 
of the DSMC strongly for a5, and integrin (31, with and weak to moderate 
staining for av and av|33 antibodies. Similarly, there was strong 
immunostaining of the DSMC basal lamina for a generic laminin antibody, and 
weak to moderate immunostaining for integrin a3. a6(34, although only the (34 
component was examined, is the integrin that forms hemidesmosomes in 
epithelia and endothelia, and this was the pattern described by the authors in 
this paper. There was no (34 immunostaining of the detrusor muscle, only 
epithelial basement membrane.
Integrin (33 has been shown by analysis of mRNA to be expressed in the fetal 
murine bladder (Le Gat et al 2003).
Urothelial integrins
The bladder urothelium was shown to express integrin a3, some integrin av, 
integrin (31 and p4 strongly in immunohistochemistry performed on adult
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human bladder (Wilson et al 1996). There was no staining of the urothelium 
with an antibody to integrin a5. Southgate et al (1995) report that in 
urothelium, integrin a2(31, a3p1 are expressed in all layers of the urothelium, 
whereas a6p4 and av|34 are expressed in the basal lamina. In cell culture, 
these urothelial cells expressed integrin a5|31 (Southgate et al 1995). Similarly 
it has been shown that adhesion of cultured urothelial cell lines including 
HCV29 (a non malignant urothelial cell line held by the Polish Academy of 
Sciences) to laminin is blocked by antibodies to integrin subunits a3 and pi; 
to fibronectin by antibodies to a5 and a3; but that anti-a3 antibody increased 
adhesion to collagen IV (Litynska et al 2002). Normal integrin a6p4 
expression in urothelial bladder cancer has been correlated with improved 
long-term patient survival (Grossman et al 2000). Conversely, loss of integrin 
p4 expression in specimens of human bladder carcinoma significantly 
correlated with tumour grade (Mialhe et al 1997).
Cell shape and fate
Physical factors such as the space a cell occupies (cell shape), and degree of 
mechanical stretch can alter cell fate. It has been demonstrated that the 
degree of spread of a cell can influence cell survival, independently of the 
area of contact between ligand (fibronectin) and receptor (p1 integrin) (Chen 
et al 1997). The degree to which cells can spread has also been shown to 
influence differentiation: mesenchymal cells limited in their ability to spread do 
not differentiate, but if allowed adequate space will differentiate into smooth 
muscle cells (Yang et al 1999).
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Mechanical stretch and normal development of the bladder
Integrins as mechanoreceptors
How is mechanical stretch detected by cells? It has been demonstrated that 
integrins can act as mechanotransducers (Chicurel et al 1998; Alenghat and 
Ingber 2002). The degree of stretch of human detrusor cells in culture 
(obtained from a 2 year old boy undergoing ureteric reimplantation) has been 
shown to influence whether cells undergo hypertrophy or proliferation (Orsola 
et al 2002). That integrins are important in this response has been shown by 
the inhibition of the proliferative response to stretch when RGD oligopeptides 
are added to stretched, cultured adult rat detrusor cells (Upadhyay et al
2003). Stretch-injured rat bladders also demonstrated an upregulation of 
collagen genes I and III, and of integrin sub-units including (31, (33 and av 
(Upadhyay et al 2003).
Mechanical stretch in vivo
That a degree of normal ‘physiological stretch’ is necessary for normal 
bladder growth has been demonstrated in explant and animal in vivo models. 
In an explant model of fetal rat bladder growth, sealing the urethra and ureters 
of rats’ bladders caused more normal collagen alignment, on histological 
examination of these explants (Beauboeuf et al 1998). Similarly if a fetal 
sheep bladder is bypassed by performing ureterostomies bilaterally at day 90
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of gestation, and ligating distal ureters then bladder growth is affected: 
defunctioned bladders weighed less; on histological examination there was a 
decrease in the surface area of the muscle bundles with increased amounts of 
connective tissue through out all layers and a loss of the normal muscle 
morphology as compared to controls, as assessed by histology (Matsumoto et 
al 2003).
Is it stretch, or pressure, or both?
Intravesical pressure is easily measured in the clinical setting with a urethral 
catheter. The measurement of intravesical pressure, and use of a rectal line to 
allow subtraction of intra-abdominal pressure, allows a calculation of detrusor 
pressure to be made. The pressure and volume of a bladder (radius) will 
determine the wall tension (LaPlace’s law for spheres, wall tension=(pressure 
x radius)/wall thickness), so stretch has been used in cell culture to mimic this 
effect (Baskin et al 1993a; Upadhyay et al 2003).
However, Haberstroh et al have reported that hydrostatic pressure itself (in 
the absence of stretch) can modulate DSMC behaviour in culture (Haberstroh 
et al 1999). These DSMC were harvested from neonatal lambs, and passaged 
between 3 and 5 times. DSMC grown under even moderate hydrostatic 
pressures of 4 to 8 cm of water induced a proliferative response, at least in 
part mediated by a soluble mitogenic factor (Haberstroh et al 1999). 
Furthermore, exposure to hydrostatic pressures of 20 cm or 40 cm of water for 
24 hrs has been shown to result in cultured human DSMC upregulating matrix 
metalloproteinase -1 (MMP-1) and over 7 days down regulation of MMP-2 and
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MMP-9. Simultaneously there was an upregulation of tissue inhibitor of matrix 
metalloproteinase (TIMP), an inhibitor of MMPs. Taken together this could 
mean a decrease in the breakdown of extracellular matrix components, and a 
possible mechanism for increased connective tissue deposition (Backhaus et 
al 2002). When cultured ovine DSMC are simultaneously stretched (25% 
strain) and exposed to pressures of 40cm water then HB EGF and collagen III 
transcripts were both significantly upregulated (Haberstroh et al 2002). None 
of these pressure studies, however, used fetal DSMC. Indeed, the only study 
to examine stretch in cultured fetal DSMC has been Baskin et al (1993), which 
used fetal bovine DSMC.
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Origins of connective tissue
Connective tissue and the cells that produce it
The basal lamina and interstitial collagens are produced by the cells 
embedded in them (Alberts et al 1994). Myofibroblasts are capable of 
producing collagens (e.g. collagen I, III, IV) as well as laminins and fibronectin 
(Gabbiani 2003). In a similar manner, bovine fetal detrusor smooth muscle 
cells in culture have been shown to produce collagens I, III and IV, and 
fibronectin (Baskin et al 1993b).
A hypothetical feedback loop is possible (figure 1.16A): the local basal lamina 
is secreted by the developing fetal smooth muscle cells, which in turn 
influences the behaviour and fate of the cells which produced it. Fibronectin 
as discussed above has been associated with a synthetic and proliferative 
phenotype in vascular smooth muscle cells. It can be speculated that further 
production of fibronectin might reinforce this proliferative, synthetic phenotype. 
However laminins have been associated with a contractile smooth muscle 
phenotype that no longer produces any ECM. What is the signal for this 
change? When do cells stop reinforcing their synthetic phenotype by down 
regulating fibronectin? Other factors such as growth factors and cytokines, 
physiological stretch, and the geometric shape, may play a role in modifying 
the genetic programme that the cells are following (figure 1.16B).
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Figure1.16: Connective tissue cells make matrix, which in turn modifies 
cell behaviour (A) Connective tissue cells make matrix. (B) the matrix 
substrate and the space into which cells can expand are important factors 
in determining cell behaviour, and ultimately differentiation and fate.
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Soluble growth factors involved in bladder development
Normal patterning
Cell-cell interactions are vital in determining patterning during embryonic 
development. Many of these interactions are controlled by signalling proteins 
such as the hedgehog group of peptides. There are three members of this 
group Desert, Indian and Sonic hedgehog (Dhh, Ihh, and Shh). Shh can act 
as a morphogen in a dose dependent manner -  inducing differentiation in 
target cells, but is also capable of acting as a mitogen -  inducing a 
proliferative response (Bitgood and McMahon 1995).
Shh binds to the cell surface receptor patched (Ptch) which in turn stops Ptch 
from inhibiting/binding to smoothened (Smo) -  another transmembrane 
protein. Smo can then dissociate from Ptch and activate downstream 
intracellular signalling pathways - including the upregulation of BMP-4. The 
presence of Shh in the developing epithelium of the urogenital sinus in fetal 
mice from embryonic day 11.5 has been demonstrated by (Bitgood and 
McMahon 1995). Similarly bone morphogenic protein -  4 (BMP-4), a down­
stream signalling element, is present in the surrounding mesenchyme 
(Bitgood and McMahon 1995). Homozygous knockout mice express anorectal 
malformations (Mo et al 2001). Similarly in the ureter, Shh is expressed in the 
urothelium, with Ptch expressed in the mesenchyme subjacent to this, with 
BMP-4 induced as a result (Yu et al 2002).
Yu et al have gone on to suggest a model for ureteral smooth muscle 
maturation whereby Shh has a morphogenic and mitogenic effect: 1)
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expressed by the ureteral urothelium acts through Ptch to induce Bmp-4 
expression which causes smooth muscle differentiation in the smooth muscle, 
but 2) that this differentiation is inhibited by the local effect of Shh, whilst 3) 
Shh acts locally as a mitogen to cause proliferation of the mesenchymal cells 
that are the smooth muscle progenitor cells (Yu et al 2002).
Vascular endothelial growth factor (VEGF) is present as are its receptors 
VEGF receptors 1 and 2 (VEGFR1, VEGFR2) in murine fetal bladders at E14 
and E18 (Burgu et al 2006). Exogenous VEGF increases endothelial cell 
growth, but also increase DSMC growth, and decreases DSMC apoptosis in 
fetal murine bladder explant culture (Burgu et al 2006), an effect inhibited by 
adding VEGFR1/Fc, a blocker of VEGF. This work was done using the fetal 
bladder explant model established in this thesis.
Response to stretch
Soluble factors have been implicated in the response of DSMC to stretch in 
cell culture. Angiotensin II has been implicated in the response of cultured 
DSMC to stretch -  acting in a paracrine fashion, through angiotensin II 
receptors, to cause release of heparin-binding epidermal growth factor-like 
growth factor (HB-EGF) (Park et al 1998). Mice deficient in angiotensinogen 
converting enzyme, angiotensin II and angiotensin II receptor I deficient mice 
have hydronephrosis with poor muscle development in the renal pelvis and 
ureter (Yosypiv et al 2006). Angiotensin II receptor 1 null mutant mice develop 
renal failure, massive hydronephrosis with deficient smooth muscle of the 
renal pelvis and ureter. In organ culture, these mutants are resistant to
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angiotensin II (Yosypiv et al 2006).
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Congenital bladder outflow obstruction
Causes of fetal bladder outflow obstruction
Bladder outflow obstruction in the fetus can be mechanical or functional in 
origin. Mechanical causes include conditions that may occur in the male 
posterior urethral valves (PUV), conditions which may occur in either sex such 
as urethral atresia, BOO due to an ectopic ureterocele, and female pseudo­
prune belly syndrome (associated with urethral atresia). Functional 
obstruction may occur when the bladder fails to empty either because of 
smooth muscle myopathy as in megacystis microcolon syndrome, or 
neuropathy -  although this predominantly presents postnatally. Prune belly 
syndrome may be the end-point of mechanical obstruction, or could be due to 
a primary mesodermal defect, and therefore overlaps both the mechanical 
obstruction group and the functional obstruction group (Workman and Kogan 
1990; Shimada et al 2000).
Posterior urethral valves
Posterior urethral valves are the single commonest cause of fetal BOO, 
occurring in approximately 1/4000 live male births. Furthermore, PUV are the 
single commonest urological cause of end stage renal failure in children 
(Woolf and Thiruchelvam 2001). Originally classified as type I, II or III by 
Young in 1919 -  type II valves are not now thought to be obstructive (Young 
et al 1919). Posterior urethral valves arise from the inferior edge of the 
verumontanum, and pass distally to the membranous urethra, attaching to the
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proximal part of the membranous urethra (in Young’s classification Type I 
valves), or form a ring-like membrane just distal to the verumontanum 
(Young’s type III valves) (Gonzales et al 2004). Type I valves are thought to 
arise as remnants of the distal mesonephric duct with an ectopic anterior 
insertion (Gonzales et al 2004), whereas type III membranes may represent a 
persistence of the cloacal membrane (Gonzales et al 2004). Anterior urethral 
valves occur but are rare, and often associated with an anterior urethral 
diverticulum as a result of a ruptured Cowper’s gland (McLellan et al 2004). 
Transient obstruction of the anterior urethra may occur fetally as a result of a 
syringocele arising in Cowper’s glands.
Prune belly syndrome (Triad syndrome, Eagle-Barrett syndrome)
This is a triad of absence or hypoplasia of the anterior abdominal wall 
muscles, a large, hypotonic bladder with tortuous ureters, and bilateral 
cryptorchidism (Smith et al 2004). By definition this complete form of the 
condition has to affect male fetuses only, with an incidence of 1 in 35,000 to 1 
in 50,000 live births.
There are two hypotheses for the pathogenesis of this condition: either it is 
due to over distension of the bladder (perhaps with transient fetal ascites that 
is subsequently reabsorbed), resulting in stretching and attenuation of the 
musculature, and a blockage to normal descent of the testes; alternatively it 
may be due to a primary defect of the mesoderm during embryogenesis 
(Shimada et al 2000). Gestation may proceed without complication, but 
oligohydramnios is common. The urethra may be hypoplastic, but 
megalourethra may also occur (Smith et al 2004). Weber et al (2005) describe
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a consanguinous family in which four boys were born with PUV, one of the 
boys also having Prune belly syndrome. There was a normal daughter in this 
family.
Female pseudo-prune belly
Although prune belly syndrome strictly is a male syndrome, the term pseudo­
prune has been applied to females with laxity of the anterior abdominal wall 
musculature, although they often do not have severe urological abnormalities 
these may coexist (Smith et al 2004). Of nine prune belly syndrome fetuses 
(Shimada et al 2000) found that five were male, two female and two were of 
indeterminate sex. Reinberg et al (1991) described seven female patients with 
the female equivalent of Prune belly syndrome. Urethral atresia was common 
in these cases and may have been central to the pathogenesis of the 
condition.
Urethral atresia
Urethral atresia occurs either when there is a complete obstruction of the 
urethra by a membrane, or when the urethra has failed to form. The urethra 
distal to the obstruction is hypoplastic as it has never been dilated by the 
passage of urine. In males this membrane is distal to the prostatic urethra 
(Gonzalez et al 2001). Survival is only possible if there is some 
communication from the bladder to the amniotic cavity by a vesicocutaneous 
fistula, or a patent urachus, or vesicoamniotic shunt placement (Gonzalez et
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al 2001). Very often this condition coexists with Prune belly syndrome, 
affecting both males and females (Reinberg et al 1993).
Patent urachus
The urachus, which arises from the allantois, forms a blind ending 
diverticulum of the yolk sac, and comprises part of the body stalk. During 3D 
body folding the urachus becomes incorporated into the base of the umbilical 
cord. It is associated with formation of the umbilical vessels. In the chicken 
egg amnion, and allantois remain separate (Piechotta et al 1998).
In clinically normal neonatal calves there is no urachal remnant in the 
umbilicus (Watson et al 1994), whereas there is a patent urachus passing into 
the umbilicus in newborn foals (Reef and Collatos 1988). In fetal sheep the 
urachus is patent and opens into the amniotic cavity (Nyirady et al 2002). 
There is a spectrum of urachal patency amongst different species of 
mammals at birth.
In human fetuses the urachus has previously been reported to close by 12 
week (Begg 1930). Antenatal diagnosis of patent urachus involves detection 
of a cyst of the umbilical cord -  suggestive that even when persistence of this 
diverticulum occurs, there is no communication with the amniotic cavity unless 
a pathological rupture occurs (Tolaymat et al 1997; Schiesser et al 2003; 
Shima et al 2003; Kilicdag et al 2004). At birth, the patent urachus passing 
into the umbilical cord could be divided with cutting of the umbilical cord -  
leaving a patent route connecting bladder to skin. In reviews of postnatally 
presenting urachal abnormalities, no BOO was associated (Mesrobian et al
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1997; Cilento et al 1998), although it has been described as a rare association 
with PUV (Kaefer et al 1995).
Accuracy of radiological diagnosis of antenatal bladder outflow obstruction
In currently-established clinical practice, antenatal radiological diagnosis of 
congenital BOO, which is most commonly due to PUV, depends on the 
identification of the structural features that go with this congenital 
obstruction. These include bilateral hydronephrosis, a thick-walled bladder, a 
dilated posterior urethra, and oligohydramnios. These appearances can also 
occur in urethral atresia and prune belly syndrome. It has been reported that 
only 35% of antenatally-diagnosed 'obstructive uropathy' actually had PUV (14 
of 40 patients), on postnatal imaging, cystoscopy and postmortem (Holmes et 
al 2001). Similarly Abbott et al report that after an antenatal diagnosis of PUV 
was made on the basis of megacystis and hydronephrosis (10/22 had 
oligohydramnios), only 8 of 19 followed up had confirmation of posterior 
urethral valves, and 1 had urethral atresia (47% congenital BOO) post natally. 
(Abbott et al 1998). Aspiration of fetal urine and measurement of electrolytes 
has been advocated to detect the renal impairment that may be associated 
with abnormalities of the lower urinary tract, however this is invasive and 
carries with it a risk of miscarriage and fetal death, and may also occur in a 
non-obstructed fetal urinary tract. In a recent report elevated fetal urinary 
sodium was only 44% sensitive, but 100% specific for predicting abnormally 
elevated infant creatinine and renal impairment (Miguelez et al 2006).
Similarly fetal cystoscopy has been advocated, but this has only been
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reported to be diagnostic, in one report, in five of 13 suspected cases of 
obstructive uropathy, with fetal loss in two cases soon after the intervention, 
and 2 further late deaths (Welsh et al 2003). In another report of antenatally 
diagnosed obstructive uropathy (bilateral hydroureteronephrosis, megacystis, 
dilated posterior urethra, and oligohydramnios), in whom fetal cystoscopy was 
performed, 14 of 36 had PUV, 1 of 36 had urethral atresia (42% congenital 
BOO), whereas the others did not have obstructive uropathy (Holmes et al 
2001). There was a fetal mortality rate of 43% in this series (Holmes et al 
2001).
Uncertainty of diagnosis of BOO in post mortem specimens
Fetuses could be identified from antenatal diagnosis and from postnatal 
examination and investigation. The available antenatal modalities include 
anatomical description (fetal ultrasound), fetal urine electrolyte estimation, and 
fetal cystourethroscopy. All these modalities have limitations as described 
above.
Postnatal anatomical description can be suggestive of BOO, but without 
examination of the posterior urethra histologically or by imaging either directly 
or radiologically, must be considered to be a ‘presumed’ diagnosis. The 
histological examination of the urethra is not done as part of the routine 
postmortem examination of the urethra at UCH as the yield in identifying any 
obstructive lesion is poor. Similarly post natal cystourethrograms have not 
been performed as part of the routine post mortem examination at UCH, so 
retrospective use of the specimens from this embryo bank do not have this 
information. The reliability of this investigation in the post mortem fetus has
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not been quantified. Postmortem examination of the urethra by 
cystourethroscopy has not been described.
Postnatal BOO is again suggested by an antenatal and postnatal history. 
Postnatal imaging by ultrasound examination of the urinary tract may be 
suggestive of BOO, however confirmation by radiology (micturating 
cystourethrography (MCUG)) and direct examination (cystourethroscopy) is 
necessary. MCUG can be diagnostic in many cases, but are not always 
predictive. In a recent study, abnormal MCUG predicted an infravesical 
obstruction that was only confirmed by cystourethroscopy in 76%, but 24% of 
abnormal MCUGs as assessed by a panel of radiologists and urologists were 
subsequently shown to have no infravesical urethral obstruction (de Kort et al 
2004). The ‘gold-standard’ in children has been taken to be 
cystourethroscopy, but this still includes a value judgement by the surgeon on 
whether a urethral ‘ring’ visualised is in fact obstructive. Urodynamic 
investigation (urine flow rate measurement) to diagnose BOO is widely and 
reliably used in adults, as reviewed by (Belal and Abrams 2006).
In discussing fetuses who have had a post mortem examination to determine 
the presence of BOO, if no other imaging modality is used, the term presumed 
bladder outflow obstruction (presumed BOO) will be used in this thesis.
Consequences of fetal bladder outflow obstruction
Severe BOO is associated with renal hypoplasia (Potter IV abnormality-see 
below) and dysplasia (Potter II abnormality-see below), oligohydramnios-
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pulmonary hypoplasia sequence (Potters sequence) and consequent neonatal 
death from respiratory failure, or termination of pregnancy following antenatal 
detection (Scott and Goodburn 1995; Clark et al 2003). Obstructive uropathy 
is also a leading cause of neonatal ascites (Gonzales et al 2004).
Renal dysplasia and obstructive uropathy
By 28 days of gestation in the human, the ureteric bud has branched from the 
mesonephric duct (Woolf et al 2004). Over the next few days renal 
mesenchyme condenses from the intermediate mesenchyme around the tip of 
the ureteric bud, or ampulla. Urothelium of the renal pelvis and ureter is 
derived from the ureteric bud, whereas the epithelial lining of the urogenital 
sinus gives rise to the bladder urothelium. Some of the renal mesenchyme 
undergoes epithelial conversion to form nephrons. The ureteric bud 
undergoes repeated branching: the first 6-10 branches become the calyces 
and renal pelvis, the last 6-9 divisions form the collecting ducts. Early ureteric 
branching is not associated with nephrogenesis in the human. From 8 to 15 
weeks, with each generation of branching one branch of the ampulla is 
associated with the already formed nephrons, whilst the other branch is 
associated with new nephron induction. Nephrogenesis continues up to 32-36 
weeks of gestational age, resulting in ‘arcades of nephrons in the cortical 
‘nephrogenic zone’ (Woolf et al 2004).
Potter described four types of congenital cystic kidneys (reviewed by (Woolf et 
al 2004)): Type I (autosomal recessive polycystic kidney disease (PKD)); type 
II severely dysplastic kidneys (MCDK); type III (mostly autosomal dominant
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PKD); and type IV. Type II kidneys lack of normal tissues (nephrogenic zone, 
glomeruli and collecting ducts) and instead have primitive tubules embedded 
in fibro-muscular stroma, with cartilage, and abnormal nerves and blood 
vessels. In type IV malformations, the first layers of nephrons form normally, 
but the outermost nascent glomeruli become cystic, the nephrogenic zone 
disrupted and collecting ducts are dilated. It is thought that back-pressure due 
to BOO most affects the ‘newest’ nephrons, ie those still attached to the 
ampullae, resulting in subcortical cysts. Early branching is unaffected, as are 
the first nephrons formed, so urine production is possible. In contrast, Potter 
originally described type II cystic kidneys as non-functional, but more recent 
studies have suggested that there are some functioning nephrons present, in 
which case this type may represent the most extreme end of the spectrum 
(Woolf et al 2004).
In both animal and human models early obstruction can result in severe renal 
malformations, as well as bladder distension and hydronephrosis, but later in 
gestation only bladder distension and hydronephrosis, with milder nephron 
deficits occur, as reviewed by (Aslan and Kogan 2003). In a late model of 
ureteric obstruction in second and third trimester rhesus monkeys it has been 
shown that changes of renal dysplasia occur including development of sub- 
cortical cysts (Tarantal et al 2001). Ultrasonographically demonstrated cortical 
cysts correlated with renal dysplasia (Crombleholme et al 1990), as did 
oligohydramnios, whereas maintenance of liquor volume predicted better 
renal function (Glick et al 1985).
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Response of the bladder to obstruction
In congenital uropathies, such as PUV, fetal urinary obstruction is associated 
with derangement of normal development, leading postnatally to a fibrotic, 
poorly compliant, high-pressure reservoir (the ‘valve bladder’) and renal 
impairment. In man, posterior urethral valves are the commonest single cause 
of end-stage renal failure in childhood (Woolf and Thiruchelvam 2001) and 
PUV-associated bladder dysfunction is associated with progressive damage 
of the kidneys postnatally (Parkhouse et al 1988). Postnatal renal functional 
and structural outcome is therefore apparently linked to bladder function and 
hence bladder development.
Levin et al (1997) have described a rabbit model of partial bladder outflow 
obstruction in adult rabbits, and compared these changes with those in the 
human bladder as a result of benign prostatic hyperplasia (Levin et al 2000): 
first, there is an initial hypertrophic response of the DSMC which lasts 1-14  
days; second the rabbit bladder reaches a compensated phase, during which 
bladder mass and contractility remain approximately constant, and the patient 
asymptomatic; third, there is a decompensation with deterioration in 
contractility and function. In the rabbit model the initial phase is associated 
with smooth muscle hypertrophy, increased collagen synthesis, urothelial and 
interstitial fibroblast hyperplasia. The specific triggers for decompensation are 
unknown: further increase in bladder mass may result in loss of response to 
stimulation, and progressive loss of bladder contractility. Ischaemia could be 
one of these triggers for decompensation (Ghafar et al 2002). (Levin et al
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2000) have suggested five markers associated with this decompensation: 1) 
increasing muscle mass, 2) denervation, 3) progressive decrease in 
compliance, 4) decreased sarcoplasmic reticulum calcium ATPase and 5) 
mitochondrial dysfunction. In the rabbit, end-stage decompensation may take 
two forms, a large thin walled, fibrous bladder, with large capacity, or a small, 
thick walled, poorly compliant fibrous bladder. Contractility is poor or absent in 
either case, with loss of smooth muscle cells. A change in smooth muscle 
phenotype has been described in animal models with a shift towards synthetic 
phenotype. Histological evidence for this in humans has been seen by 
connective tissue infiltration around smooth muscle cells within smooth 
muscle bundles in adult human bladders (Levin et al 2000). A similar 
histological pattern was described by Nyirady et al in an ovine model of fetal 
bladder outflow obstruction (Nyirady et al 2002;Thiruchelvam et al 2003). If 
partial BOO is created at 75 days of gestation in fetal sheep, by urachal 
ligation with partial urethral obstruction using a ring, and the fetuses are 
examined at 30 days then the bladders are grossly distended, and thin walled 
compared to sham operated controls (Nyirady et al 2002;Thiruchelvam et al
2003), consistent with decompensation as described in adult human bladders. 
If however the same model, created at around 75 days is allowed to run for 
only 9 days, then a thick-walled, hyperplastic bladder is generated (Farrugia 
et al 2006a). Similar increase in detrusor muscle mass (marked hypertophy, 
some hyperplasia), has been described in a fetal ovine model as a result of 
BOO created at 60 days (Peters et al 1992b). The fetal BOO pattern 
described by Nyirady et al and subsequently by Farrugia would be consistent 
with the changes described in the post natal rabbit model: first, an initial
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hypertrophic, hyperplastic response as (Buttyan et al 1997;Farrugia et al 
2006a, b); ultimately, if obstruction persists then ‘decompensation’ occurs 
(Buttyan et al 1997;Nyirady et al 2002;Thiruchelvam et al 2003).
Partial fetal BOO in a rabbit model results in an increase in bladder weight, 
urodynamic changes of ‘denervation hypersensitivity’ (loss of field sensitivity, 
but increased contraction when stimulated with potassium chloride or 
bethanecol), with histological changes of smooth muscle hypertrophy and 
increased connective tissue within the detrusor layer (Rohrmann et al 1997). 
This differed from the response of adult rabbit bladders to obstruction, in 
which there was increased connective tissue subserosally. However, in fetal 
bladder outflow obstruction there was a similar time-course in the response 
with compensatory hypertrophy, followed by decompensation at a variable 
time later.
In cultured human DSMC (2 year old), stretch initially resulted in increased 
protein synthesis, a ‘hypertrophic’ response, but prolonged stretch induced 
increased DNA synthesis, a ‘hyperplastic’ response (Orsola et al 2002).
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Figure1.17 : Partial bladder outflow obstruction in a rabbit model (Levin et al 
2000).
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Extracellular matrix in BOO
The change in the pattern of collagen expression has been described during 
fetal bladder development in normal and obstructed human fetal bladders by 
(Kim et al 1991a, b). In comparison between 15 normal bladders from fetuses 
between 20 and 35 weeks gestational age (GA), and ten BOO fetuses (Kim et 
al 1991b), the muscle thickness was markedly increased, with an increase in 
thick collagen fibres compared to thin fibres, as assessed by histological 
examination. Thick collagen fibres have a larger proportion of collagen I than 
collagen III, compared to thin fibres (Romanic et al 1991). There was a 
relative increase in muscle compared to collagen in the obstructed bladders 
(Kim et al 1991b). Freedman et al (1997) compared 9 fetuses with BOO (6 
PUV, 3 urethral atresias) with 10 urologically normal fetuses (GA 9-40 weeks) 
and found the bladder wall was markedly increased, but that the 
muscle/connective tissue ratio was unchanged (Freedman et al 1997). In a 
study comparing normal fetal bladders to those diagnosed with PUV and PBS, 
muscle thickness was found to be increased in the PUV group, and in a 
subset of the PBS group, compared to the rest of the PBS group and normals 
(Workman and Kogan 1990). In this series the proportion of connective tissue 
was unchanged (Workman and Kogan 1990).
In postnatal human bladders that have been obstructed either mechanically, 
or by neurogenically an increase in the interstitial connective tissue of the 
lamina propria has been described, with an increase, or infiltration of 
connective tissue between the muscle bundles, and within the muscle
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bundles, with disruption of the normal architecture in extreme cases. In a 
comparison of 9 men suffering form benign prostatic hyperplasia causing 
chronic BOO, with 8 non-obstructed controls (aged 46-73 years) no smooth 
muscle hypertrophy was described, but dense connective tissue was seen in 
the detrusor layer separating the muscle fibres, and separating the muscle 
cells in the muscle bundles (Gosling and Dixon 1980). Whereas Gilpin et al 
(1985) described 14 BOO (66-76 years) compared to 37 controls (20-72 
years), in which smooth muscle hypertrophy was histologically present in 
BOO, in comparison to the controls (Gilpin et al 1985). There was similar 
infiltration of connective tissue into the muscle bundles in BOO as described 
in the previous series (Gilpin et al 1985). In a comparison between 9 non- 
compliant neurogenic bladders (1-21 years) and 14 controls (6weeks-8years), 
there was increased expression in the detrusor of in BOO, with marked 
upregulation of collagen III, as assessed by immunohistochemistry, between 
and within the muscle bundles (Ewalt et al 1992).
Fetal DSMC are contractile, but also synthetic. Baskin et al have 
demonstrated that cultured (primary culture passaged once) fetal bovine (mid 
to late gestation) and human (3, 6 and 8 yrs of age) DSMC can produce 
fibronectin and collagens I and III in culture (Baskin et al 1993b). At an 
ultrastructural level, fetal rat DSMCs are surrounded by fibronectin fibrils (Wu 
et al 1999a), which are intimately associated with focal adhesions forming the 
‘fibronexus’ (Wu et al 1999a;Eyden 2001). Fibronectin expression peaks 
neonatally in the mouse model, as assessed by immunohistochemistry and 
Western blot (Smeulders et al 2003), and is then down-regulated with 
postnatal maturation. Murine detrusor laminin expression and is then
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upregulated, as assessed by immunohistochemistry and western blot 
(Smeulders et al 2003). Fibronectin has been implicated as a factor in normal 
collagen synthesis (Veiling et al 2002), so could be expected to also be 
expressed in the interstitial spaces between muscle bundles and in the lamina 
propria. The pattern of fibronectin expression has not been described 
however in the human fetal bladder.
Cyclical stretch of cultured mid to late gestation fetal bovine DSMC results in 
upregulation of collagen I, down regulation of collagen III and upregulation of 
fibronectin, whereas cyclical stretch of cultured urothelial cells results in 
downregulation of collagen III and upregulation of collagen I and fibronectin, 
as assessed by enzyme linked immunosorbent assays (ELISA) of protein 
levels (Baskin et al 1993a). Similarly in an adult rat model in which bladders 
were transurethrally over-distended, collagen I mRNA transcription was 3 fold 
decreased, whereas collagen III was upregulated 2.5 fold (Capolicchio et al
2001). Whereas (Upadhyay et al 2003) have described in vivo distension of 
rat bladders resulting in upregulation of both collagen I and collagen III mRNA 
(Upadhyay et al 2003).
Fibronectin is a signal for cardiac smooth muscle cell hypertrophy (Chen et al
2004). It can be postulated in fetal partial bladder outflow obstruction that 
fibronectin would initially be increased as bladder hypertrophy and 
hyperplasia occurred. In decompensation there might be infiltration of the 
muscle bundles and loss of DSMC, with a loss of their basal lamina 
fibronectin.
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Another mechanism altering fibronectin expression might involve over-stretch 
of the lamina propria causing tissue damage. This could be associated with 
expression of a primary injury matrix with deposition of fibronectin and fibrin, 
which in turn could be associated with activation of fibroblasts to 
myofibroblasts and a wound healing response. In the lamina propria, and 
between the muscle bundles increased collagen synthesis could be expected 
to occur, as in other models of fibrosis, such as in pulmonary fibrosis and liver 
fibrosis (Gabbiani 2003).
The consequences of human fetal BOO include three types of urodynamic 
abnormality: myogenic failure, hyperreflexia, poorly compliant (Peters et al 
1990). Particularly in the final group, the so-called ‘valve bladder’, the bladder 
becomes thick walled and fibrotic. The abnormal bladder in turn goes on to 
further compromise renal function, and can also produce incontinence. 
Abnormal matrix deposition is part of the pathological process in the 
development of this ‘valve bladder’.
It would therefore seem likely that integrin ECM interactions would be 
important in normal and pathological bladder development. It can be 
hypothesized that specifically: 1) during normal human bladder development 
DSMC would proliferate and hypertrophy in close association with fibronectin.
2) In human fetal bladder outlet obstruction, there is a spectrum of bladder 
responses from compensation to decompensation. The degree of 
decompensation would in turn be related to the severity of obstruction. 
Decompensated bladders would be associated with severe obstruction. 3) 
Detrusor hyperplasia and hypertrophy would be associated with increased
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fibronectin expression in the basal lamina. Loss of smooth muscle cells in the 
decompensated bladders would be associated with loss of the basal lamina 
fibronectin. 4) Tissue damage and activation of fibroblasts in the lamina 
propria would be predicted to be associated with increased fibronectin and 
collagen synthesis.
Conclusion
ECM is an evolutionarily ancient and preserved structure. The basal lamina 
components can influence cell fate and differentiation: it can be hypothesised 
that fibronectin reinforces the proliferative synthetic fetal smooth muscle cell 
phenotype, and laminin provides a differentiation signal favouring mature 
DSMCs. The cell surface receptors for ECM include integrins, which are also 
ancient and highly preserved molecules. There is a structural hierarchy that 
extends from the interstitial collagens to the basal lamina, through cell surface 
receptors -  predominantly integrins -  to the cytoskeleton of the cell. Integrin 
receptors are not just structural but also mediate instructive signals from 
fibronectin and laminins respectively. Integrins can also act as 
mechanotransducers allowing normal physiological stretch to contribute to 
normal detrusor morphology and development. In pathological obstruction, 
integrin/ECM interactions may be important in determining the pathological 
response.
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ECM molecules studied in this thesis
Fibronectin
Three main lines of evidence suggest that fibronectin might play a functional 
role in bladder organogenesis: firstly, abnormalities of fibronectin null 
knockout mutants show that fibronectin may have a (non-bladder) role in 
organogenesis; secondly, the descriptive work demonstrating presence and 
developmental regulation of fibronectin in murine bladder development; 
thirdly, VSMC culture experiments using different substrates, such as 
fibronectin and laminin modulate the phenotype of these cultured cells.
1) Fibronectin null knockout mouse mutants
That fibronectin is essential for normal embryogenesis can be seen by the 
lethal nature of homozygous fibronectin null knockout mice. These mutants 
have mesodermal abnormalities that cause lethality at around the time of 
implantation (embryonic day 8.5). This is before the bladder is recognizable 
as a distinct structure so these mutants are not specifically informative for 
bladder development (George et al 1993).
2) Descriptive studies of fibronectin expression in developing murine bladder
Work by Smeulders et al (2003) has demonstrated that fibronectin is present 
in the detrusor of fetal murine bladders, and that this ECM protein is 
upregulated antenatally then downregulated postnatally.
3) Cell culture experiments
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Fibronectin can modify the behaviour of vascular smooth muscle cells 
(VSMC) grown in culture. These VSMC become proliferative and synthetic 
(Thyberg and Hultgardh-Nilsson 1994;Morla and Mogford 2000) in the 
presence of fibronectin.
Laminin
That laminin might play a functional role in maturation of DSMC is suggested 
by several lines of evidence: 1) cell culture work; 2) descriptive studies of 
murine bladder development; 3) differentiation of mesenchymal cells in 
murine lung bud; 4) role of laminins in skeletal muscular dystrophy.
1) Cell culture experiments
VSMC in culture become less proliferative, and more contractile when 
cultured on laminin (Thyberg and Hultgardh-Nilsson 1994; Morla and Mogford
2000).
2) Descriptive studies of mouse bladders
Work by Smeulders et al (2002, 2003) has shown that maturation of DSMC 
during development is associated with generic laminin upregulation.
3) Laminin-1 and laminin-2 in the developing lung bud
Based on Schuger and colleague’s work (1997) laminin-1 is initially expressed 
at the interface between the primitive epithelium and mesenchyme in the lung- 
bud (Schuger et al 1997), and influences subsequent differentiation of the
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mesenchyme into smooth muscle, with expression of laminin-2 and 
reinforcement of the smooth muscle phenotype (Relan et al 1999).
4) Muscular dystrophy
Colognato et al (1999) have shown that laminin polymerization is a key step in 
the development of basal lamina, that this is receptor mediated, and that 
COOH terminal domains, and the receptors that bind them are crucial in this. 
Human and mouse muscular dystrophy is associated with mutations in 
laminin genes (Yurchenco et al 2004b).
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Candidate integrin receptors studied in this thesis
Candidate fibronectin integrin receptor
Possible candidates include integrins a 4 p i, a 5 p i,  avp3, a8p1. Integrin allbp3  
is predominantly a platelet expressed integrin although ectopic expression 
has been described in tumours. Integrin a 5 p i is the archetypal fibronectin 
receptor and important not just in ligation of fibronectin, but also in 
fibrillogenesis. For these reasons it was the candidate fibronectin receptor 
studied in this thesis.
Candidate laminin integrin receptor in detrusor
From preliminary results reported in Chapter 5 and the review of laminin 
subunits described above, receptors for laminin 1 (a ip iy 1 )  G domains (i.e. 
integrins a 6 p i and a 7 p i)  and laminin 2 and 4 (a2p1y1 and a2p2y1) G 
domains (i.e. integrin cx3p1, a 6 p i and a 7 p i)  would be appropriate choices. In 
the Appendix preliminary immunohistochemistry results for integrin a6  
immunostaining are described. No immunostaining was found in the 
developing murine detrusor layer. Integrin a 7 p i was therefore chosen as the 
candidate integrin laminin receptor for this thesis.
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Chapter 2. Hypotheses and Experimental strategy
Overall Hypothesis
Fibronectin acting through a candidate integrin receptor (integrin a5(31) may 
be important during bladder smooth muscle development in that it may 
maintain fetal smooth muscle cells in a proliferative phenotype. Laminins 
acting through a candidate muscle laminin receptor integrin a7p i, may induce 
a maturation response, and might help maintain adult smooth muscle cells in 
the differentiated form.
Specific hypotheses
Study 1 (Chapter 5): Analysis of expression of adhesion molecules fibronectin 
and laminin-1/2 and their candidate receptors during fetal mouse bladder 
development
Hypothesis: During murine bladder development, the candidate fibronectin 
receptor integrin a5|31 may be expressed by detrusor smooth muscle cells 
(DSMC), and that laminin 1/2 candidate receptor integrin a7 may be 
expressed by DSMC.
Background: In order for a ligand and receptor to interact, their expression 
should temporally and spatially overlap, i.e. they need to be in the same place 
at the same time to allow a response to occur. If these putative ligands 
(fibronectin and laminin-1 or lamini-2) are not expressed in the basal lamina of
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the DSMC, and these DSMC do not express the putative receptors (integrin 
a5p1 and a7|31) then the hypothesis is disproved.
Aims: 1) To examine if expression of candidate fibronectin receptor integrin 
a5|31 occurs in mouse bladders during fetal development and postnatal 
maturation by immunohistochemistry; and to further quantify this protein 
expression by using Western blots, or flow cytometry. 2) Determine if laminin 
1/2 are expressed in the basal lamina of DSMC, and if this coordinates with 
the candidate receptor integrin a7(31.
Study 2 (Chapter 6): Functional interaction between DSMC and fibronectin 
matrix in cell culture.
Hypothesis: In Vitro DSMC may adhere to fibronectin, possibly modifying cell 
behaviour, and that this adherence may be mediated by the candidate 
fibronectin receptor integrin a 5 p i.
Background: That fibronectin is present in ECM of fetal DSMC during murine 
bladder development has been shown by (Smeulders et al 2003).
Furthermore bovine DSMC are capable of secreting fibronectin in cell culture 
(Baskin et al 1993b). In cell culture vascular SMC adhere to fibronectin and 
become proliferative and synthetic on this substrate (Morla and Mogford 2000; 
Thyberg and Hultgardh-Nilsson 1994). Bourdoulous et al (1998) has shown 
that for endothelial cells and fibroblasts, fibronectin is necessary for cell cycle 
progression and proliferation. Hornberger et al (2000) has shown that 
adhesion dependent EGF stimulated growth of human fetal myocytes is 
enhanced by stimulation of integrin a5(31. Nguyen et al (2005) have shown
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that p i integrins including integrin a5p1 are important in airway smooth 
muscle growth on collagen I, or fibronectin substrate. Could there be a 
functional interaction between the fibronectin and fibronectin receptor integrin 
a5p1, and modulation of proliferation of these murine DSMC?
The strategy of this chapter was to use whole bladders disaggregated into a 
bladder cell suspension. The cells in suspension would therefore closely 
resemble those from the in vivo bladder. Using this heterogenous suspension 
of detrusor, connective tissue, vascular and urothelial cells the following 
aspects could be examined: 1) did bladder cells stick to fibronectin; 2) what is 
the nature of these cells, this would be examined by immunocytochemistry: 
are DSMC cells adhering, as demonstrated by smooth muscle markers such 
as aSMA and desmin; and do these cells express the candidate integrin 
receptor a5|31; 3) what is the nature of the effect of fibronectin adhesion on 
these cells with regards proliferation; 4) can adhesion of these cells be 
inhibited either by antibody blocking the fibronectin, or by use of RGD 
oligopeptides to block the integrin binding site for fibronectin.
Aims: 1) to examine adhesion of disaggregated bladder cells from fetal and 
mature murine bladders to a fibronectin substrate, 2) characterise these 
adherent cells. 3) Examine any proliferative effect that fibronectin adhesion 
may have on fetal bladder cells. 4) Examine any effect blockade of 
fibronectin/integrin interaction may have on adhesion of cells from whole 
bladder suspensions.
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Study 3 (Chapter 7): Mouse fetal bladder explant fibronectin blocking 
experiment.
Hypothesis: Fibronectin-integrin interactions in ex vivo bladders may be 
important in modulating DSMC development.
Background: Two strategies are possible for the examination of the role of 
ECM and integrin interactions in-situ in whole bladder development: first 
examination of the phenotype of null mutant mice lacking these genes in vivo; 
second, using ex-vivo organ culture. Unfortunately null mutant mice for 
fibronectin, integrin a5 and (31 are embryonically lethal before bladder 
development occurs, and are therefore not informative. Embryonic bladder 
organ culture has not, however, been used to specifically examine 
fibronectin/integrin interactions, although a comparable, metanephric, model 
has been used to study the role of matrix using blocking antisera (Zent et al
2001). The functional role of fibronectin and integrin receptors in branching 
morphogenesis have also been studied in mouse salivary gland explants 
(Sakai et al 2003). Cell culture has been extensively used to examine the 
effects of different ECM substrates on cell behaviour, but recreating the 
mesenchymal-epithelial interactions that occur during bladder development 
and the 3D ECM is difficult. Using an explant model of mouse bladder 
development is a novel strategy to explore the functional relationship between 
matrix, integrins and DSM development. This would allow mesenchymal- 
epithelial reciprocal induction to occur, and would have the correct progenitor 
cells embedded in their native 3D matrix. Generating these 3D arrangements 
and interactions in cell culture would be challenging.
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Aims: 1) Generate a fetal bladder explant model; 2) use this model to 
investigate the effect of disrupting fibronectin-integrin interactions on fetal 
bladder DSMC development.
Study 4 (Chapter 8): Fibronectin expression in normai and pathological 
development of human fetal bladders
Hypothesis: Fibronectin may be expressed in the basal lamina during normal 
human fetal DSMC development; furthermore altered fibronectin expression 
might be implicated in detrusor smooth muscle pathology in human bladder 
outflow obstruction (presumed BOO), and correlate with dysmorphogenesis of 
the whole urinary tract.
Background: Fibronectin is upregulated in the ECM of fetal murine DSMC 
(Smeulders et al 2003), which are proliferative (Smeulders et al 2002). This 
leads to questions about the expression of fibronectin in human bladders; 1) is 
fibronectin expressed in the basal lamina of fetal human bladders? 2) What 
the pattern of expression of fibronectin and the morphology of these bladders 
in obstruction? 3) How does normal development and development of the 
urinary tract (kidneys and bladder) in obstruction differ? In order to be able to 
compare the normal and obstructed kidneys and bladders a measure of renal 
dysplasia (renal dysplasia score) needs to be generated, as does a scoring 
scheme for muscle abnormality in the bladder (muscle dysmorphology score).
Ethical committee approval to identify normal and abnormal human fetuses 
(diagnosed as having congenital bladder outflow obstruction on post mortem)
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from the human embryo bank held at UCH by Dr R Scott, was sought from 
University College, London. Information from the post mortem certificates, and 
from IHC examination of the urinary tracts (bladders and kidneys) could be 
used to answer these questions.
Aims: 1) Demonstrate if fibronectin is expressed in human fetal bladders, and 
to correlate this with gestational age, and measures of cell turnover. 2) 
Describe the abnormal pattern of muscle, and possible fibronectin expression 
in fetal presumed BOO and to compare this with normal development.
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Chapter 3. Materials
Mouse tissue
The mouse strain used in this study was the CD1 mouse from Charles River. 
This is a wild-type mouse strain. Bladders were harvested from timed mated 
CD1 mice, where the time of finding the plug was taken as the start of 
gestation (EO). Embryonic bladders from day 14, 16 and 18 of gestation, 
postnatal day 1 (D1) and 6 weeks of age (6Wks) were harvested, and the 
specimens separated into male and female sex. For fetuses the male and 
female gonads are distinctly different at E14: the testis is ovoid and ‘striped’, 
whereas the ovary has greater longitudinal length and is not ‘striped’. 
Postnatal animals can be differentiated by examination of the perineum: in 
males the urethral meatus and the anus are widely separated, whereas the 
urethral meatus and anus are close together in the females. All animals were 
sacrificed by cervical dislocation, under Schedule 1 of the Animals Act (1987), 
this was initially covered by Prof AS Woolfs informal license, then by my own 
personal license.
Human fetal tissue
Human fetal material came from the archive held by Dr R. Scott (Consultant 
Fetal Pathologist) at University College Hospital, London. This work was
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covered by local ethical committee approval (UCH/UCLH joint research ethical 
committee 03/0080). Fetuses with presumed bladder outflow obstruction 
(BOO), and morphologically normal controls, were identified from the 
database held by Dr Scott. Cases which had appropriate consent for scientific 
examination were used in this study. Annonymised post mortem reports were 
obtained for each case, kidney slides were examined, and sections of formalin 
fixed, paraffin embedded bladder were obtained for each case.
Normal unmacerated fetuses were identified from the database. Twelve 
normals were initially identified, with gestational ages from 16-30 weeks. Four 
were spontaneous abortions, five had been still births and 3 were terminations 
of pregnancy for intra-uterine death. All these fetuses were morphologically 
normal. Data from the post-mortem forms is detailed in table 3.1.
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Table 3.1: Morphologically ‘Normal’ human fetuses
Number Sex GA Cause of Delivery Associated Anomalies
1 M 16 SA Nil
2 F 16 TOP - IUD, Chorioamnionitis Nil
3 M 18 SA Nil
4 M 20 SA - Chorioamnionitis Nil
5 F 20 SA Nil
6 M 21 TOP - IUD Nil
7 M 24 SB Nil
8 M 26 SB - Chorioamnionitis Nil
9 F 27 SB IUGR
10 F 28 SB Nil
11 M 30 TOP - IUD IUGR
12 F 31 SB Nil
SA -  Spontaneous abortion, SB -  Still Birth, TOP -  Termination of pregnancy, IUD -  Intra-uterine death, 
IUGR -  intra-uterine growth retardation
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Fetuses which had evidence of prune belly syndrome were excluded, as were 
isolated urethral atresias. No specific attempt had been made either to 
demonstrate the obstructing valve histologically, or to demonstrate obstruction 
on a post-mortem cystogram. Instead macroscopic examination, looking 
particularly for a wide-open bladder neck, and dilated posterior urethra (an 
equivalent of the antenatal ultrasound ‘keyhole’ sign, as used in some series 
to define infravesical bladder outflow obstruction (Welsh et al 2003)), was 
used to diagnose these fetuses. These specimens were analysed 
retrospectively, so this clinical description was all that was available for 
analysis. The diagnosis of bladder outflow obstruction is therefore presumed, 
and so the term presumed BOO is used in this thesis.
Fetuses with a diagnosis of bladder outflow obstruction were identified from 
the database. Three ‘prune belly’ fetuses were also identified (2 male, 1 
female), and two urethral atresias were found (1 male, 1 female). These were 
not included in the obstructed group, and have not been analysed further.
The indications, as detailed in the post mortem forms, for the decision leading 
to termination of pregnancy have been listed in table 3.3. These included: 
possible bladder rupture; oligohydramnios and bilateral 
hydroureteronephrosis; bilateral hydroureteronephrosis and megacystis; 
megacystis with hydrops; hydroureteronephrosis with increased renal 
echogenicity (suggests renal dysplasia) with a thick-walled bladder; 
oligohydramnios, ascites, hydronephrosis and megacystis; bilateral 
hydronephrosis, oligohydramnios and trisomy 21; and megacystis with
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megaureters. The post mortem findings for these fetuses are described in 
table 3.2, and reflect the pathologists’ interpretation of the gross appearances 
of the specimens, and any postmortem imaging performed.
147
Table 3.2: Human fetuses with presumed bladder outflow obstruction
Number Sex GA
Cause
of
Death
BOO Bladder Ureters Kidneys/Ureters Associated anomalies
1 M 18 TOP Sub-total
PBOO
distended, thick 
wall
dilated, left VUR normal kidneys, no 
hydronephrosis
single umbilical artery
2 M 18 TOP PBOO thickened wall, 
PUV
gross distension gross
hydrourteronephrosis
Pulmonary hypoplasia
3 M 18 TOP PBOO thickened wall, 
distended
No comment hydronephrotic,
dysplastic
hypospadias, 
imperforate anus, 
micrognathia. Low set 
ears
4 M 19 TOP PBOO distended, thin 
walled
mild distension mild hydronephrosis, 
renal dysplasia
hydrops
5 M 2 0 TOP PBOO thick walled, 
distended
distended hydroureteronephrosis, 
dysplastic kidneys
6 M 21 TOP PBOO distended bilaterally
dilated
hydronephrotic,dysplas 
tic kidneys
bilateral talipes
7 M 2 2 TOP PBOO distended, thick 
walled
bilaterally 
dilated and 
tortuous
hydronephrotic, 
dysplastic kidneys Trisomy 21
8 M 24 TO P-
IUD
PBOO thick walled mega-ureters cystic dysplasia, left 
kidney, hydronephrosis 
right kidney
dilated urachus
PBOO -presumed bladder outflow obstruction; TOP -  termination of pregnancy; VUR -  vesico-ureteric reflux; GA -  gestational 
age; IUD -  in utero death
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Table 3.3: Clinical indications leading to termination of pregnancy.
Fetus GA Reason for TOP / Delivery
1 18 ?ruptured bladder. (Not ruptured at PM), left VUR, right megaureter,
2 18 probable PUV, Oligohydramnios and right hydro-ureteronephrosis 16/40, left hydro- 
ureteronephrosis 18/40
3 18 bilateral hydronephrosis, hydro-ureter and distended bladder
4 19 distended bladder in utero with hydrops
5 2 0 dilated ureters, increased renal echogenicity, thick-walled bladder
6 21 severe oligohydramnios, ascites, enlarged bladder and hydronephrosis
7 2 2 bilateral hydronephrosis, oligohydramnios and Trisomy 21.
8 24 IUD megacystis and mega ureters
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Reagents
2-mercaptoethanol (M6250, Sigma)
5-bromo-2-deoxyuridine (BrdU) kit (1444611, Roche Diagnostics GMBH, 
Mannheim, Germany)
ABC horse-radish peroxidase detection kit (K0355, DAKO)
Acetone (15296, BDH)
Acrylamide (A3699, Sigma)
Alcohol (Ethanol, UN1170, Hayman)
Ammonium persulphate (A-7460, Sigma)
Animal research kit (ARK) (K3954, DAKO)
Anti-mouse IgG, FITC conjugated (11-4011-85, eBioscience)
Aprotonin (Protease inhibitor bovine lung) (A-6279, Sigma)
Bicinchoninic acid (BCA) protein assay (23227, Pierce, Perdio Science UK 
Ltd, Cheshire, UK)
Bovine serum albumin (fraction V) (A-2153, Sigma)
Bromophenol blue 
Butanol (100616J, BDH)
Calcium Chloride (C5080, Sigma)
Citifluor (Glycerol/PBS) (AF1, Citifluor, London, UK)
Citric Acid (C0759, Sigma)
Collagenase A (103 578 Roche Diagnostics GMBH, Mannheim, Germany) 
Cytotoxicity detection kit (1 644 793 Roche Diagnostics GMBH, Mannheim, 
Germany)
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Diaminobenzidene (DAB) (K3466, DAKO)
Dispase (17105, GIBCO)
DMEM/F12 (31330-038, Gibco/lnvitrogen)
DNase I (1 284 932 Roche Diagnostics GMBH, Mannheim, Germany)
DPX (360294H, BDH)
Enhanced chemiluminescence reagent (ECL) for Western Blotting (RPN 
2106, Amersham Bioscience, Buckinghamshire, UK)
Envision kits (anti mouse IgG labelled polymer K4006, anti-rabbit IgG labelled 
polymer K4011, DAKO)
Fat-free milk powder (Marvel) (Premier foods Ltd, Spalding, Lines, UK)
Fetal calf serum (01020-160, Gibco BRL)
Fluorescent TUN EL detection kit (1 684 795 Roche)
Glycerol (G5516, Sigma)
Glycine (G8898, Sigma)
Goat anti-rabbit IgG (P0448, DAKO)
Goat anti-rabbit IgG FITC conjugated (65/6111 Zymed)
Goat ant-mouse IgG conjugated with TRITC (SC2092, Santa Cruz)
Goat ant-rabbit HRP conjugated (P0448 Dako)
Haematoxylin (Mayers) (MHS-32, Sigma)
Haemocytometer (962-9 Sigma Brightline Z35)
Hanks’ balanced salt solution (HBSS; 14170-088; Gibco BRL)
Histoclear (HS-200, RA Lamb)
Hydrogen Peroxide (H1009, Sigma)
Hybond C nitrocellulose membrane (RPN 303C, Amersham)
Insulin, selenium and transferrin supplements (ITS) (13146, Sigma)
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L15 Leibowitz medium (11415-049, Gibco/lnvitrogen)
Lab-tek 4 chamber slides (177399), 8 chamber slides (177402, Nunc Nalge 
International, Naperville, Illinois, USA)
Magnesium Chloride (M8266, Sigma)
Methanol (65548, Fluka Chemikon)
Methylene blue (180-8, Sigma)
Milli-Q water
Monoclonal mouse ant-human PGP 9.5 (13C4, Ultraclone, Isle of Wight, UK) 
Monoclonal mouse anti-human Ki67 MEB-1 (M7240, DAKO)
Monoclonal mouse anti-human p-actin (A5441, Sigma)
Mouse anti-integrin a7 monoclonal antibody (3C12, MBL, Japan) 
N,N,N-N-tetramethylethylenediamine (TEMED) (T9281-Sigma)
Nonidet P40 (NP40) (NP-40 alternative, 492016, Calbiochem)
O.C.T Tissue Tech (4583, RA Lamb, Eastbourne, Sussex, UK) 
Phenylmethanesulfonyl fluoride (PMSF) (P7626, Sigma)
Phosphate buffered saline (PBS) (BR0014G, Oxoid, Basingstoke, UK) 
Ponceau S (P7170, Sigma)
Proliferative cell nuclear antigen (PCNA), biotinylated mouse anti-human IgG 
(555567, Pharmingen)
Propidium iodide (P4170, Sigma)
Rabbit anti-human fibronectin IgG (A0245, DAKO)
Rabbit anti-mouse fibronectin (AB2033, Chemicon)
Rabbit anti-mouse HRP conjugated (P0260 Dako)
Rabbit anti-mouse integrin a5 -  gift Dr K. Hodivala Dilke 
Rabbit anti-mouse integrin pi -  gift Dr K. Hodivala Dilke
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Rabbit anti-mouse integrin (33 -  gift Dr K. Hodivala Dilke 
Rabbit immunoglobulin G ( Chemicon)
Rabbit immunoglobulin G (IgG) (15006 Sigma)
RAD - cyclo-arginine-glycine-aspartate-D-Phenylalanine-Valine (H4088, 
Bachem)
Rainbow marker (RPN 800, Amersham life Science)
Rat immunoglobulin G (IgG) (14131, Sigma)
Rat plasma fibronectin (F0635 Sigma)
RGD - cyclo-arginine-glycine-aspartate-D-Phenylalanine-Valine (H2574 
Bachem)
Sodium azide (S8032, Sigma)
Sodium chloride (S7653, Sigma)
Sodium deoxycholate (D6750, Sigma)
Sodium dodecylsulphate (SDS) (15525-017, Invitrogen)
Sodium orthovanadate (S6508, Sigma)
Tonsillar tissue -  GOSH histology department.
TRIS (T1503, Sigma)
Triton X-100 (X100, Sigma)
Trypan blue (T-8154, Sigma)
TUNEL test - Promega deadend colorimetric system (G7360, Promega) 
Tween-20 (P9416, Sigma)
Van Gieson stain
Whatman 3mm paper Chromatography (3030917, Whatman)
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Chapter 4. Methods
Study 1i: Immunohistochemistry
Frozen sections
Bladders were frozen in an optimum cutting temperature (OCT) formulation of 
water-soluble glycols and resins (Tissue-Tek) at -20°C, along with positive 
control tissue - normally a paw (see section below on positive controls), and 
subsequently cut into 8-10 pm sections using a cryostat. The sections were 
then air dried and stored at -80°C until used. Prior to staining, the slides were 
warmed and dried, then either (1 ) re-hydrated using phosphate buffered 
saline (PBS) for 5 minutes and fixed using 4% paraformaldehyde solution 
(diluted using PBS with magnesium and calcium chloride to 1mM -  PBSABC) 
for 10 minutes as described by (Hertle et al 1991); or (2) fixed using acetone 
at -20°C for 10 minutes. Following this, the slides were rinsed in PBSABC and 
wax rings were drawn around the individual sections. These were then 
permeabilised using 0.5% NP40 in PBSABC, at room temperature for 10 
minutes. Endogenous peroxidase activity was quenched with 10% H2O2 in 
PBSABC. The sections were then blocked with 0.1%-1% bovine serum 
albumin (fraction V) with 0.2% Triton X-100 in PBSABC.
Most of the immunostaining was performed using rabbit anti-mouse 
antibodies, in which case the staining is described below. However for 
antibodies raised in mice the DAKO animal research kit (ARK) was used, as 
described below.
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Test-runs were performed to find optimal dilutions of rat and rabbit primary 
antibodies (using a range 1/50 to 1/500). Primary antibody (1/100-1/200 
dilutions of 1 mg/ml), depending on type, were added to each section and 
incubated for 1 hour at 37°C, or overnight at 4°C. The antibody was tipped off, 
and the slide rinsed in PBSABC three times. The horse-radish peroxidase 
(HRP) secondary antibody (DAKO anti-rabbit P0448) was allowed to incubate 
for 30 minutes at room temperature, tipped off and the slides rinsed three 
times with PBS. Finally diaminobenzidene (DAB) was added. The reaction 
was allowed to proceed until a brown stain was visible. The slides were then 
washed in running water for 2  minutes, counter-stained with haematoxylin for 
1 minute, dehydrated by being placed in serial alcohols of ascending 
concentration, and then Histoclear for 2 minutes. Coverslips were mounted 
using DPX.
Controls
A negative control was included on each slide by substituting the primary 
antibody for a non-immune antibody of the same isotype i.e. non-immune 
rabbit immunoglobulin G for primary rabbit antibody. This was added in the 
same concentration as the optimised primary antibody.
A positive control tissue was present on each slide in the form of a paw from a 
fetus from the same time-point as the bladders had been harvested from (fetal 
and neonatal timepoints), or skin from an adult mouse. This provided skin and 
skeletal muscle positive controls for integrin expression.
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Mouse primary antibodies on mouse tissue -  immunostaining using Dako 
animal research kit (ARK)
Detecting exogenous mouse IgG in the presence of endogenous mouse IgG 
in the tissue section, may require a modified technique. If the primary antibody 
is conjugated with biotin or horse-radish peroxidase (HRP) then detection of 
the primary antibody is not confounded by the endogenous IgG.
Unfortunately, the only commercially available anti-integrin a7 antibody is 
raised in mice. The Dako ARK system obviates this technical problem: the 
primary antibody is mixed with a solution containing an excess of anti-mouse 
Fab fragments of a secondary antibody (these are biotinylated). The primary 
and secondary antibodies bind, leaving an excess of the secondary. This is 
then bound by an excess of non-immune mouse IgG. No secondary antibody 
is left to bind with endogenous mouse IgG in the histological sections when 
this solution is added to the slide. The secondary antibody is detected using 
streptavidin-conjugated HRP, and DAB as described above.
Antibody specificity
Rabbit anti-mouse integrin a5 -  gift Dr K. Hodivala Dilke, St. Bartholomew’s 
Hospital Medical School and The London Queen Mary's School Of Medicine 
and Dentistry, UK. This antibody was raised against a synthetic peptide 
equivalent to the terminal 23 amino acids of human integrin a5 subunit,
(Hynes et al 1989). This sequence (KRSLPYGTAMEKAQLKPPATDSA) is 
from the cytoplasmic tail of this integrin sub-unit.
Rabbit anti-mouse integrin (31 was a gift Dr K. Hodivala Dilke. This antibody 
was prepared against an antigen from the carboxy terminus of the integrin (31
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subunit (amino acid sequence
CREFAKFEKEKMNAKWDTGENPIYKSAVTTWNPKYEGK) (Marcantonio 
and Hynes 1988).
Mouse anti-integrin a7 monoclonal antibody (3C12, MBL, Japan). This 
commercially available monoclonal antibody was originally prepared by 
immunization of integrin a7 knockout mice with mouse myoblasts. 
Subsequently, hybridomas were produced by fusion of mouse myeloma cells 
with spenocytes from the immunized mice. The antibody was purified using 
protein-A sepharose from the hybridoma supernatant (Mayer et al 1997).
Rabbit anti-human fibronectin IgG (A0245, DAKO). This polyclonal antibody is 
commercially available, prepared by immunising rabbits using pooled citrated 
human plasma fibronectin. Cross reacting antibodies were removed by solid 
phase absorption with other human plasma proteins (A0245 DakoCytomation 
data sheet).
Rabbit anti-mouse fibronectin (AB2033, Chemicon). Rabbits were immunised 
with fibronectin purified from mouse plasma. Radioimmunoassay shows less 
than 0.1% reactivity with mouse laminin, and collagen types I, III, and IV, as 
described in the Chemicon datasheet.
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Table 4.1: Primary antibodies
Primary antibody 
(Source)
Isoform control Secondary antibody Reference
Rabbit anti-mouse 
integrin a5 (Gift K 
Hodivala-Dilke)
Pre-immune rabbit 
IgG
DAKO anti-rabbit 
P0448
(Hynes et al 1989)
Rabbit anti-mouse 
integrin (31 (Gift K 
Hodivala-Dilke)
Pre-immune rabbit 
IgG
DAKO anti-rabbit 
P0448
(Marcantonio and 
Hynes 1988)
Mouse anti-integrin 
□7 (3C12, MBL, 
Japan)
Pre-immune mouse 
IgG
DAKO ARK kit K3954 (Mayer et al 1997)
Rabbit anti-mouse 
fibronectin (AB2033, 
Chemicon).
Pre-immune rabbit 
IgG
DAKO anti-rabbit 
P0448
AB2033,
Chemicon
datasheet
HRP-labelled mouse 
anti-human Desmin 
(U7023, DAKO)
HRP labelled mouse 
anti-human a-SMA 
(U7033, DAKO)
(Skalli etal 1986)
Rat anti-mouse CD31 
(550274;
Pharmingen)
Pre-immune rat IgG Vector Biotinylated 
anti-rat, DAKO HRP- 
stretavidin
(Piali etal 1995)
Mouse monoclonal 
anti-cytokeratin 18 
(MAB3234 
Chemicon)
Pre-immune mouse 
IgG
DAKO ARK kit K3954 (Smedts et al 
1992)
Rabbit anti-human 
fibronectin IgG 
(A0245, DAKO).
Pre-immune rabbit 
IgG
DAKO Envision kit 
K4011
(Kirkpatrick and 
d'Ardenne 1984)
Biotinylated mouse 
anti-human PCNA 
IgG (555567, 
Pharmingen)
DAKO HRP-stretavidin (Smeulders et al 
2002)
(Mathews et al 
1984)
Monoclonal mouse 
anti-human Ki67 
MEB-1 (M7240, 
Dako)
Pre-immune mouse 
IgG
Dako Envision kit 
K4006
(Huuhtanen et al 
1999)
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Study 1 ii : Western blotting
Proteins were extracted from tissue samples, denatured and separated on 
sodium dodecyl sulphate polyacrylamide gels (SDS-PAGE). These were then 
transferred to a nitrocellulose membrane; the primary antibody was applied to 
bind the protein of interest. This was detected as a band on the membrane by 
using conjugated secondary antibodies, and a chemiluminescent technique, 
as described by Sambrook et al (1989).
Protein extraction. This was performed by collecting the tissues from timed 
mated animals as discussed above, and homogenising them in 4°C RIPA 
buffer (150 mM NaCI, 50 mM TRIS pH 8.0, 1% Nonidet P40, 0.5% sodium 
deoxycholate, 0.1% SDS) to which were added fresh proteinase inhibitors (30 
pg/ml aprotonin, 100 mM sodium orthovanadate, 100 mM phenoxymethyl 
sulfoxide (PMSF)). Homogenisation was performed by mincing the tissues, 
and then triturating the sample through increasing fine calibre pipette tips. The 
suspension was then sonicated for 10-15 seconds twice. This was then spun 
at 20,000g on a desk top centrifuge for 30 minutes, at 4°C. At the end of this 
the supernatant containing the protein was aspirated and saved. This was 
either used immediately or stored at -80°C.
Protein quantification. The protein concentration was measured in duplicate 
for each sample using the bicinchoninic acid (BCA) protein assay (Smith et al 
1985). This involves the reduction of copper II to copper I ion, by protein in an 
alkaline medium. Two molecules of BCA chelate with one cuprous ion to 
produce a purple coloured product. This has a strong absorbance at 562 nm,
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with a linear response to protein concentrations from 2 0  -  2 ,0 0 0  pg/ml. 
Standard protein concentrations of bovine serum albumin (BSA) were made 
by serial dilution in the range from 2 mg/ml (stock solution) to 62.5 ng/ml. 
These were measured in duplicate each time the BCA protein assay was 
performed.
Each protein specimen was diluted to the same concentration as the most 
dilute protein specimen used. Fifteen pi of sample were then mixed an equal 
volume of electrophoresis sample buffer (1 ml glycerol, 0.5ml (3- 
mercaptoethanol, 3 ml 10 % SDS, 1.25 ml of 1M Tris pH 6 .8  and 1 mg of 
bromophenol blue). These mixed samples were heated to 98°C for 5 minutes 
to denature the protein and allow SDS to bind. By heating the sample of 
protein with an excess of thiol and SDS, any disulphide links are cleaved and 
the proteins are dissociated into component polypeptides. SDS is an ionic 
detergent, which, under these conditions, binds to the polypeptide backbone 
in a constant ratio of 1.4g SDS: 1g polypeptide. This imparts a negative 
charge to the polypeptides according to size (Weber and Osborn 1969). 
These were then placed on ice prior to loading into lanes on a SDS-PAGE 
gel.
Gels. The gels were divided into an upper ‘stacking’ low percentage (5%) low 
pH (6 .8 ) and resolving higher percentage (8 %) higher pH (8 .8 ) resolving gel. 
The stacking gel has larger pores, allowing the SDS bound negatively 
charged protein to move through it more easily than through the resolving gel 
with its smaller pores. Glycine exists as a zwitterion (no charge, favoured by 
low pH) in equilibrium with glycinate (negatively charged, favoured by high
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pH). When the electric field is applied, the glycinate moves towards the 
anode, but when it enters the lower pH stacking gel, the equilibrium shifts 
towards glycine zwitterions, which are immobile. This generates a high local 
localized voltage gradient between a leading edge of Cl' ions and a trailing 
edge of glycinate. Anionic SDS-protein migrate rapidly, but if they migrate in 
front of the Cl" ions, the high local voltage difference is lost and so they slow 
down. This concentrates the protein in a disc between the Cl' front and the 
glycinate. As the proteins encounter the running gel, with its small pore size, 
their migration slows. Once the glycine reaches the higher pH running gel, the 
glycinate ion is favoured, and there is no longer an ion deficiency, and the 
local voltage gradient is lost. There is a uniform voltage gradient across the 
gel. The protein samples enter the resolving gel as a tight band, and 
resolution of the gel is improved (Davis 1964;Ornstein 1964). 8 % SDS-PAGE 
resolving gels have been used for all the western blots. The resolving gel was 
made in 20 ml aliquots, enough for 2 gels. Each aliquot contained 9.3 ml milli- 
q water, 5.3 ml of 30 % acrylamide, 5 mis of 1.5M Tris (ph 8 .8 ), 200 pi 10% 
SDS, 200pl of freshly made, and 12pl N,N,N,N-tetramethylethylenediamine 
(TEMED). Polymerisation of the acrylamide was caused by the action of 
ammonium persulphate and TEMED. The 5% stacking gel was made in 10 ml 
aliquots using 6 .8  mis milli-q water, 1.7 ml 30% acrylamide, 1.25 ml of 1.0M 
Tris pH 6 .8 , 100pl 10% SDS, 100pl of ammonium persulphate and 10 pi of 
TEMED.
Setting up the apparatus. The Mini-Protean gel apparatus was used with two 
glass plates, separated by 1.5 mm spacers. The resolving gel (8 %) was 
poured between the glass plates, up to a level a third from the top, and the
161
remaining space topped up with water saturated butan-1-ol.This ‘flattens’ the 
top of the gel and prevents oxygen diffusing in and inhibiting polymerisation. 
Once the gel had set (normally 45 minutes at room temperature), the butanol 
was washed off, and the space above the resolving gel was washed twice 
with milli-q water, and dried using Whatman 3mm paper. The stacking gel was 
then poured on top. A 10 lane comb was then placed into the top of the gel 
frame, and the stacking gel allowed to set.
A Laemmli discontinuous buffer system was used, with the upper part of the 
gels bathed in one bath of buffer (of which the gel plates formed 2  walls) 
connected to the anode, and the base of the gels was bathed by another -  
acting as the cathode(Laemmli 1970). Tris-glycine buffer was used (diluted 
from a 10x stock solution containing 25 mM trizma-base, 250 mM glycine, 
0.1% SDS).
Loading and running the gel: A molecular weight marker (15pl) was loaded 
into lane 1 on each gel. All lanes were loaded with protein specimens to 
ensure even running. Electrophoresis was performed at 80 V, with the 
cathode at the top of the gel, the proteins running towards the anode at the 
base. This was continued until the correct size of molecular weight marker 
had reached the bottom of he gel.
Electroblotting. Proteins were transferred from the gel onto a nitrocellulose 
membrane using a semi-dry electroblotter. The glass plates were removed 
form the running tank, and the resolving part of the gel placed in transfer 
buffer (0.02 M Tris base, 0.15M glycine, 20% methanol, 0.00275% SDS). On 
the lower plate (anode) were placed 3 sheets of Whatman 3MM paper
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(soaked in transfer buffer). Bubbles and excess buffer were removed by 
rolling a glass pipette over each layer after it was applied. The nitrocellulose 
membrane was then placed on this followed by the resolving gel. Saran wrap 
was placed around the gels, to prevent a short circuit by-passing the gels.
This was then covered with 3 more layers of 3MM paper. The cathode was 
then placed on top of the stack, and electroblotting performed at 12V for 45- 
55 minutes.
Ponceau S staining. To confirm that protein transfer had occurred, the 
membranes were washed in Ponceau S for 2 minutes, and then rinsed in de­
ionised water for 2 minutes. The Ponceau S reversibly binds to protein, 
especially immunoglobulins. Pink protein bands were visible where protein 
had been transferred.
Blocking, primary and secondary antibodies: Once the proteins had been 
transferred onto the nitrocellulose membrane, blocking of non-specific binding 
was performed. The membrane was then probed with a primary antibody, 
washed and blocked again, then this was detected with a secondary antibody, 
conjugated with horse-radish peroxidase. This was then detected using 
chemiluminescence.
The membranes were immersed in blocking solution (5% wt/vol fat-free milk 
powder (Marvel), 0.1% BSA, 0.1% Tween-20 in PBS) for a period of 1 hour at 
37°C, or overnight at 4°C.
Probing of the membrane was performed using primary antibodies: rabbit anti­
mouse integrin a5 1/2,000 overnight at 4°C; rabbit anti-mouse integrin |31
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1/1,000 overnight at 4°C; rabbit anti-mouse integrin P3 1/1,000 overnight at 
4°C; Rabbit anti-mouse fibronectin (Chemicon AB2033) 1/2,000 overnight at 
4°C. The house keeping gene p-actin was detected using monoclonal mouse 
anti-human P-actin (Sigma A5441) at 1/10,000 dilution for 30 minutes at room 
temperature. The membranes were then washed twice using PBS / 0.1% 
Tween-20 for 10 minutes, and once using the blocking solution. Secondary 
antibody was applied (Dako goat ant-rabbit HRP conjugated (P0448), 1/1,000 
dilution, or Dako rabbit anti-mouse HRP conjugated (P0260), 1/2,000), as 
appropriate for the primary antibody. This was allowed to incubate for 30 
minutes at room temperature. The membranes were then washed three times 
in PBS/Tween-20 for 5 minutes, then PBS twice for 5 minutes. Excess PBS 
was then allowed to drain off the membranes.
Chemiluminescence. The secondary antibodies used were all HRP 
conjugated. Enhanced chemiluminescence reagent (ECL), was applied to 
each membrane for exactly 1 minute. The excess was drained off and the 
membranes wrapped in saran wrap and placed in an X-ray cassette. X-ray 
films were then exposed, the timing depending on the intensity of the signal. 
Comparison with the molecular weight markers allowed the size of the protein 
band to be detected.
Loading controls. Two controls were used: Firstly, Ponceau S staining was 
performed to show equal loading of the original gels and transfer onto the 
nitrocellulose membrane; and secondly, the house keeping gene p-actin was 
measured.
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Densitometry of the bands was measured using scanned images of the x-ray 
films, and the ImageJ analysis software produced by the National Institute of 
Health, USA. All protein loading was standardized by factoring each result 
against the p-actin band density for that sample on that blot. The time-points 
E14, E16, E18, D1 and 6 wks were compared by ANOVA, with a p<0.05 
defined as significant.
Probing the blots with antibody against integrin a5 produced a band at the 
expected size (140 kD), similarly probing blots with rabbit anti-mouse p1 
produced a band at the expected size. I therefore re-used blots to measure 
both these integrins. Mouse anti-human p-actin antibody produced a very 
strong band at 40 kD, the expected size.
Determination of linearity of densitometry data. A particular problem 
associated with the use of western blots is the possibility of saturating the 
densitometry data. This would produce a non-linear result for quantitation. In 
order to 1) ensure equivalent antibody exposure for all samples, 2 ) determine 
a linear response all samples were run on 4 blots at the same time (figure 
4.1). These samples were run with 3 control proteins from a dayl sample -  
each blot used the same dayl sample. These control proteins were loaded at 
200%, 100% and 25% of the normal protein loading per well. The absorbance 
of these control bands therefore allowed a plot of concentration against 
densitometry to be made. Blots were exposed ‘instantly’, 1min, 3 mins 5 mins 
and then 10 mins etc. The exposure that produced the most linear response 
for the loading controls was then analysed (figure 4.2).
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Linearity/saturation controls
Figure 4.1: Linearity/Saturation controls in Western blots. Variation was 
reduced by running 4 blots simultaneously, and exposing all blots to the 
same antibody at the same time. 2 of 4 blots shown here.
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Figure 4.2: Demonstration of linear response from 25%-200% protein 
loading Recognition of linearity/prevention of saturation in densitometry 
data Western Blots. (A) raw densitometry data from b-actin blot in figure 
4.1. (B) Protein concentration vs. densitometry data -  linearity 
demonstrated from 25%-200% of protein loaded in each well.
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Study 1iii: Flow Cytometry
Flow cytometry allows measurement of cells or particles individually, as they 
pass a sensing point. Light from a laser (or arc-lamp) is scattered by the cell 
as it passes the detection point: light transmitted forwards, or scattered 
sideways can be collected. This allows particles to be separated by size and 
their scattering properties. Fluorescence is the process whereby fluorophores 
absorb light of a particular range of frequencies, going from a low energy 
ground state to an excited state. Some energy is then lost in this transient 
excited phase, after which the fluorophores drop back down to a ground state 
in the process emitting light of a longer wavelength than the light absorbed. 
This process can be repeated until photobleaching has occurred, and the 
fluorophores can no longer fluoresce. By using a higher frequency, lower 
wavelength excitatory light source and a filter to remove stray light of this 
frequency, only longer wavelength emitted light may be detected. This allows 
the signal from fluorophore labelled antibodies to be detected with great 
sensitivity (e.g. fluorescein isothyocyanate -  FITC). Cells labelled this way can 
then be counted. This technique requires that the tissue specimen be 
converted to a cell suspension (see below). The antigen expressed by the 
cells in question can then be detected by using an appropriate antibody 
labelled with an appropriate fluorophore, and excited with an appropriate 
wavelength of light, by measuring light emitted at the appropriate emission 
spectra.
168
Unfortunately antibodies can also bind non-specifically. By using an isotype 
control, non-specific binding can be measured, allowing this to be subtracted 
from the total binding, giving a measurement of specific antibody/antigen 
binding. This allows the binding of the antibody to be measured in terms of 
signal strength and number of positive cells. A positive control is used in 
which cells known to express the target antigen are exposed to the primary 
antibody.
Generating a cell suspension. Bladders were harvested at E14, E18 and 
postnatally as described above. These whole bladders were immersed in a 
known volume of dispersal solution containing collagen, dispase, DNase 
(CDD). This solution was composed of medium (DMEM/F12 with Insulin, 
selenium and transferrin supplements (ITS)), with 1.4 mg/ml collagenase A 
(103 578 Roche), 4 mg/ml of Dispase (17105 GIBCO), and 0.1 mg/ml of 
Dnase I (1 284 932 Roche). The collagenase A is derived from Clostridium 
histolyticum, and besides acting as a collagenase, has some clostripain, 
trypsin and protease activity. Ineffective disaggregation may be due to DNA 
release from digested cells, so DNase I was added. Dispase, a 
metalloenzyme produced by Bacillus polymyxa, separates epithelium form 
underlying substrate by cleaving the basement membrane zone, leaving the 
cells viable. Large bladders were minced using sterile scissors. The bladders 
were then repeatedly aspirated in and out of using large bore pipettes (1ml 
pipette with tip cut-off), then medium bore pipettes (intact 1ml pipette). This 
process of repeated aspiration used the shear forces as the suspension 
passed through the tip of the pipette to break the tissue down into component 
cells. The solution was then incubated at 37°C for 30 minutes in a water bath.
169
Repeated aspiration was repeated with medium bore pipettes, and then with 
fine bore pipettes (200 pi volume). The solution was again incubated for 30 
minutes at 37°C. A final trituration was performed using fine bore pipettes.
The cell suspension was then spun down in a desktop centrifuge at x3,000 g 
for 5 minutes. The CDD solution was discarded and the cell pellet 
resuspended in twice the volume of normal DMEM F-12 medium, producing a 
cell suspension of cells from whole bladders.
Labelling cells. Cell suspensions containing 1-4 x 105 cells in a 1 ml volume 
were made from E14, E18, dayl and 6  week mouse bladders as above.
These were spun down in a desk top centrifuge at x3,000 g for 5 minutes and 
then resuspended in 1ml of FACS buffer. (FACS buffer contained 5% fetal calf 
serum in phosphate buffered saline, containing 0.02% sodium azide.) This 
was repeated twice.
This part of the experiment was performed by Mrs Vanita Shah, research 
assistant. Using a 96 well plate, 200 pi of cell suspension was loaded per well. 
The plate was placed in a centrifuge and spun down using a centrifuge for 5 
minutes at 3,000g. The supernatant was discarded and the cells resuspended 
in 20 pi of 50 mg/ml primary antibody (mouse anti-integrin a7 monoclonal 
antibody 3C12 -  MBL, Japan) and allowed to incubate for 30 minutes at 4°C , 
or with 20pl of isotype control mouse IgG (50pg/ml). The cells were washed 
three times by spinning down the suspensions (5 minutes at 2,000 rpm) and 
resuspending them in 200 pi FACS buffer. The secondary antibody was 
added (20 pi of 50 pg/ml solution), and incubated for 30 minutes at 4°C. The 
cells were then washed once more three times by spinning down at 2 ,0 0 0  rpm
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for 5 minutes and resuspending in FACS buffer. The suspensions were then 
transferred to flow cytometry tubes and read on the flow cytometry performed.
FACS analysis. Control cell suspensions without antibody were used to set a 
gate on a dot-plot of forward versus sideways scatter data. Using a dot-plot of 
the FITC reading against the sideways scatter quadrants were set for each 
control suspension (i.e. the upper limit for the non-specific binding of the 
isotype control), and then the number of cells specifically labelled by the 
primary antibody and FITC labelled secondary antibody could be obtained. 
Numbers of positive cells are given as percentage of total cell numbers, and 
expressed as a mean, ± standard error of the mean, and analysed using 
ANOVA, where p<0.05 was taken as statistically significant. For this 
experiment because 3 separate cell suspensions from 3 different litters were 
prepared for E14, E18 and dayl time-points and for 3 adults for the 6  week 
suspensions, n was taken as 3.
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Study 2: Adhesion blocking experiments
The experimental strategy for this experiment was to produce a cell 
suspension containing DSM from whole just-harvested bladders, and then to 
measure the adhesion of these cells to a fibronectin substrate. This provided 
an assay for the effectiveness of the blocking agents, but also tested whether 
the cells at that particular time-point expressed receptors for the substrate 
used.
Generating a cell suspension.
Bladders were harvested at E14, E18 and postnatally as described above, 
and cell suspensions were generated as described above.
Quantification of cell counts.
A haemocytometer was used to count the cell density in the cell solution. In 
the haemocytometer used (Sigma Brightline Z35,962-9) the floor of the slide 
is etched, dividing the area into 9 squares. Nine pi of cell suspension is 
pippetted onto the slide. With a coverslip in place each of these 9 squares has 
a volume of 0.1 mm3, or 10-4 ml. Averaging the cell counts from the 4 outer 
squares will give the number of cells per 10*4 ml. Multiplying by 10,000 will 
give the cell density per millilitre (ml). In order for the counts to be reliable: 1) 
cells touching the top or left borders were counted, 2) cells touching the
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bottom or right sides were not counted, 3) The average count of the 4 corner 
squares should be in the range 25-100.
Cell viability
Cell viability was ascertained by exclusion of Trypan blue. Trypan blue (Sigma 
T-8154) is a blue dye that is taken up by dead cells. An equal volume of cell 
suspension and Trypan blue is mixed in a tube. Living cells exclude the dye 
and appear retractile and colourless in comparison. The cell viability is given 
by the number of unstained living cells divided by the total number of cells 
present (stained and unstained), and expressed as a percentage.
Coating of slides with fibronectin
Mouse fibronectin is not commercially available in a preparation for coating 
slides. Rat plasma fibronectin has therefore been used (Sigma F0635). This is 
a lyophilised extract of rat plasma. It is reconstituted with sterile water, and 
must not be excessively agitated, or vortexed during this process. This stock 
solution had a concentration of 1 mg/ml, and was stored in 50 pi (50 pg) 
aliquots. Dilute working solutions using Hanks balanced salt solution (HBSS) 
can be prepared up to 0.01% of the original stock solution. To coat slides an 
appropriate volume was made up to allow 1-5 pg/cm2 of fibronectin to be 
deposited. Lab-tek 4 or 8 chamber slides (177399) were used in the adhesion 
experiments. Each 4-well slide has a culture area of 1.8 cm2 with a suggested 
working volume of 0.5-0.9 ml. Two hundred and fifty pi of diluted fibronectin in 
HBSS was allowed to coat wells of the 4 chamber slides (125 pi for the 8 well
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slides) overnight, at 4°C under sterile circumstances. The next morning 
(approximately 16 hours later) the excess liquid was tipped off, and the slides 
allowed to air dry.
Adhesion experiment
A homogenous suspension of cells from whole bladders was prepared. This 
was diluted aiming for 200-400,000 cells per ml, 250 pi of cell suspension (5- 
10x104 cells) being loaded per well on 4-well plates and 125 pi (2.5-5x104 
cells) for 8-well plates. Two controls were compared to each blocking strategy: 
1) cell suspension without additives -  blank control; 2) control compound e.g. 
non-immune immunoglobulin G (IgG) for blocking antibodies. The blocking 
compound or the control compound were thoroughly mixed with the cell 
suspensions by vortexing, and then left to stand for 15 minutes at room 
temperature. The blank control cell suspensions were simply vortexed and left 
to stand. The cell suspensions were then applied to the slides in 250 pi 
aliquots, complete coverage of each well being ensured by agitation of the 
slide. The slides were incubated at 37°C in a 5% CCVair atmosphere in a 
humidified incubator for 4 hours. At the end of that time the cell suspension 
was tipped off the slides. The chambers were removed as was the sealing 
gasket. Any non-adherent cells were washed off by rinsing twice using PBS 
solution at room temperature. Cells were initially counted after staining with 
methylene blue as described below, or were counted using phase contrast 
microscopy. For methylene blue staining slides were fixed by immersion in 
acetone at -20°C for 10 minutes. Following this the slides were rinsed in PBS
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3 times, then the adherent cells were stained with methylene blue (Sigma 
180-8, diluted 10 fold in deionised water) for 20 minutes at room temperature. 
These were then rinsed in running water and dehydrated using ascending 
alcohols, finally placed in histoclear for 2 minutes. Coverslips were mounted 
using DPX.
For cell adhesion experiments, bladders were minced using sterile blades, 
and then dispersed to single cell suspensions using solution containing 
collagenase A (1.4 mg/ml) (103 578; Roche Diagnostics GMBH, Mannheim, 
Germany) dispase (4 mg/ml) (17105; Gibco BRL, Invitrogen Ltd, Paisley, UK), 
and DNase I (0.1 mg/ml) (1 284 932; Roche) in ‘culture medium’, composed 
of Dulbecco’s modified Eagles medium/F-12 medium (DMEM/F12) (31330- 
038; Gibco BRL) with insulin, selenium and transferrin supplements (13146). 
2.5x104 cells in culture medium were placed in each well of 8-chambered 
glass slides (Lab-Tek, Fisher Scientific UK, Loughborough, UK). Some wells 
were coated with rat plasma fibronectin (F0635) at concentrations from 5 to 
20 pg/ml in Hanks balanced salt solution (HBSS; 14170-088; Gibco BRL) 
overnight at 4°C, control wells were incubated with HBSS alone. In some 
experiments blocking RGD, or negative control RAD peptides were added to 
the cell suspensions and incubated for 15 minutes; the oligopeptide 
concentration used was 20 pg/ml after testing doses from 10-40 pg/ml, based 
on published studies on other cell systems (Romanov and Goligorsky 1999). 
Suspended cells were allowed to adhere for 1 hour, at 37°C, in a 5% CCVair 
humidified atmosphere. Culture medium was decanted, and the slides gently 
washed twice with PBS. Adherent cells were counted using either phase 
contrast microscopy of unfixed cells, or using fixed cells (see below). For each
well, four medium power fields were randomly selected and adherent cells 
counted; the average was then used for subsequent analysis. Cell 
morphology assumed either a round, or spread appearance, and therefore we 
were able to express results as ‘total’, ‘spread’, and ‘round’. Some slides were 
fixed in acetone at -20°C for 10 minutes, rinsed in PBS, permeabilised with 
NP40 (0.5%) and probed, for 30 minutes at room temperature, with the 
following primary antibodies: a-SMA, CD31, cytokeratin-18, desmin, integrin 
a5, integrin p1. Primary antibodies were detected with appropriate secondary 
antibodies using HRP/DAB, and slides were counter-stained with hematoxylin. 
Proliferation was assessed by 5-bromo-2-deoxyuridine (BrdU) incorporation 
as described in a commercially available kit (1444611, Roche) (See below). 
BrdU was added for 1 hour, before the experiment was terminated at 1 hour 
and 12 hours after the cells were plated either on to fibronectin coated plates 
or uncoated controls; the proliferation experiments were repeated twice, both 
with 10% fetal bovine serum (FCS) added to the medium, and without. Data 
were presented as mean±SEM. Parallel experiments on the same cell 
suspensions were analysed by paired Student’s t-tests. Comparison over 
multiple conditions were performed using analysis of variance (ANOVA), with 
p<0.05 taken as significant. Analyses were performed using Microsoft Excel.
Analysis
Phase contrast microscopy was performed using an Olympus IX70 inverted 
microscope. The fixed slides were photographed using the computer 
controlled Zeiss Axiophot 2 microscope, and Photoshop 5 software. Four
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medium power fields were counted per well, and averaged. The number of 
adherent cells in each well was then compared, using ANOVA, with a 
Bonferroni post-hoc test of significance.
Quantification of proliferation
In the adhesion experiments proliferation was measured by PCNA expression 
and, BrdU uptake. For PCNA expression, immunocytochemistry was 
performed, as described above.
When 5-bromo-2’-deoxy-uridine is added to cell culture, proliferative cells 
incorporate it into DNA in place of thymidine. Monoclonal antibodies to BrdU 
(either peroxidase conjugated or fluorescent conjugated) can then be used to 
detect cells in which BrdU has been incorporated -  and so used as a marker 
of proliferation. This technique provided an alternative to the use of 
radioactive thymidine incorporation without the risk of radiation exposure.
In order to measure BrdU incorporation, cell cultures were exposed to BrdU 
(10pM) for 1 hour, i.e. BrdU was added at the start of the adhesion 
experiment for the 1 hour slides and at 11 hours for the 12 hour adhesion 
studies. At the end of the experimental period, slides were rinsed twice with 
PBS three times (room temperature) and then fixed in acetone at -20°C. 
PCNA immunocytochemistry was performed as described above. For BrdU 
detection cells were washed three times in PBS containing 10% FCS. The 
slides were then incubated with nucleases for 30 minutes at 37°C, and 
washed again, three times more with PBS/ FCS. The wash medium was
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removed and anti-BrdU peroxidase labelled antibody (200 mll/ml in Washing 
Buffer with 10% FCS) was incubated for 30°C at 37°C (5-Bromo- 
2deoxyuridine labelling and detection kit 1444611, Roche Diagnostics GMBH, 
Mannheim, Germany). The antibody was then washed off using the washing 
buffer, and DAB added. The reaction of the peroxidase was terminated after 5 
minutes by washing in tap water and the slides counter-stained with 
haematoxylin (30 secs), washed once more, and dehydrated using ascending 
alcohols (30secs each), then histoclear 5 minutes, twice. Coverslips were 
mounted using DPX, and the slides photographed when the DPX had dried.
Quantification of Apoptosis 
TUNEL test
Apoptosis or programmed cell death (PCD) are terms used to describe an 
active form of ‘suicide’ in response to local signals, or lack of those signals. 
There are 3 processes involved in activation of apoptosis: initiation, regulation 
and execution (Renehan et al 2001). Apoptosis may be triggered by either the 
death receptor pathway or by the mitochondrial pathway. The death receptor 
pathway is activated by binding of Fas ligand to Fas (CD95), or tumour 
necrosis factor (TNF) to TNF receptor-1. This leads to receptor clustering and 
formation of a death inducing signalling complex. Fas-associated death 
domain protein (FADD) is recruited and multiple procaspase-8  molecules are 
bound. The close proximity of these molecules leads to caspase-8  activation 
(Hengartner 2000). Execution occurs after caspase 3, 6  and 7 are activated, 
with DNA fragmentation (by caspase activated DNase (CAD), which results in
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DNA-ladder visulaised upon electrophoresis), chromatin condensation after 
cleavage of nuclear lamins, and surface alterations (‘blebbing’) (Hengartner 
2000). Alternatively, the mitochondrial pathway can be initiated by a variety of 
factors: growth factor deprivation, steroids, DNA damage leading to 
upregulation of p53, loss of adhesion to a substrate (Michel 2003). These lead 
to mitochondrial membrane permeabilization by inactivation of anti-apoptotic 
Bcl-2 family members such as Bcl-2, and activation of pro-apoptotic Bcl-2 
proteins such as Bax, with release of proteins such as cytochrome-c. This 
combines with Apaf-1 and procaspase-9 to form the apoptosome, which is 
then capable of activating caspase-3 and starting the execution programme 
(Hengartner 2000).
Apoptotic cells shrink, chromatin condenses and endonucleases cut the DNA 
into 180-200 bp fragments, nuclei become pyknotic, cytoplasmic membrane 
blebs and then apoptotic bodies form containing cytoplasm, organelles, and 
nuclear fragments. These apoptotic bodies are then phagocytosed.
Apoptosis can be detected by:
Propidium iodide staining of cell nuclei: apoptotic nuclei are pyknotic, then 
fragmented.
DNA laddering, DNA can be observed to form a series of bands on agarose 
gel electrophoresis.
Terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate 
biotin nick end labelling (TUNEL) test labels the cut ends of the DNA in-situ. 
Using recombinant terminal deoxynucleotidyl transferase (rTDT), either
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biotinylated nucleotides (Promega DeadEnd colorimetric system G7360 
Promega), or fluorescein labelled nucleotides (ROCHE Fluorescent detection 
kit -  1 684 795) are incorporated at 3’ -O H  ends of the DNA. These can then 
be identified either through chromagenic detection with DAB, using an avidin- 
biotin detection system linked to horse radish peroxidase (HRP), or by 
fluorescent microscopy.
Chromagenic TUNEL test in immunocytochemistry
Parallel E18 bladder cell suspensions were prepared as described above. 
Each suspension was incubated with RAD, RGD oligopeptides and HBSS, 
then and plated onto slides coated with fibronectin at 1 0 pg/ml, and allowed to 
adhere for 1 hour. These slides were washed and then the slides were fixed 
using acetone at -20°C as described above. Slides were rinsed twice with 
PBS and then permeabilised with 0.2% Triton X-100 in PBS for 5 minutes. 
These were then rinsed in PBS for 5 minutes, repeated twice. Slides were 
incubated in equilibration buffer (G7360 Promega) for 5 minutes. The 
adherent apoptotic cells were then labelled using TUNEL reaction mixture 
incorporating equilibration buffer (contained 40 mM potassium cacodylate, 25 
mM Tris, 0.2 mM DTT, 0.25 mg/ml BSA and 2.5 mM cobalt chloride -100 pi of 
reaction mixture contained 98pl of equilibration buffer, 1 pi rTDT and 1 pi 
biotinylated nucleotide mix and was applied to each well). A negative control 
was provided by making a control mixture without rTDT. The reaction was 
allowed to proceed for 1 hour at 37°C. The reaction was then terminated by 
washing the slides in SSC for 15 minutes at room temperature. (SSC
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contained 0.3M sodium chloride and 0.34M sodium citrate at pH 7.2- Part 
G3297 Promega). The slides were rinsed three times in PBS for 5 minutes, 
before endogenous peroxidase was quenched using 0.3% H20 2 for 3 minutes 
at room temperature. Streptavidin labelled horse radish peroxidase (1 ng/ml) 
was then allowed to ligate the biotinylated nucleotides for 30 minutes at room 
temperature. Slides were again washed three times in PBS. Finally the 
Streptavidin-HRP was detected by the application of DAB -  chromagenic 
reaction was allowed to run for 10  minutes before being terminated by rinsing 
in water. The slides were counter-stained in Meyer’s haematoxylin for 20 
seconds, and then rinsed with running water for 2 minutes. The slides were 
dehydrated by passing through ascending alcohols, and then histoclear for 2 
minutes, twice. Coverslips were mounted with DPX and adherent cells were 
counted. The results were recorded as total adherent cells and TUNEL 
positive cells. No false positive staining was seen in the control wells (no rTdT 
present). Four medium power fields were counted per well, and averaged. 
Results were then compared between same suspensions under different 
conditions using paired t-test.
Measurement of cell death using LDH assay
This assay was a colorimetric quantification of cell death and lysis as opposed 
to apoptosis. This assay is based on measuring the activity of lactate 
dehydrogenase (present in all cells) released from dying cells into a 
supernatant. This enzyme is stable. LDH detection is a two-step process 
whereby LDH catalyses the reduction of NAD+ to NADH+ as lactate is
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oxidised to pyruvate. The second stage, catalysed by diaphorase) involves 
the transfer of H/H+ to a (yellow) tetrazolium salt, reducing it to a (red) 
formazan salt. This reaction can be followed by absorption at 500nm of this 
formazan salt. I used a commercially available cytotoxicity detection kit 
(Roche 1 644 793).
The cell suspensions from 1 hour adhesion experiments using no block, or 
RGD, or RAD, with and without substrate were aspirated and spun down at 
13,000 rpm (desk top centrifuge) for 30 minutes at 4°C. The reaction mixture 
was made up by mixing 250 pi of solution 1 (catalyst) with 11.25 ml solution 2 
(dye mixture). The supernatant was retained and subsequently used in the 
LDH assay. 10 pi of supernatant was added to 100 pi of reaction mixture in an 
ELISA plate. This was incubated for 30 minutes at 18°C, and covered to 
protect it from light. The absorbance of the wells in the plate was read at 490 
nm. Each reaction was repeated in triplicate for 4 parallel cell suspensions.
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Study 3: Organ Culture Experiment
The experimental strategy for this experiment was to generate an embryonic 
model of explant bladder growth, starting at organ inception at E14. I have 
investigated the functional effect of fibronectin/integrin a5p1 interactions on 
DSM maturation, by attempting to block fibronectin itself with a polyclonal 
antibody raised to mouse fibronectin (Chemicon), as described by Moursi et al 
(1997) in osteoblast culture.
Generating the model.
I generated a model of bladder development that started with murine bladders 
harvested at E14.This is the first time-point that murine bladders are a 
discrete structure which can easily be dissected. These were dissected under 
aseptic conditions and grown on Millipore filters (0.4 pm pore size), using 
serum-free, defined media (DMEM/F-12 supplemented with insulin (10 pg/ml), 
transferrin (5.5 pg/ml) and selenium (5 ng/ml)) (Figure 4.3A and B). Up to five 
explants are grown on each filter in an air/5% CO2 atmosphere, at 37 C. 
Bladder explants were collected for analysis at the start of the experiment 
(E14 bladders), after 3 and 6  days in culture. One bladder from each plate 
was taken for frozen section, and the rest were dissociated into single cell 
suspensions as described above. The read-outs from this experiment were an 
assessment of growth, by cell numbers, weight and total protein; an 
assessment of bladder morphology by examination of explant histology; 
differentiation, by immunostaining and Western blot of smooth muscle
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markers a-smooth muscle actin (a-SMA) and desmin, and proliferation, by 
PCNA IHC, which also allowed quantification by counting the proportion of 
proliferative cells present, as well as by western blot.
Embryonic bladder explant experiments using anti-fibronectin antibody
Bladders were harvested from 3-4 litters at E14 and dissected from the 
embryos, as described above. Two bladders from each litter were taken and 
weighed, then a cell suspension was created from them, cell numbers 
counted and protein extracted from the cell suspensions, again as described 
above.
In a 6  well plate (figure 4.4), the left hand wells were harvested at 3 days, and 
the right hand wells at 6  days. The top row were grown in the growth medium 
without any added immunoglobulin (ITS), the second row were grown in the 
presence of isotype control immunoglobulin (IgG), and the bottom row were 
exposed to the anti-fibronectin antibody. Bladders from each litter were placed 
on placed on the Millipore filters, such that each different experimental 
condition had (as evenly as possible) bladders from each litter allotted to it.
When harvested the bladders were weighed, dissociated into a cell 
suspension and cell numbers counted, and then protein was extracted. A 
bladder chosen at random from each filter (i.e. experimental condition) was 
mounted in OCT for frozen section and subsequent immunohistochemistry.
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Figure 4.3: Generating fetal murine bladder explant model. (A) 
Embryonic day 14 mouse urogenital tract. (B) Diagrammatic 
representation of explant culture with bladders (Yellow), growing on 
filter (blue), resting in and in contact with defined medium DMEM/F-12 
(pink). K - kidney; O - ovary; B - Bladder
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Figure 4.4: Setting up explant blocking experiment using immunoglobulins 
(yellow dots are bladders).
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Study 4: Human fetal immunohistochemistry, morphometric 
analyses
Paraffin Sections
Slides were cut from formalin-fixed, paraffin-embedded blocks at 0.4pm 
thickness using a microtome.
Masson’s trichrome
This histological staining was carried out by the histology laboratory at Great 
Ormond Street Hospital. Slides were dewaxed by incubating at 60°C for 5 
minutes then by placement in histoclear for 5 minutes twice. Rehydration was 
performed by placing the slides in decreasing concentrations of alcohol 
(100%, 90%, 80%, 70%, 50%) for 1 minute each, then rinsing in water for 5 
minutes. Slides were pre-treated in 3% potassium dichromate for 1 hour at 
60°C. Nuclei were stained with Mayer’s Haematoxylin, slides were washed in 
water. Slides were stained with Chromotrope green mixture (Chromotrope 2R 
0.6g, Fast Green FCF 0.3g, Phosphotungstic acid 0.6g, glacial acetic acid 1 
ml, dissolved in 1 0 0 ml of distilled water), for 10  minutes at room temperature, 
then rinsed in 0.2% acetic acid. The slides were blotted dry, then dehydrated 
by passing through increasing concentrations of alcohol, then xylene and then 
coverslips were mounted using DPX. Muscle and fibrin was stained red, as 
were red blood cells. Collagen was stained green. Nuclei were stained black.
Quantification of the percentage area of muscle present was performed by 
measuring the area of the section stained red, and measuring the total area of 
the lamina propria and detrusor in each section (figure 4.5). These
187
measurements were performed by using ImageJ software: each image was 
converted into an image stack consisting of hue, saturation and brightness. 
Thresholds were set to detect the red staining (equivalent to 185 to 255) and 
the area measured. The total area of the lamina propria was also measured, 
so that the area of muscle could also be expressed as a proportion of the total 
area (muscle percentage of surface area) (figure 4.5C).
This method of quantification was similar to that employed by previous 
authors, except that these authors described it as area density (Workman and 
Kogan 1990;Kim et al 1991b, a;Freedman et al 1997).
The thickness of the bladder wall (urothelium, lamina propria and detrusor) 
was measured, using ImageJ, on each section at 3 different points as was the 
lamina propria thickness, and the detrusor thickness. The average of all three 
measurements for thickness was then used in subsequent analyses (figure 
4.6). (All measurements were converted into millimetres (mm)).
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Figure 4.5: Muscle area measurement using ImageJ . (A) Masson’s Trichrome 
staining of bladder (B) Image with thresholds set to detect red staining of muscle in 
ImageJ (C) ImageJ image trimmed of serosa. This is the image used to calculate 
area of muscle and total lamina propria and detrusor area.
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Figure 4.6: Morphometric analysis of bladder wall thickness . Minimum 
distance lines connecting mucosa to the outside of the detrusor layer were 
drawn in 3 places on each section. The total wall thickness as well as the 
lamina propria thickness and detrusor thickness were measured. The 
average of each was taken as the wall thickness of that bladder. This was a 
20 week gestation normal male fetus. U urothelium; LP lamina propria; D 
detrusor.
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Van Gieson stain
This procedure was carried out by the histology laboratory at Great Ormond 
Street Hospital. Slides were dewaxed by incubating at 60°C for 5 minutes 
then by placement in histoclear for 5 minutes twice. Rehydration was 
performed by placing the slides in decreasing concentrations of alcohol 
(100%, 90%, 80%, 70%, 50%) for 1 minute each, then rinsing in water for 5 
minutes. Slides were stained with Celestin blue for 5 minutes, then Mayer’s 
haematoxylin for 5 minutes, followed by rinsing in water. Sections were then 
counter-stained with Van Gieson stain. Slides were blotted dry, the 
dehydrated and coverslips mounted as described above. Nuclei were stained 
blue; collagen red; muscle, RBCs and cytoplasm were stained yellow.
Again quantification of the area of collagen was performed by measuring the 
area of the section stained red (figure 4.7). A close-up view shows that the 
staining and measurement of this collagen area measured the area of 
collagen fibres (figure 4.8). A measurement was generated of the collagen 
percentage of surface area (%) (Collagen area divided by total cross-sectional 
area of urothelium, lamina propria and detrusor, expressed as a percentage).
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Figure 4.7: Measurement of Collagen proportion of surface area of 
sections of bladder using ImageJ. (A) Van Gieson staining of bladder (B) 
Image with thresholds set to detect red staining of collagen in ImageJ (C) 
ImageJ image trimmed of serosa. This is the image used to calculate area 
of collagen and total lamina propria and detrusor area.
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Figure 4.8: High power view of collagen fibres .(A) Close-up of van 
Gieson stain of bladder showing staining of collagen fibres. (B) 
Threshold image where red colour represents region to be measured.
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Immunohistochemistry
Slides were dewaxed by incubating at 60°C for 5 minutes then by placement 
in histoclear for 5 minutes twice. Rehydration was performed by placing the 
slides in decreasing concentrations of alcohol (100%, 90%, 80%, 70%, 50%) 
for 1 minute each, then rinsing in water for 5 minutes. Antigen retrieval was 
performed by treating slides with citrate (2.1 g/l) at pH6 , and micro-waving for 
6  minutes at full power (750W). Slides were rinsed in PBS with 0.02% NP40 
(PBS/NP40). Peroxidase block was applied for 5 minutes at room 
temperature, then rinsed off with PBS/NP40. Non-specific binding was 
prevented by incubating with 0.1% bovine serum albumin (BSA) 0.02% Triton 
X-100 block for 20 minutes at room temperature. Slides were then rinsed 
once more. Sections were then incubated with the following primary 
antibodies: rabbit anti-human fibronectin (1/2000) dilution, Ki67 MEB-1 
monoclonal mouse anti-human (1/50), and mouse anti-human desmin-HRP 
conjugated antibody (1/4) overnight at 4°C. These antibodies were detected 
using DAKO Envision kit (anti mouse labelled polymer, or anti-rabbit IgG 
labelled polymer as appropriate). Conjugated horse radish peroxidase caused 
a brown colour change in diaminobenzidene (DAB), allowing detection of the 
primary antibodies. Slides were rinsed in water, and then counter-stained with 
haematoxylin, dehydrated, finally coverslips mounted using DPX.
Once again, quantification of the fibronectin area present was made by 
measuring the area of the section occupied by immunostained fibronectin. 
However in this case the quantification was done separately in the lamina
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propria or detrusor layers, and expressing this as a proportion of the total area 
of lamina propria or detrusor respectively (figure 4.9). This was done because 
the fibronectin expression data from the mouse model described previously 
was for the detrusor layer alone, and so this was the most appropriate 
comparison. The resultant measurements were: 1) the total fibronectin area 
for lamina propria; 2) lamina propria fibronectin percentage of surface area; 3) 
detrusor fibronectin area; and 4) detrusor fibronectin percentage of surface 
area.
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Figure 4.9: Semi-quantification of fibronectin expression in fetal bladders. 
(A) Immunostaining of fibronectin, detected with DAB -  brown colour. (B) 
Detrusor ‘cut-out’ of image in (A). (C) lamina propria and urothelium 
‘cut-out’ from image (A). (D) ImageJ thresholds set to detect brown colour 
of fibronectin immunostaining in detrusor layer. (E) same thresholds as 
used in (D), but for lamina propria layer.
Desmin-fibronectin colocalization.
Immunofluorescent microscopy using FITC conjugated anti-rabbit secondary 
antibody to detect anti-fibronectin antibody, and TRITC labelled anti-mouse 
secondary to detect mouse anti-human desmin antibody allowed 
colocalization of smooth muscle cells and fibronectin to be seen.
Muscle morphology (‘Muscle dysmorphology’ score)
Muscle morphology was graded from 0 to 2, by 3 different observers who 
were blinded to the details of each specimen (These were Professor AS 
Woolf, Dr P Winyard, and Mr D. Jenkins. Each observer was experienced in 
examining histological sections of fetal urinary tract). Muscle fibre morphology 
could be divided into normal fibres where each fibre was complete. Each 
observer was asked to compare the specimen to the high power views shown 
in figure 4.10. ‘O’ represented muscle bundles with no connective tissue 
present within the bundles, T  represented muscle bundles that had increased 
amounts of connective tissue, but in which muscle bundle outlines were 
recognizable and ‘2 ’ represented completely disrupted muscle bundles, 
lacking any normal muscle bundle definition. The scores for each bladder 
were totalled giving a ‘muscle dysmorphology’ score ranging from 0  (normal) 
to a maximum of 6 , as advised by the statistical support unit at ICH.
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Figure 4.10: Muscle dysmorphology score. Each observer was blinded to all 
details about the bladders. They were asked to grade the detrusor muscle 
morphology in each of the bladders on a three point scale where 0 was 
normal (A). Muscle bundles (MB -  outlined with dotted black and white line) 
were easily identified, with minimal connective tissue replacement. Or 
graded 1 , where muscle bundles were identifiable but there was increased 
connective tissue expression (B). Muscle morphology was graded 2 where 
the detrusor muscle bundles was disrupted, with no identifiable muscle 
bundles and increased connective tissue (C).
connective
Normal
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Renal dysplasia
Three observers, blinded to the details of each specimen, independently 
graded the severity of kidney malformation of all the normal and obstructed 
fetal kidneys (again these were experts used to examining fetal kidneys, 
Professor AS Woolf, Dr P Winyard and Dr R. Scott). The score ranged from 0 
for normal kidneys to 5 for the most dysplastic kidneys (figure 4.11). The 
kidneys associated with fetal presumed BOO showed a spectrum of 
abnormalities from fibrosis of the medulla to sub-cortical cysts, loss of the 
nephrogenic zone and dilatation of the renal tubules with pelvi-calyceal 
dilatation (Woolf et al 2004). Kidney morphology was assessed by three 
blinded experts in fetal kidney histology. They graded each kidney from 0 -  
normal, to 5 -  most dysplastic. Medium power views of cortex and medulla 
from each fetus were provided for assessment, but no further information was 
given. There was very high concordance in grading between all 3 observers 
(p<0.001 Spearman nonparametric test for all comparisons between 
observers). The dysplasia score was therefore given as a sum of all 3 
observers’ scores for each bladder.
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Figure 4.11 : Renal dysplasia associated with congenital bladder outflow 
obstruction. This ranged from normal (dysplasia score 0) (A), to severe 
dysplasia (score 5) (B,C).(B) cortex, (C) medulla. Scale Bar 400 \xm.
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Pulmonary hypoplasia
From the post mortem reports the following information was obtained: fetal 
weight, weight of each lung, and presence of oligohydramnios. The 
percentage of fetal weight represented by total lung weight allowed an 
estimate of pulmonary hypoplasia to be made ^1.5% taken to mean significant 
pulmonary hypoplasia (Scott and Goodburn 1995).
Proliferation in human fetal tissues
Immunohistochemistry was performed as described above. Preliminary test 
experiments were performed by myself. The tonsillar tissue produced the 
expected proliferation in the lymphoid follicles, and a positive result was seen 
in the human fetal tissue. This IHC was repeated by the Histology department 
of Great Ormond Street Hospital for all the slides.
Immunofluorescent TUNEL assay
The TUNEL test labelled the cut ends of the DNA in-situ. Using recombinant 
terminal deoxynucleotidyl transferase (rTDT), fluorescein labelled nucleotides 
(ROCHE Fluorescent detection kit -  1 684 795) were incorporated at 3’ -O H  
ends of the DNA. These were then be identified by fluorescent microscopy. 
Nuclei were counter-stained by propidium iodide.
Images were captured using Axiophot computer controlled microscope, and 
Photoshop 6.0 software. Quantification of the expression of collagens, muscle 
and fibronectin was performed by analysing the proportion of surface area of 
the section that these represented. This calculation was done using ImageJ
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(NIH) software, the results being expressed as a percentage of the total 
surface area for the section for collagens and muscle, but as a proportion of 
lamina propria and detrusor for fibronectin. For Ki67 and TUNEL 
quantification, 6  separate images of each bladder were captured (3 detrusor 
and lamina propria, 3 detrusor), and positive cells were counted for each 
compartment as well as total numbers of cells being estimated. The result was 
given as the percentage of positive cells for that compartment. For each fetus, 
these 3 numbers were averaged, and then used in further analysis.
Statistical analyses
Data were presented as means plus or minus standard error of the mean 
(SEM). Where 2 populations have been compared Student’s t-test was 
employed where p<0.05 was taken as significant. Parallel experiments 
allowed the use of paired analyses, and the paired t-test was used in these 
analyses. Comparison of multiple groups over multiple time-points was 
performed using analysis of variance (ANOVA), again with p<0.05 taken as 
significant. Bonferroni post-hoc tests of significance were performed to 
differentiate between different groups as appropriate. Analyses were 
performed using Microsoft Excel and SPSS v11.
In analysing the human fetal bladder material, statistical advice was obtained 
from the Statistical Support Unit at ICH. For correlations between data, where 
data were parametric, then the Pearson correlation coefficient was 
determined using SPSS v11.5. If the data were not parametric, ie for scales
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where the data were more correctly described as ordinal, then a non- 
parametric rank correlation (Spearman) was performed. These results were 
taken to be statistically significant if p<0.05.
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Chapter 5. Analysis of expression of adhesion 
molecules fibronectin and laminin-1/2 and their 
candidate receptors during fetal mouse bladder 
development
Hypothesis
During murine bladder development, the candidate fibronectin receptor 
integrin a5|31 may be expressed by detrusor smooth muscle cells (DSMC), 
and that laminin 1 /2  candidate receptor integrin a l  may be expressed by 
DSMC.
Background
In order for a ligand and receptor to interact, their expression should 
temporally and spatially overlap, i.e. they need to be in the same place 
(DSMC surface and surrounding basal lamina) at the same time to allow a 
response to occur. If these putative ligands (fibronectin and laminin-1 or 
lamini-2) are not expressed in the basal lamina of the DSMC, and these 
DSMC do not express the putative receptors (integrin a5pi and a7p i) then 
the hypothesis can have no basis.
Aims
1) Seek potential expression of the fibronectin receptor integrin a5p1. 2) 
Describe if the a-subunits of laminin-1 and laminin-2 (laminin a1 and a2
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respectively) are expressed in the basal lamina of murine DSMC; and seek 
potential expression of the candidate laminin receptor (integrin a7(31).
Results
Fibronectin and candidate fibronectin receptor expression
For the immunohistochemistry, blocks of OCT embedded bladders were used 
that included positive control tissue (paw), surrounded by bladders: 6 -8  
bladders at E14, E18 and D1, with 3-4 bladders at 6 wks. Each slide contained 
4 sections -  3 were immunostained with primary antibody, one was the 
negative control section.
The expression of fibronectin was examined by using frozen sections, from 
organ inception at embryonic day 14 to maturity at 6  wks (figure 5.1). 
Throughout the stages examined fibronectin was expressed in the lamina 
propria and the detrusor layer, surrounding muscle cells. No immunostaining 
was seen at any time-point in the urothelium.
Immunohistochemistry was performed to look at the pattern of expression of 
fibronectin receptor integrin a5p1 (figure 5.2). Figure 5.3 shows the control 
sections performed at the same time, using non-immune rabbit antibody of the 
same isotype. At the start of organ development at embryonic day 14 there 
was no detectable immunostaining for integrin a5. By E16, there was 
expression in what will become the detrusor layer, which appeared to peak 
neonatally, and then decreased somewhat postnatally. The expression of the 
a5 integrin subunit appeared to be on the cell membranes of the fetal smooth 
muscle cells in the detrusor layer, but the presence of non-specific staining in
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the DSM of the postnatal time-points makes the integrin a5 immunostaining of 
the DSM more ambiguous.
For the Western blot data each sample contained protein from multiple 
bladders (urothelium was dissected off the DSM and discarded, as described 
by Smeulders et al (2002)): E14 each sample was composed of the DSM of 
16 bladders, E16 similarly, E18 approximately 8 bladders, 8  postnatal dayl 
bladders, and 8  from 6  week time-point, as described by (Smeulders et al 
2002). Multiple samples were used, as described below, for subsequent 
statistical analysis.
Western blot data (Sample n=4 for E14, n= 6  for E16, E18, Day1, and 
6 weeks), showed firstly a band at the expected size (140kD) (Hynes et al 
1989) and when densitometry was performed a marked increase in 
expression of a5 integrin from organ inception during in utero development 
(ANOVA p< 0.0001 -figure 5.4). During post-natal development (D1 to 6 wks) 
there was no change in the expression of integrin a5. Bonferroni post-hoc test 
of significance showed that there was significant upregulation of integrin a5 
between E14 and postnatal time-points Dl and 6 wks (p=0.001 both 
comparisons), and between E16 and 6  wks (p=0.001), but no difference 
between E14, E16, and E18, and between D1 and 6 wks. This Western blot 
data confirmed the presence of integrin a5 subunit in the DSM throughout 
bladder development from E14 to 6 wks.
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Figure 5.1 Fibronectin expression E14 to 6 wks postnatal. (A) Fibronectin 
assessed by immunohistochemistry (brown) at embryonic day 14 (E14), at 
E18 (B), at dayl neonatally (C) and at 6 weeks (D). Close-up of E18 
detrusor reveals basal lamina staining around fetal smooth muscle cells 
(E). Control slide of E18 using isotype rabbit immunoglobulin -  showing no 
staining (F). The black scale bar is 200 |uim in A-D,F and 25 p,m in (E).
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Figure 5.2: Integrin a5 expression E14 to 6 wks postnatal (Integrin a5pl is a 
fibronectin receptor): Expression from E14 (A and B), E18 (C and D), day1(E 
and F), 6 Weeks (G and H). A,C,E and G low power view of bladder wall 
(scale bar 200 pm), B,D,F and H high power view detrusor (scale bar 50 pm).
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Figure 5.3 Rabbit isotype control antibody E14 to 6wks postnatal: Non­
specific immunostaining from E14 (A and b), E18 (c and d), day1(e and f), 
6 Weeks (g and h). A,C,E and G low power view (scale bar 200microns), 
B,D,F and H high power view (scale bar 50 microns).
209
E14 E16 E18 D1 6 wk
fibronectin
integrin a5 
integrin p1 
p-actin
negative isotype 
control
B
D
<*-250 KDa
-160 KDa
05 KDa
Tim e-point
Tim e-point
160 KDa 
105 KDa
35 KDa
250 KDa
160 KDa 
105 KDa
Integrin a5
100%
c
o 75% -
<A
(A
£ 50% -
a.x
<D 25%
0%
E14 E16 E18 PI P42
Integrin
100%c
o 75% -vt
(A© 50% -
CLX
© 25%
0%
E16 E18 PI P42E14
Fibronectin100%  -c
o 75% -«A
<A<Di - 50% -a.
xo 25% -
0%
E14 E16 E18 P42
Time-point
Figure 5.4: Quantification of fibronectin and fibronectin receptor by WB. (A) 
Representative blots for fibronectin, integrin a5, integrin p1, p-actin, and pre- 
immune rabbit IgG. (B) Integrin a5 levels factored for p-actin. Data 
expressed as mean±SEM (n=4 for E14, n=6 for other time-points), given as a 
percentage of the maximum level of integrin a5 expression. (C) Integrin p1 
levels. (D) Fibronectin levels.
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Figure 5.5 shows the pattern of expression of the integrin (31 subunit.
Multiple replicants were immunostained for each time-point, as described 
above for integrin a5 subunit.
Expression of the (31 integrin subunit showed that it was present at the 
periphery of the bladder at the start of bladder development, but by E18 there 
was marked immunostaining of the detrusor layer which persisted throughout 
development. In contrast to the a5 staining, (31 was also present in the 
urothelium.
Western blot data for the (31 subunit (figure 5.3) showed a band was present 
at the expected size (Marcantonio and Hynes 1988), and analysis of the 
densitometry (n=3 for E14, n=5 for E16, n= 6  for all other time-points), showed 
that there was a significant increase in expression of this subunit during 
antenatal development of the bladder, but that there was subsequently a 
(non-statistically significant) decrease post-natally (ANOVA p<0.01). 
Bonferroni post-hoc test revealed that there was significant upregulation 
between E14 and D1, but that comparisons of expression between E14, E16 
and E18 were not significantly different. Comparisons of postnatal expression 
between D1 and 6 wks showed no significant difference.
These data show that the integrin sub-units a5 and (31 were expressed by the 
fetal and mature smooth muscle cells in the same spatial arrangement as
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each other, in an appropriate pattern to act as a fibronectin receptor during 
the development of the bladder smooth muscle.
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Figure 5.5: Integrin (31 expression E14 to 6wks post natal murine 
bladders. Expression from E14 (A), E18 ( B ) , day 1(C), 6 Weeks 
(D). A,C low power view (scale bar 200 pm), B,D high power view 
(scale bar 50 pm).
Laminin and laminin binding integrins
Expression of specific laminin a sub-units (a1 and o2) was studied, because 
these are components of laminin-1 and laminin-2/4 respectively.
As described above multiple replicants were used for each time-point.
Laminin-1: (Laminin a1p1y1) Expression of this laminin sub-type was present 
at the start of bladder development at E14, at the interface between the 
epithelium and mesenchyme. By E18, the laminin was expressed in the basal 
lamina of the developing detrusor layer and in the basal lamina of the 
urothelium, but not in the lamina propria. Post-natally this pattern was 
maintained, but with apparently less intense staining (figure 5.6). No western 
blot data is available as the antibody did not bind its antigen using this 
technique
Laminin-2 and 4: (Laminin a2p1y1, Iaminina2p2y1 respectively). Expression of 
this laminin sub-type appeared at a latter stage than laminin-1 , and was 
expressed in the same spatial pattern as laminin-1 thereafter, being present in 
the basal lamina of the detrusor layer, and of the urothelium, but not the 
lamina propria. Similarly no western blot data is available as the antibody did 
not bind its antigen using this technique (figure 5.7).
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Figure 5.6:Laminin a1 expression E14 to 6wks post natal murine bladders. 
Laminin a1 (laminin-1): Expression from E14 (A and B), E18 (C and D), 
day1(E and F), 6 Weeks (G and H). A,C,E and G low power view (scale bar 
200 (Lim), B,D,F and H high power view (scale bar 50 |nm).
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Figure 5.7: Laminin a2 expression E14 to 6 wks post natal murine bladders 
Laminin a2 (laminin-2/4): Expression from E14 (a and b), E18 (c and d), 
day1(e and f), 6 Weeks (g and h). A,C,E and G low power view (scale bar 
200 |im), B,D,F and H high power view (scale bar 50 fxm).
Candidate Laminin receptor: Integrin a7p1
On preliminary immunohistochemistry integrin a6  expression was present in 
the urothelium, and also in the basal lamina of blood vessels in the lamina 
propria and detrusor. It was not expressed by fetal or adult smooth muscle 
cells (Appendix 1: figure 1.2).
Once fixation and the use of the ARK kit had been optimised, integrin a7 
immunostaining could be easily detected (Appendix 1 figures 1.3-1.7). 
Positive control tissue in the form of myoblasts could be seen immunostained 
with this probe (which was originally generated by inoculating a7 null mutant 
mice with myoblasts from a wild type mouse). Integrin a7, in contrast, was 
highly expressed by adult smooth muscle cells in the detrusor and blood 
vessels. Fetal expression by smooth muscle precursors or fetal smooth 
muscle cells was weak on IHC (figure 5.8). A high power view of mature 
smooth muscle cells in 6  week old mouse bladder showed the integrin 
expressed in the cell membrane of these cells (figure 5.8E).
The only commercially available antibodies (MBL 3C12 and MBL 6A11) 
against integrin a7 are not recommended for probing Western blots, but are 
recommended for use in for flow cytometry. Three parallel cell suspensions 
were prepared from whole bladders, for the time-points E14, E18 and dayl 
from 3 separate litters, and from 3 separate individuals for 6  weeks. Flow 
cytometry was performed by Mrs V. Shah (Research Assistant, Institute of 
Child Health) as described above. This data is included in appendix 1 figure 
1.8 and table 1.6. These analyses were performed with the technician blinded
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to the nature of the samples. The pattern of expression of the laminin receptor 
integrin a l  increased from E14 to E18, by FACS, remained constant until day 
1 and then doubled with maturation at 6  weeks (n=3, ANOVA p=0.0001), and 
was undetectable at E14 by IHC, with weak immunostaining in the detrusor at 
E18 and D1, but with strong immunostaining of the DSMC at 6  wks, figure 
5.8F. Bonferroni post-hoc tests of significance revealed that upregulation of 
integrin a7 between E14 and E18 and D1 was significant (p<0.005, both 
comparisons), with no significant difference between E18 and D1, but that 
there was significant upregulation from D1 to 6  wks (p<0.001). Comparing 
E14 to 6  wks there was an upregulation of integrin a l  that was significant 
(p<0 .0 0 1 ).
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Figure 5.8: Integrin a l  expression E14 to 6 wks post natal. E xpression  from 
E14 (A), E18 (B ) , day 1(C), 6 Weeks (D). (E) High power view of detrusor 
muscle at 6 weeks. (F) FACS data for integrin a7 (n=3 for each time-point). 
A-D low power view (scale bar 200 pm); E high power view (scale bar 25 n 
m).
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Discussion
Fibronectin and integrin a5(31 (a candidate DSMC fibronectin receptor)
The candidate integrin fibronectin receptor components a5 and p1 are both 
expressed by cells in the detrusor layer of the bladder. It has been 
demonstrated that there is an antenatal upregulation of these receptor 
components that parallels the temporal expression of fibronectin described by 
(Smeulders et al 2003) -  the data from the current study is illustrated in figure 
5.9. The pattern of fibronectin expression was in close agreement to that 
which found when fibronectin Western blots were performed for this study 
(figure 5.4).
This is the first report of changing pattern of expression of fibronectin, in 
association with a possible candidate fibronectin receptor, integrin a5p1.
This part of the descriptive work supports the hypothesis that fibronectin and 
its integrin a5pi receptor is expressed in forming DSM of the embryonic 
mouse bladder. In other words the ligand and its receptor are in the right 
place at the right time to have an effect. The postnatal IHC for integrin a5 
subunit is more equivocal because of the high background staining seen, 
however the Western blot data is more convincing. In the future immuno- 
electron microscopy could be performed to define to sites of expression of 
fibronectin inside and outside fetal DSMC. Wilson et al (1996) describe a 
similar pattern of expression of integrin a5 and p1 in the adult human bladder, 
corresponding with detrusor fibronectin expression. When fibronectin is down
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regulated post-natally, however, no striking down-regulation of integrin a5p1 
was found. The error bars from the Western blot data mean that it is possible 
that there may be a smaller degree of down-regulation of this integrin or 
indeed no down-regulation at all.
There are many integrin receptors described that can ligate fibronectin. These 
include a4|31, a5|31, av|33, a 8 pi, allbp3 (predominantly a platelet expressed 
integrin although ectopic expression has been described in tumours), as 
discussed in the Introduction. Other potential RGD-binding, fibronectin 
receptors have been described in DSMC, integrin avp3 expression has been 
described in stretched bladder DSMC using by RT-PCR (Upadhyay et al 
2003), and IHC studies in human bladders have demonstrated both integrin 
a5pi and p3 integrin expression in DSMC (Wilson et al 1996). Any signalling 
effect due to fibronectin may therefore be mediated by these alternative 
receptors. However, of note it is integrin a5p1 that is present in fibrillar 
adhesions associated with fibronectin fibrillogenesis (Pankov et al 2000), and 
blockade of integrin a5pi inhibits many of the biological effects of culturing 
fibroblasts in 3-d culture (Cukierman et al 2001). A full assessment of the 
potential fibronectin receptors in developing detrusor would require an 
assessment of expression of all the potential receptors described above 
perhaps by a combination of IHC, Western blot and RT-PCR as has been 
described for laminin sub-type expression in the ureter (Hattori et al 2003).
Conversely, integrin a5pi is capable of ligating other ECM molecules. The 
study of ECM and integrin interactions is complicated by the redundancy of 
these systems, whereby an ECM component can be replaced by another
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molecule, or a receptor can be knocked out and its function taken over by 
another integrin, as reviewed by (De Arcangelis and Georges-Labouesse 
2000). In order to demonstrate that fibronectin interacts with integrin a5|31 in a 
functionally important manner, functional tests of this interaction are 
necessary. A possible technique to investigate this immunohistochemically 
would be to examine the activation state of the integrins present, using 
antibodies that detect the active conformation of integrin (31 (e.g. Chemicon 
MAB2079Z, mouse anti-human active conformation (31 integrin), as described 
by (Luque et al 1996). Similarly integrin activation could be assessed by 
immunostaining for activated, phosphorylated FAK, and examining for 
colocalization of this to focal adhesions containing integrin a5(31 (e.g. anti- 
FAK phospho-Y397 antibody ab4803, Abeam) (Sieg et al 2000).
A functional assessment of fibronectin-integrin interactions forms the next part 
of this thesis.
Does this failure of down-regulation of the candidate receptor integrin a5(31 
have any significance?
No significance can be drawn form this, but possible explanations include the 
presence of unligated integrin cx5(31 on the cell membrane of DSMC; or, the 
integrin is ligated to an alternative ECM component; or fibronectin is in great 
excess of the integrin a5(31 receptor transiently (perhaps ligated to another 
integrin receptor), and that all the integrin a5(31 is in fact ligated to fibronectin.
It is possible to speculate that if the ligand is no longer present to stimulate its 
receptor then there is no signal, but that potential for this signalling
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mechanism remains present in fully differentiated DSMC. It is possible that the 
presence of a5p1 integrins on the cell membranes of mature SMCs would 
then allow a proliferative response to the provisional fibronectin matrix laid 
down as a result of tissue damage (Okada et al 1985). This might be a 
mechanism of response to fetal bladder outflow obstruction (BOO).
Alternatively, there are is evidence to suggest that unligated integrins can 
actively cause down-stream signalling effects: (Varner et al 1995) and have 
shown that unligated integrin a5p1 activates signalling pathways, including 
growth arrest specific gene-1 (gas-1), which positively inhibit proliferation, and 
similarly tumorigenicity of hepatocellular carcinoma in mice is inhibited by 
over-expression of integrin a5p1 (Zhou et al 2000).
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Figure 5.9: Relative trends in fibronectin and fibronectin receptor expression 
expression (western blot densitometry), plotted against trends in relative 
expression for the fibronectin receptor integrin a 5 p i. All data from this thesis.
224
Laminin and integrin a7p1 (laminin receptor)
Preliminary IHC on the expression of laminin a1 shows that it was present at 
the interface between the primitive urothelium and the mesenchyme at the 
start of bladder development. The means that it is possible that 
mesenchymal/epithelial interactions, described by Schuger et al (1997) for the 
developing lung bud, were occurring in the embryonic bladder. Laminin a1 
(and laminin-1 which has a1(31y1 subunits) was markedly upregulated by E18, 
and remained expressed at high levels in the basal lamina of the detrusor 
layer. Laminin-1 was not generally expressed in the lamina propria, except by 
blood vessels. This pattern of expression with a ‘gap’ between the laminin-1 
expressed in the basal lamina of the urothelium and expression in the DSM 
layer is not seen in the developing lung, and suggests that smooth muscle 
myogenesis after initiation in the bladder is not following the same pattern as 
the lung bud (Schuger et al 1997). I was unable to get Western blots to work 
with this antibody, so quantification of the relative changes in expression 
during DSMC development are limited to interpretation of the IHC data only. 
These data are not so robust as the data for integrin sub-types discussed 
above. In general, integrin antibodies are not useful Western blot probes if the 
antigen to which the antibody is raised is an extracellular epitope (personal 
communication from Dr Kairbaan Hodivala-Dilke).
Laminin a2, present in laminin-2/4, followed a similar pattern of expression to 
laminin-1 .
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In this study expression of the integrin a7 sub-unit is specific for smooth 
muscle cells in the bladder, and that the two components of this receptor (a7 
and (31) are both expressed in the mature bladder on the cell membranes of 
mature smooth muscle cells where they would be able to act as receptors for 
laminins in the surrounding basal lamina. The temporal pattern of expression 
of this integrin as assessed by flow cytometry is very similar to that described 
by (Smeulders et al 2003) for generic laminins- the fits of the data form this 
thesis and Smeulders et al (2003) are compared in figure 5.10. Expression of 
integrin a7 by mature mouse bladder detrusor has been previously described 
by (Yao et al 1997), with a similar pattern to these observations.
This pattern is what was expected from the previous lines of evidence 
described in the Introduction. It would also fit with an initial mesenchymal 
phenotype, with a paucity of fibronectin surrounding it, which then changes 
into the fetal smooth muscle phenotype with a large component of fibronectin. 
Finally, a second change in phenotype with down-regulation of fibronectin, 
loss of proliferation and final differentiation to the contractile mature smooth 
muscle phenotype. Similarly the laminins were expressed at low levels at E14, 
then upregulated at E18 coincidental with the fetal smooth muscle cell 
phenotype, as was the laminin receptor integrin a7(31. Both laminins and a7(31 
remained at the same level of expression, until a final change in phenotype to 
the mature smooth muscle phenotype in the adult bladder.
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Figure 5.10: Western blot expression laminins versus Integrin a7 flow 
cytometry plotted against flow cytometry data (% positively staining cells) 
for integrin a7. (FACS data from this thesis, generic laminin data 
Smeulders et al, 2003),
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The strengths of this descriptive work are firstly that expression has been 
assessed first by IHC, and then secondly quantified by an alternative 
technique, either western blot or flow cytometry. That these different 
techniques produce similar results makes interpretation of the results more 
reliable and robust.
IHC was performed on frozen sections that had been fixed using acetone at - 
20°C. Cross-linking of proteins and concealment of antigenic epitopes was 
therefore limited. Isotype controls were used to the primary antibodies so that 
non-specific antibody binding could be determined. Similarly, in the integrin a7 
IHC, other confounding factors such as endogenous biotin and IgG were 
present and experimental protocol modified accordingly. Endogenous biotin is 
produced by the mature renal tract and bladder. Using an avidin-biotin 
detection system is therefore unreliable with a risk of false-positive results 
(Wang and Pevsner 1999;Banks et al 2003). This was detected in my IHC 
experiments and a biotin blocking kit (Vector) was used. Similarly the use of 
mouse primary antibodies would have produced marked false positive results 
unless the animal research kit (ARK-Dako) had been used.
The antibodies used in Western blot experiments were the same antibodies 
used in IHC. Western blots were performed using several controls. Successful 
electroblotting was assessed by Ponceau S staining; reliability of loading, 
electroblotting and probing of WB filters was demonstrated by reliable and 
consistent p-actin levels. Any loading errors that could have biased the results
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were discounted by only analysing WB densitometry data once it was 
controlled for by p-actin expression for that protein sample lane. Statistical 
reliability was ensured by using separate litters to prepare the protein samples 
for E14, E16, E18 and neonatal day 1 time-points, and separate individuals 
for the 6  week time-point.
For the flow cytometry quantification of integrin a7 both negative and positive 
controls were included in every run. An isotype mouse immunonoglobulin G 
(IgG) was used, as was a positive control -  adult bladder cell suspensions 
were run in parallel to all the fetal time-points. For statistical reliability, each 
suspension represented either a separate litter (E14, E18 and dayl), or 
separate individuals (6 weeks). Three parallel suspensions were run at each 
time, each with its own positive and negative control. Furthermore the cells 
suspensions were prepared by myself, but the identity of each suspension 
was blinded from the technician who ran the flow cytometry experiments.
Co-localization of the integrin a and (3 sub-units was strongly suggested by 
IHC of similar serial sections of bladder, but no formal co-localization has 
been performed. Similarly, serial/similar sections of bladder show ligand and 
receptor temporo-spatial parallels in expression, but again no true co­
localization studies have been done.
Western blots are, at best, only semi-quantitative, providing only information 
about relative changes in expression for a particular protein. Comparisons 
between different proteins are therefore limited to examination of relative 
changes over the same time-points. An increase in the densitometry of a 
western blot band can occur as a consequence of either an increase in
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expression of that protein by ail cells from which the protein sample is made, 
or by an increase in a sub-population of cells that uniquely express the 
protein, or by some combination of the two. Flow cytometry is therefore a 
useful complementary approach as the number of cells expressing the 
antigen can be counted. A weakness for the quantification performed in this 
study is that flow cytometry has not been repeated for all the integrin sub­
units. However when the IHC and western blot data are examined together, 
then a progressive upregulation of integrin expression by substantial number 
of cells in the detrusor is the most likely explanation.
Conclusion
First, this study is consistent with the contention that the candidate fibronectin 
receptor integrin a5p1 could mediate instructive signals from a fibronectin-rich 
matrix. Second, upregulation of integrin a7p1 harmonised with the 
upregulation of laminin and DSMC maturation, allowing for the possibility that 
these molecules may interact, perhaps modulating a muscle differentiation 
signal.
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Chapter 6. Mouse bladder cell culture and adhesion 
blocking experiments
Hypothesis
In Vitro DSMC may adhere to fibronectin, possibly modifying cell behaviour, 
and that this adherence may be mediated by the candidate fibronectin 
receptor integrin a5p1.
Background
That fibronectin is present in ECM of fetal DSMC during murine bladder 
development has been shown by (Smeulders et al 2003). Furthermore bovine 
DSMC are capable of secreting fibronectin in cell culture (Baskin et al 1993b). 
In cell culture vascular SMC adhere to fibronectin and become proliferative 
and synthetic on this substrate (Morla and Mogford 2000; Thyberg and 
Hultgardh-Nilsson 1994). Bourdoulous et al (1998) has shown that for 
endothelial cells and fibroblasts, fibronectin is necessary for cell cycle 
progression and proliferation. Hornberger et al (2000) has shown that 
adhesion dependent EGF stimulated growth of human fetal myocytes is 
enhanced by stimulation of integrin a 5 p i Nguyen et al (2005) have shown 
that p1 integrins including integrin a5pi are important in airway smooth 
muscle growth on collagen I, or fibronectin substrate. From chapter 5 
upregulation of fibronectin in the ECM surrounding DSMC occurs in a similar 
spatial and temporal pattern as expression of the candidate fibronectin 
receptor integrin a 5 p i. This leads to the question of whether there is a
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functional interaction between the fibronectin and fibronectin receptor integrin 
a5|31, and modulation of proliferation of these murine DSMC.
The strategy of this chapter was to use whole bladders disaggregated into a 
bladder cell suspension. Using this heterogenous suspension (presumably 
initially a mixture of detrusor, connective tissue, vascular and urothelial cells) 
the following aspects could be examined: 1) did fetal bladder cells stick to 
fibronectin? 2 ) what is the nature of these cells? (this would be examined by 
immunocytochemistry: are DSMC cells adhering, as demonstrated by smooth 
muscle markers such as aSMA and desmin; and do these cells express the 
candidate integrin receptor a5p1?) 3) what is the nature of the effect of 
fibronectin adhesion on these cells with regards proliferation? 4) can adhesion 
of these cells be inhibited either by antibody blocking the fibronectin, or by use 
of RGD oligopeptides to block the integrin binding site for fibronectin.
Aims
Use in-vitro dissociated cells to study adhesion to defined substrates, 
examine effect substrates have on adherent cells, and to further investigate 
the mechanism of adhesion through functional blockade of integrin receptors.
Aims: 1) to examine adhesion of disaggregated bladder cells from fetal and 
mature murine bladders to a fibronectin substrate; 2 ) characterise these 
adherent cells; 3) examine any proliferative effect that fibronectin adhesion 
may have on fetal bladder cells; 4) examine any effect blockade of 
fibronectin/integrin interaction may have on adhesion of cells from whole 
bladder suspensions.
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Results
Cell adhesion to fibronectin substrate
E18 whole bladder cell suspensions were plated on top of glass slides, with 
and without fibronectin coating. Phase contrast microscopy revealed that on 
uncoated slides, adherent cells adhered did not spread, remaining in a 
‘rounded’ state (figure 6.1 A). On fibronectin coated slides, a greater proportion 
of plated cells adhered, and they adopted a ‘spread’ morphology (figure 6.1 B).
Preliminary experiments determined 1) the optimum duration for the adhesion 
experiments (figure 6.1  below); 2 ) the fibronectin coating concentration that 
should be used (appendix 2 : figure 2.1  and table 2 .1 ).
A test experiment comparing cell adhesion of uncoated slides to fibronectin 
coated slides with either 10 pg/ml (giving a maximum concentration of 1.4 
pg/cm2), or 20 pg/ml (2.8 pg/cm2), or 40 pg/well (5.6 pg/cm2) was performed, 
to find the most appropriate concentration of fibronectin for subsequent 
blocking experiments. E18 bladder cell suspensions of 200,000 - 400,000 
cells/ml in DMEM/F-12 with supplemental ITS were used, 250 pi loaded onto 
4-well slides (50-100,000 cells) and 125 pi loaded onto 8 -well slides (25- 
50,000 cells). These were incubated at 37°C in 5 %CC>2/air in a humidified 
incubator for 30 minutes to 4 hours. The non-adhesive cells were rinsed off 
using PBS, the adherent cells fixed with acetone, and stained with methylene 
blue, and counted. In terms of length of culture period there was no further
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increase in total cell adhesion after 1 hour (Figure 6.1), although there was a 
change in ratio of spread to round cells.
With regards fibronectin coating concentration, the data of E18 cell 
suspensions is described in Appendix 2: table 2.1, and illustrated in Appendix 
2: figure 2.1. This showed a 3-3.5 fold increase in adhesion of cells on 
fibronectin (20 pg/ml) versus uncoated slides (n=3, ANOVA p<0.05), over 4 
hours, with no increase thereafter. The middle of this range was therefore 
used for adhesion experiments (5-20 pg/ml coating concentration of 
fibronectin).
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Figure 6.1: Adherence of whole bladder cell suspensions to fibronectin . (A) 
Some adherence, no spreading on uncoated glass. (B) More adherence, cell 
spreading on fibronectin coated slides
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For cell adhesion studies E18 bladders were mainly used. This was due to the 
proven expression of fibronectin receptor integrin a5p1 (Chapter 5 -  
experiment 1), and because at this time-point, cell suspensions would include 
fetal smooth muscle cells (Wu et al 1999a;Smeulders et al 2002). E14 bladder 
suspensions were studied as these were most representative of 
mesenchymal cells prior to differentiation into fetal smooth muscle cells (Wu 
et al 1999a; Smeulders et al 2002). Adult bladder cell suspensions allowed 
the study of the mature phenotype (Wu et al 1999a; Smeulders et al 2002).
In the typical experiment, one hour after cells were plated, most adherent 
cells on uncoated slides were rounded, whereas most adherent cells on 
fibronectin coated slides had spread (Figure 6.1 A and B). Next, we quantified 
the total, rounded, and spread cells which were adherent. At coating 
concentrations between 0  and 2 0  pg/ml of fibronectin, increasing numbers of 
cells adhered, approximately doubling in numbers (n=6 , p<0.001 ANOVA); 
this entirely corresponded with increasing numbers of spread cells (p<0 .0 0 1 , 
ANOVA), while there was no significant effect on the substratum on numbers 
of rounded cell (Figure 6.2A, Appendix 2: figure 2.1).
Using numbers of spread adherent cells as a read-out, fibronectin coating 
also had a significant effect when dissociated cells from E14, and adult 
bladders were studied, numbers of adherent cells increasing 250% for these 
time points (n=3, p<0.001 and p<0.05 respectively, ANOVA) (Figure 6.2B).
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Figure 6.2: Adhesion of bladder cell suspensions to fibronectin. (A) E18 
whole bladder suspensions (n=9) allowed to adhere for 1 hour. (B) 
numbers of adherent and spread cells in embryonic day 14 (E14), 
embryonic day (18) and adult cells.
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Characterisation of adherent cells
Using E18 bladder cell suspensions plated onto fibronectin coated slides, 
immunocytochemistry was performed (figure 6.3 A-D): 79±12% of all cells 
which adhered to fibronectin were positive for integrin a5; and 80±4% were 
positive for integrin (31; 82±2% of all adherent cells were desmin positive -  
with similar results for a-SMA (a -S M A  immunostaining during murine bladder 
development E14 to 6 wks is shown Appendix 2: figure 2.7, a -S M A  
immunocytochemistry is shown Appendix 2: figure 2.8). Only 3% of cells 
adhering to uncoated slides were desmin positive (n=10 uncoated slides, n=4 
fibronectin 5-10 pg/ml and n= 6  fibronectin 20 pg/ml, p<0.001 ANOVA). Less 
than 2 % of all adherent cells on fibronectin substrate were found to express 
CD31 or cytokeratin 18.
CD31 is expressed by endothelial cells, positive control immunostaining of 
umbilical artery is shown Appendix 2: figure 2.2. CD31 immunostaining in 
developing mouse bladders from E14 to 6  wks is shown in Appendix 2: figure 
2.3; and CD31 immunocytochemistry for the E18 bladder cell suspension 
adhesion experiment is shown Appendix 2: figure 2.4.
Cytokeratin 18 is expressed by developing murine epithelium (Baskin et al 
1996c). Cytokeratin 18 immunostaining during mouse bladder development 
from E14 to 6  wks is shown in Appendix 2: figure 2.5. Cytokeratin 18 
immunostaining of adherent cells from E18 bladder cell suspension is shown 
in Appendix 2: figure 2.6.
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Integrin a5
B
Integrin (31
Desmin Control IgG
Figure 6.3: Immunocytochemistry of adherent cells. (A) Integrin a5. (B) 
Integrin (31. (C) Desmin. (D) Negative control using pre-immune rabbit IgG. 
Bars are 10pm.
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Effect of fibronectin on proliferation
Using the BrdU proliferation assay, less than 1% of adherent cells had 
incorporated this nucleotide in the first hour of culture, whether the 
experimental conditions used uncoated or fibronectin coated slides; in 
addition the same very low proportion of adherent cells had incorporated BrdU 
when serum-supplemented media was used. If cells were maintained in 
culture for 12 hours, BrdU incorporation remained very low (on average, less 
than 2 %) for cells grown on uncoated slides (with or without serum), or on 
fibronectin coated slides in serum-free media. However, an identical 1 hour 
pulse of BrdU was found to have been incorporated into 9±1% of cells when 
both fibronectin coated substrate and serum was used, (n= 6  p<0 .001  
ANOVA) figure 6.4). (Data shown in appendix 2). Bonferroni post-hoc test of 
significance showed that proliferation after 12  hours of adhesion on 
fibronectin, in the presence of serum, was significantly different to all the other 
7 groups (p<0.001, all comparisons). There was no significant difference 
between any of the other groups.
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Figure 6.4:BrdU incorporation by Adherent E18 Cells. (A-D) BrdU uptake in 
E18 Cells over 12 hours. (A) Fibronectin 10mcg/ml, FCS 10%.(B) Fibronectin 
10 mcg/ml, no FCS.(C) No fibronectin, FCS(10%). (D) No fibronectin, no FCS. 
(E) Proliferation as assessed by BrdU uptake. Data plotted as mean±SEM.
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Adhesion blocking experiments
Two strategies were employed to block the adhesion of bladder cells to 
fibronectin: firstly using anti-fibronectin blocking antibody (Chemicon AB2033); 
and secondly, RGD oligopeptides.
Adhesion in presence of anti-fibronectin antibody
Figure 6.5 shows the results obtained: anti-fibronectin antibody (aF) or isotype 
control antibodies (two were used obtained from Chemicon (IgGC) and from 
Sigma-Aldrich (IgGS)) reduced bladder cell adhesion by half (n=4, ANOVA 
p<0.001). This showed a non-specific blocking effect of exogenous IgG on 
adhesion of total cell numbers of bladder cells to fibronectin.
Blocking adhesion using anti-fibronectin receptor oligopeptides.
Test adhesion experiments were performed in serum free media, using 
oligopeptides at 10-40 pg/ml (Data shown in appendix 2). A significant effect 
was seen at 2 0  pg/ml of oligopeptides, so this concentration was used 
subsequently.
The potential effects of fibronectin blockade, as assessed by using RGD 
peptides (2 0  pg/ml), were explored by quantifying different populations of 
adherent E18 cells. RGD oligopeptides significantly reduced adherent cells 
which were desmin positive at 10  and 2 0  pg/ml of fibronectin coating, 
compared to both the control peptide (RAD) and no additives (figure 6 .6A): 
71±9% of adherent cells expressed desmin in the presence of RAD 
oligopeptide; whereas the number was 48±9%, significantly fewer (n=6 , 
p<0.01), in the presence of RGD.
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Examination of the morphology of all adherent cells on fibronectin 10 pg/ml in 
the presence of RGD or RAD showed that there was a significant change in 
morphology associated with RGD integrin blockade (figure 6 .6 B). In the 
presence of RAD, 63±4% of cells were spread, whereas 54±4% spread in the 
presence of RGD, significantly less (n=6 , p<0.001). In the presence of RAD, 
37±4% of cells were rounded, whereas the number with RGD (46±4%) was 
significantly increased (n=6 , p<0.001) (figure 6 .6 B).
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ITS IgGC fcGS aF
Figure 6.5: Non-specific effect of immunoglobulin on E18 whole 
bladder cell suspensions. ITS, DMEM/F12 supplemented with insulin, 
transferrin, selenium. IgGC, rabbit isotype control IgG from Chemicon. 
IgGS, rabbit isotype control IgG from Sigma. aF, rabbit anti-mouse 
fibronectin antibody (Chemicon AB2033)
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Desmin positive adherent cells, effect of RGD 
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Figure 6.6: RGD oligopeptide adhesion blocking experiments. (A) adhesion of 
desmin positive cells. MPF medium power field (x20 objective on axiophot 
computer controlled microscope) Fibronectin coating concentration in 
mcg/ml). (B) Morphology of all adherent cells.
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RGD/RAD oligopeptide apoptosis activation and toxicity
It has been reported that higher doses of RGD peptides are capable of 
directly activating caspases (Aguzzi et al 2004). Quantification of apoptosis in 
adherent cells using the TUNEL test did not demonstrate any increase in 
apoptosis (figure 6.7A).
To examine if there was a toxic effect due to the RAD or RGD oligopeptides 
used in the blocking experiment a ‘death assay’ was performed. By 
measuring the release of LDH from cells (figure 6.7B), a measure of necrosis 
as opposed to apoptosis could be obtained. In the presence of no additives 
there was a low level of necrosis. The RAD oligopeptide demonstrated a 
fibronectin independent toxicity, whereas the RGD cell-death doubled as the 
fibronectin substrate doubled, p<0.01 paired t-test, n=4. (From figure 6 .6 A it 
can be seen that there was a larger inhibition of adhesion at 10 pg/ml of 
fibronectin, than at 5 pg/ml). It could be speculated that the RGD associated 
death was therefore perhaps related to inhibition of cell adhesion. Therefore 
experiments were limited to using a dose of 2 0  pg/ml or oligopeptides.
Discussion
Whether fibronectin could indeed modify the behaviour of differentiating 
DSMC was explored by studying the potential effects of this ECM molecule in 
a cell adhesion model. Firstly it has been shown that the number of adherent 
cells from dissociated E18 bladders was strikingly increased on fibronectin
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substrate in a concentration dependent manner; this effect was explained by 
an increase in spread versus rounded cells. Furthermore, similar effects were 
found using dissociated E14 and adult bladders. Because whole bladders (our 
starting material) contained urothelial, endothelial and fibroblast cells as well 
as DSMC, and because fibronectin is known to alter the behaviour of 
endothelia (Shono et al 2001), the phenotype of the adherent cells in our 
experiments was investigated by immunocytochemistry. On a fibronectin 
substrate, the great majority (80%) expressed desmin and a-SMA, whereas 
only a small minority (less than 2 %) expressed the urothelial marker 
cytokeratin 18 or the endothelial marker CD31. Collectively, these support the 
hypothesis that fibronectin is a functional substrate for differentiating DSMC. 
This also explains why the proportion of cells exhibiting a smooth muscle 
marker in the fibronectin adhesion experiments was found to be far higher 
than the proportion of cells expressing integrin a7 in the FACS experiment 
described in the previous chapter: DSMC preferentially adhere to fibronectin, 
so the proportion of DSMC in the fibronectin adhesion experiment is enriched 
compared to the number of smooth muscle cells in an in vivo bladder.
Fibronectin has been implicated in enhancing proliferation (Thyberg and 
Hultgardh-Nilsson 1994), and was therefore assessed in this model system. It 
was found that at 1 hour after initial plating of cells, at a point when the 
fibronectin substrate was shown to have a profound effect on adhesion and 
particularly on cells which expressed smooth muscle markers, this adhesion 
molecule had no effect on proliferation as assessed by BrdU incorporation.
On the other hand, when cell culture was prolonged to 12 hours, it was 
observed that the fibronectin substrate appeared to have a synergistic effect
on proliferation in the presence of serum. Interestingly it has been shown that, 
using vascular smooth muscle cells, fibronectin enhanced entry into G1, but 
that serum was necessary for completion of the cell cycle (Roy et al 2002).
This data also demonstrated that, as assessed by immunocytochemistry, the 
majority of the adherent cells expressed integrin a5 and integrin p i, the 
components of the integrin fibronectin receptor. Other integrin sub-types were 
not examined, however, so other integrin-fibronectin interactions are possible. 
The RGD motif of fibronectin has been shown to be important in the ligation of 
integrins (Pytela et al 1985b), so blocking peptides to the RGD motif were 
next used in this cell culture model. Versus RAD negative control peptides, it 
was observed that the RGD peptides reduced absolute numbers of desmin 
positive adherent cells by about 40%, and that this was accompanied by a 
shift in the appearance within the whole population of adherent cells from a 
spread to rounded phenotype. These data link the processes of adhesion, cell 
shape change and the expression of a muscle differentiation marker namely 
desmin. This is consistent with other work that supports a fundamental role for 
cell shape in determining cell fate. Smooth muscle differentiation has been 
shown to be at least in part dependent on cell shape, and specifically cell 
spreading by Yang et al (1999). They demonstrated that mesenchymal cells 
from lung, intestine and kidney all differentiated into smooth muscle lineage 
cells if given sufficient space to spread, whereas cells in identical but 
restricted conditions were inhibited from this pattern of differentiation. That 
fibronectin and pi and p3 integrins have a role in geometric control of cell 
shape, and that these fibronectin/integrin interactions influence cell fate, has 
been shown by Chen et al (1997).
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Although the above data does strongly suggest that the RGD motif is 
functionally important in these fetal DSMC, peptide blockade did not abolish 
all adhesion. There are at least two possible explanations for this. First, the 
degree of RGD blockade may have been incomplete. Second, adhesion could 
be occurring by a non RGD-dependent mechanism. The RGD motif is one of 
several mechanisms of fibronectin integrin interaction (Pankov and Yamada
2002). Hence other fibronectin domains would need to be blocked to elicit a 
more complete biological effect.
It has been reported that higher doses of RGD peptides are capable of 
directly activating caspases (Aguzzi et al 2004). Measurement of apoptosis in 
adherent cells using the TUNEL test did not demonstrate any increase in 
apoptosis (figure 6.7A). A death assay was also performed by measuring the 
release of LDH from cells (figure 6.7B), a measure of necrosis as opposed to 
apoptosis. In the presence of no additives there was a low level of necrosis. 
The RAD oligopeptide demonstrated a fibronectin independent toxicity, 
whereas the RGD cell-death doubled as the fibronectin substrate doubled, 
p<0.01 paired t-test, n=4. (From figure 6 .6 A it can be seen that there was a 
larger inhibition of adhesion at 10 pg/ml of fibronectin, than at 5 pg/ml) The 
RGD associated death was therefore presumably related to inhibition of cell 
adhesion. Therefore the dose of RGD/RAD was limited in the blocking 
experiments to a dose of 2 0  pg/ml.
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Figure 6 .7:Apoptosis and death associated with RGD oligopeptides (A) 
Apoptosis of adherent cells. (B) Necrosis measured by ‘Death assay’.**, p<0.01
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Different integrin fibronectin interactions may have different functions in the 
process of adhesion and cell spreading. Lamellipodia extension has been 
shown to be dependent on integrin a4p1 and avp3, with formation of initial 
focal complexes at the leading edge of migratory cells not being dependent on 
RGD integrins a5|31 or avp3 (Pinco et al 2002). In migratory cells, it is after 
this initial formation of focal complexes that integrin a5p1 is recruited, as the 
focal complexes grow into focal adhesions (Laukaitis et al 2001). These 
observations may shed light on the process of adhesion in the experiments 
reported here: a rounded, floating cell may initially adhere through RDG 
binding (fibronectin 11110), by synergy sequence (fibronectin III9), or amino- 
terminal fibronectin 11-9 and fibronectin II2-3 repeats binding of integrin a5pi, 
or by integrin a4pi mediated binding. Only one of these four mechanisms is 
RGD dependent, and so the 19% reduction in adhesion of desmin positive 
cells by the use of RGD blocking peptides becomes understandable. Once 
the cells have adhered, then fibronectin causes the cells to spread. 
Lamellipodia extension may well be mediated by integrin a4pi in our 
experiments, with recruitment of integrin a5p1 occurring subsequently -  
stabilising the spread shape (figure 6 .8 ).
251
Integrin a4pi
Integrin a5p1
Fibronectin substrate -
(i) Lamellipodia 
extension -  
C integrin a4pi
n
Figure 6.8: Hypothetical model of cell adhesion and spreading on fibronectin. 
(A) Cell in suspension. (B) initial adhesion through integrin a4p1 ‘round cell’. 
(C) Cell spreading takes place with (i) lamellipodia extension involving a4p1 
integrin adhesion, (ii) maturation of focal complexes with recruitment of 
integrin a5pi forming focal adhesions, to produce ‘spread cell’.
(ii) Focal complexes mature 
with recruitment of integrin a5p 
Iforming focal adhesions
1
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It can be speculated that, in vivo, fibronectin is associated with the fetal 
DSMC differentiation and proliferation. Furthermore, at least some of this 
effect is mediated by RGD integrins such as integrin a5(31. This could have 
been further explored by using antibodies specific for the activated state of 
integrin pi: if these colocalized with integrin a5  on the surface of the adherent 
cells this would provide more evidence for an active signalling effect (e.g. 
Chemicon MAB2079Z, mouse anti-human active conformation |31 integrin), as 
described by (Luque et al 1996). Similarly, integrin activation could be 
assessed by immunostaining for activated, phosphorylated FAK, and 
examining for colocalization of this to focal adhesions containing integrin a5pi 
(e.g. anti- FAK phospho-Y397 antibody ab4803, Abeam) (Sieg et al 2000).
The contention that fibronectin is associated with the fetal DSMC 
differentiation and proliferation could be further explored by fibronectin 
blockade in a fetal embryonic bladder organ model.
Another avenue for further exploration could be to study the effect of fetal 
DSMC in response to stretch because, in mice, the first vascularized and 
hence filtering glomeruli are evident from E15 and so the fetal bladder 
undergoes physiological cycles of filling and emptying from this time onwards.
There are problems with the use of whole bladder cell suspensions in the 
adhesion experiments: the population of cells would be mixed, and cells could 
have been damaged by the process of generating the cells suspension. The 
cell types present could include urothelium, cells of smooth muscle lineage,
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endothelial cells and fibroblasts, as well as a small number of neural cells 
amongst others. In the adhesion experiments so far performed, the adhesive 
cells may be of several different types, and therefore might well be expected 
to express a different pattern of integrin receptors. From the IHC described 
above SMCs whether fetal or adult in phenotype express integrin a 5 p i, but 
fibroblasts from the lamina propria would not be expected to have this 
integrin, as no immunostaining could be demonstrated for the integrin a5 
subunit in the lamina propria at any age. Fibronectin however was expressed 
in the lamina propria throughout development, so some fibronectin receptor 
might reasonably be expected to be present on cells from this compartment -  
for example integrin avp3. The use of RGD oligopeptides to block integrin 
receptors would be a useful strategy, as all integrin fibronectin receptors 
would be blocked by them.
These adhesion experiments have demonstrated that E18 bladder cells 
adhered to fibronectin. This suggests that a functional role for fibronectin is 
possible.
As described above, all immunoglobulins, whether anti-fibronectin, or non- 
immune IgG, had a large inhibitory effect on the adhesion of bladder cells to 
fibronectin. This non-specific effect has not previously been reported. 
Reasons for this occurring in this cell adhesion system include: 1) the dose of 
blocking antibody had not been optimised, perhaps any effect was 
overwhelmed by adding too much antibody and therefore swamping the 
specific effect with a non-specific effect; 2 ) the blocking antibody used simply 
did not have an adequate specific fibronectin blocking action. This could have
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been tested by using a different model system, for example that described 
using osteoblast maturation (Moursi et al 1997); 3) This may be because 
fibronectin itself will bind IgG molecules, as described by (Rostagno et al 
1996). It is not an effect reported in the literature however, so this mechanism 
is speculative. The fibronectin blocking experiment did not however advance 
our knowledge of the mechanism of adhesion involved
Conclusion
Fibronectin facilitated adherence and spreading of DSMC harvested from the 
developing bladder. These fetal DSMC expressed integrin a5, p1 and desmin. 
Blocking integrin receptors using RGD oligopeptides not only modestly but 
significantly decreased adherent cells which expressed desmin, but also 
reduced cell spreading. Fibronectin and serum had a synergistic effect on 
proliferation of bladder cells. Thus, integrin a5pl is probably one factor that 
mediates adhesion of fetal DSMC to fibronectin, and could potentially mediate 
a proliferative signal from fibronectin to these cells.
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Chapter 7. Mouse fetal bladder explant culture
Hypothesis
Fibronectin-integrin interactions in ex vivo fetal bladders may be important in 
modulating DSMC development.
Background
Fibronectin is upregulated in the ECM of fetal murine DSMC (Smeulders et al
2003), which are proliferative (Smeulders et al 2002). A putative fibronectin 
receptor, integrin a5p1, is also upregulated antenatally in these DSMC 
(chapter 5). Desmin positive cells from E18 bladders adhere to fibronectin and 
express integrin a5p i, a process at least in part modulated by RGD integrins 
such as integrin a 5 p i. Fibronectin adhesion is synergistic with serum in 
promoting proliferation. The environment of a fetal DFSMC in a developing 
fetal bladder is far more complex than this. Cells in 3-d culture behave 
differently to those in 2-D culture (Cukierman et al 2001). Furthermore 
mesenchymal-epithelial reciprocal induction is important in the differentiation 
of both the detrusor and urothelium (Baskin et al 1996b). Similarly there are 
other ECM proteins present (Chapter 5) (Smeulders et al 2003), as well as 
cell-cell interactions, the local growth factor and cytokine environment, and 
mechanical forces (stretch of the bladder), all of which contribute to the 
signals that control proliferation and differentiation of these cells. To examine 
the role of fibronectin and its receptor in normal bladder development by 
generating a homozygous knockout mouse mutant would be an ideal way of 
preserving the other factors, but both the fibronectin null mutants and integrin 
a5 null mutants are lethal before bladder development as a discrete organ is
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present in the mouse. By using an explant model the interaction between 
fibronectin and its putative receptor integrin a5pi could be investigated (Sakai 
et al 2003).
The first part of the strategy would be to generate the explant model, the 
second part would be to perform blocking experiments of ligand/and or 
integrin receptor.
Aims
First, generate a fetal bladder explant model which recapitulates at least some 
of the differentiation features seen in vivo; second, use this model to 
investigate the possible role of fibronectin-integrin interactions on fetal bladder 
DSMC development by attempting to blocking the function of the ligand using 
antibodies.
Results
Generating the explant model.
Preliminary experiments showed that addition of either antibiotics and FCS, or 
FCS alone inhibited growth and these were subsequently avoided (FCS data 
shown in figure 7.2A and B, comparison FCS and antibiotics, versus FCS only 
vs ITS only is in appendix 3: figure 3.1 and table 3.1). In serum-free and 
antibiotic-free culture E14 explants, which were initially composed simply of 
mesenchyme and epithelium, differentiated into three distinct morphological 
layers, with DSM, lamina propria and urothelium; moreover, DSM maturation 
was indicated by upregulation of aSMA (Figure 7.1 C and D). It was also 
observed that the bladders physiologically and functionally matured so that
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they began to undergo spontaneous contractions in this milieu. Growth was 
prominent, as assessed by total cell numbers and total protein, in the first 
three days, while differentiation continued throughout the six days of culture. 
Dissociation of bladders was performed as described in Chapter 4 (n=4 at 
each time-point). Cell counts more than doubled by day 6  (ANOVA p<0.05), 
with evidence of continuing cell division in-vitro as assessed by proliferating 
cell nuclear antigen. Using the BCA protein assay (described above), protein 
was measured for each bladder (N=4 at each time-point), and again showed a 
significant increase (P<0.01 using ANOVA).
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Figure 7.1: Generating explant model of fetal bladder development. (A) 
Genito-urinary tract dissected from E14 mouse (K=kidney; B=bladder; 
U=ureter; 0=ovary; Dots=line of dissection of bladder). (B) Bladders are 
grown on Millipore filters - capillary action draws medium through filter 
and forms a meniscus over the bladder explant. (C) a-SMA 
immunolocalised at low levels in undifferentiated mesenchyme (M) at 
day 0 of culture; U=urothelium (D) Day 6 explant with upregulated aSMA 
expression in DSM; note that the three main layers of bladder have 
differentiated (D=detrusor, L=Lamina Propria, U=Urothelium)
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Figure 7.2: Inhibitory effect of fetal calf serum on explant growth (A) 
Dissociation of bladders (n=explant experiment) showed a significant 
increase of cell numbers in culture for explants grown in ITS (P=0.008 using 
ANOVA). (B) Using BCA assay, total protein content was measured for 
each bladder (n=6 -8  for each time-point), and again showed an increase 
(P=0.008 using ANOVA) for explants grown in ITS.
260
Explant growth in presence of fibronectin blocking antibody.
For this experiment filtered, dialysed antibody at 10 pg/ml of control IgG, or 
anti-fibronectin antibody was added to the IgG and aF wells respectively, at 
the start of the experiment, and then when half the filters were harvested at 3 
days, then the remaining wells were emptied and refilled with new growth 
medium with ITS as described above. Initial experiments using the rabbit anti­
mouse polyclonal antibody AB2033 (Chemicon), and the control rabbit IgG 
(purified rabbit IgG PP64 Chemicon) both caused the explants to shrink. All 
antibodies were therefore filtered using a 0 .2  pm filter and dialysed against 
the normal growth medium using a 10,000 RMW dialysis membrane 
overnight. (A western blot confirmed that the immunoglobulin was not lost by 
filtration and dialysis -  figure 7.3A).
This experiment was repeated 4 times with the 3 different conditions (growth 
medium only (ITS) versus growth medium plus control IgG (IgG) and growth 
medium plus anti-fibronectin antibody (aF)) added to wells on the same plate 
(figure 7.3 B).
There was a large amount of biological variation between bladders, the 
majority of which was variation within a litter as opposed to variation between 
litters (figure 7.4A,B). There was no sex difference between male and female 
bladders (figure 7.4 C)
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Figure 7.3: Filtration and dialysis of IgG, Explant experimental layout (A): 
Immunoglobulin (control) and anti-fibronectin, was filtered through 0.2^m 
membrane, then dialysed against DMEM/F-12 with ITS. The first 2 tracks are 
antibody prior to filtration. The third and fourth tracks are after filtering and 
dialysing the control antibody. The fifth track is the blocking antibody 
(Chemicon AB2033) diluted (to make a large enough volume to filter and 
dialyse), the sixth and seventh tracks show that the antibody is still present 
after filtration. (B): Layout of 6 well plates for explant blocking experiments 
(yellow dots are bladders).
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Figure 7.4: Bladder variation at the start of the explant experiments. (A) 
Histogram of bladder cell numbers, from bladders harvested at embryonic 
day14. (B) Within litter and between litter variation is illustrated. Each 
vertical column represents 1 litter, (c) Male:female variation in bladder size.
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Explant growth
The cell count per bladder for each condition was averaged, and the results 
are shown in figure 7.5A. Cell numbers increased in the medium only wells 
(ITS) from 0 to day 3 to day 6  (ANOVA p= 0.017). The number of cells 
increased more in the control IgG and anti-fibronectin media, relative to the 
start of the experiment, ANOVA p<0.05 respectively. Bladder explants in the 
anti-fibronectin media grew more than those in the control media, which in 
turn grew more than those in the control media (ITS)-figure 7.5. There was no 
statistical difference between these groups.
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Explant proliferation
Proliferation was assessed by expression of proliferative cell nuclear antigen 
(PCNA) using biotinylated mouse anti-human IgG (555567, Pharmingen), as 
described in chapter 4. This produced a clean signal on IHC (figure 7.6), 
allowing quantification of proliferation by counting PCNA positive cells, and 
estimating the total number of cells in each bladder from an average of 4 
representative areas, allowing a cell density to be obtained, and multiplying by 
the area of the section. This was done using ImageJ software. At the start of 
explant culture, proliferative cells were present in all layers (figure 7.6A). By 
day 3 the proliferative cells were mostly in the lamina propria (figure 7.6B). By 
day 6 , two populations of PCNA positive nuclei were present: intensely 
staining as at earlier time-points and weakly staining. Only the intensely 
staining nuclei have been counted (figure 7.6C). The arrows in figures 7.6B 
and C also highlight that the proliferative cells were concentrated in a single 
region of the lamina propria, in a ‘proliferative centre’, which was not evident 
on IHC of in-vivo bladders over E14, E16 and E18 time-points. The patterns 
for the IgG and fibronectin blocking antibodies were similar to this.
Western blots for PCNA expression were not sensitive enough for 
quantification of the tiny amounts of protein extracted from these explanted 
organs. Quantification was therefore performed by counting PCNA positive 
cells. Only intensely stained cells were included -  as described above. Over 6
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days of organ culture PCNA expression, and by implication proliferation, 
decreased 70% in control explants (ANOVA p=0.05), whereas it decreased by 
8 6 % (ANOVA p<0.05) for control IgG treated organs and 87% (ANOVA 
p<0.05) for those exposed to fibronectin blocking antibodies. Both 
immunoglobulins had a strikingly similar effect, but were not significantly 
different from the ITS medium alone.
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B Quantification of PCNA
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Figure 7.6: PCNA expression in explants. At the start of explant culture the 
PCNA positive cells (dark brown) are present throughout the bladder (A )- the 
results for medium alone (ITS), control IgG (IgG) and blocking antibody (aF) 
are shown for dayO (start of explant experiment), day3 and day6  (D).
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Differentiation
Detrusor muscle differentiation was assessed by expression of desmin on IHC 
(figure 7.7). There was virtually no expression of desmin at E14 at the start of 
explant culture. By day 3, desmin had been unregulated and could be seen at 
the periphery of the organ, but was also expressed by some cells throughout 
what would become the lamina propria. By day 6 , there was prominent 
desmin staining throughout the detrusor, but also staining of cells subjacent to 
the urothelium (figure 7.7C). It was never expressed in the urothelium (as 
befits a smooth muscle cell marker).
Western blotting was not sensitive enough to quantify desmin expression, so 
quantification was made by measuring the proportion of the surface area of 
each section from an explant staining positively for this antigen. This was 
performed using ImageJ 1.30 software. The explant experiment had been 
repeated 3 times, so n=3 for these comparisons. In explants grown in medium 
without immunoglobulins (ITS), desmin was progressively upregulated, with a 
10-fold increase by day 6  (ANOVA p=0.008). IgG and aF treated explants 
showed a similar initial upregulation of desmin to day 3, but this then tailed off. 
There was a significant difference between ITS and aF explants by day6  (t- 
test p=0.02), but no such significance for IgG due to the wider error bars. The 
over-all effect of both the control IgG and the blocking antibody on desmin 
expression was the same.
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Figure 7.7: Desmin expression during explant culture: at the start of explant 
culture (E14) there was very little desmin expression (A). By 3 days there was 
definite expression at the periphery of the detrusor, but also some expression 
throughout what would become the lamina propria (B). After 6  days in culture 
desmin was well expressed by the outer detrusor layer of the bladder explant, 
but also by cells subjacent to the urothelium (C). Quantification was performed 
by measuring the proportion of the explant surface area on IHC, positive for 
desmin (D).
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Discussion
An ex-vivo model of fetal bladder maturation
The descriptive work as described above showed a temporal association 
between ECM and integrin expression both for fibronectin and laminin, and 
their respective receptors integrins a5pi and a7p1. However the functional 
role of these ECM/integrin interactions has not been demonstrated in the 
context of normal spatial arrangement of cell types and matrix in the normal 
fetal murine bladder.
A model for early embryonic bladder development has been generated and 
characterised: the explanted bladders grow in terms of increasing cell 
numbers and total protein, differentiate, and can become contractile. The role 
of mesenchymal /epithelial interactions in reciprocal induction of urothelial and 
mesenchymal maturation have been demonstrated in chimeric rat embryonic 
bladder explant constructs (Liu et al 2000), but smooth muscle contraction, as 
was noted in my experiments, has not been previously described. Similarly 
this experimental strategy has been employed to investigate the role of 
integrins and extracellular matrix in instructing development in ex-vivo culture 
of kidneys (Zent et al 2001).
The optimal conditions to maximise embryonic bladder explant growth 
included the use of DMEM/F-12. This is similar to the optimal growth 
conditions described by Gupta et al (2003) for metanephric explant culture.
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However, the best metanephric growth was achieved in the presence of 5% 
fetal calf serum (FCS), whereas in this study bladder explants grew best when 
supplemented by insulin, transferrin and selenium (ITS). The use of antibiotics 
(gentamicin, penicillin and streptomycin) has also been demonstrated to 
inhibit growth of metanephroi in culture (Gilbert et al 1994). This is similar to 
the inhibitory effect found with the use of antibiotics (penicillin and 
streptomycin) and anti-fungals (amphotericin) on ex-vivo embryonic bladder 
growth. However the organs grew better in serum free, antibiotic free culture 
(appendix 3: table 3.1 and figure 3.1). This model has now been used to study 
the effect of VEGF on fetal bladder development (Burgu et al 2006). In this 
model explant growth was significantly increased by the addition of VEGF, as 
assessed by the following parameters: detrusor smooth muscle area; 
percentage increase in surface area; total cells per explant; total number of a- 
SMA expressing cells per explant; total number of CD31 positive cells per 
explant; protein per explant; DNA per explant; lamina propria and detrusor 
smooth muscle proliferative index; urothelial proliferative index. Lamina 
propria and detrusor apoptotic index, and urothelial apoptotic index were 
however significantly reduced (Burgu et al 2006). Growth was therefore a 
combination of increased proliferation and increased survival (decreased 
apoptosis).
Embryonic bladder explants more than doubled their cell number, but this 
growth did not match that of in-vivo bladders -  figure 7.8. The organs did 
however undergo maturation, becoming trilaminar structures with expression 
of desmin and a-SMA in the detrusor layer. That this reflected smooth muscle 
differentiation was best illustrated by the onset of spontaneous contractions
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from 4 days of culture onwards in some explants. By assessing proportion of 
the cross-sectional area that became converted to smooth muscle, and using 
aSMA and desmin expression as markers for this, an assessment of 
differentiation was possible. The morphology of the explants most closely 
matched neonatal bladders -  figure 7.9.
Percentage of PCNA positivity was used as a measure of proliferation. This is 
a standard technique, however PCNA is present in cells as they go into S1 
phase, and remains present after mitosis has occurred. PCNA is therefore 
present in cells about to undergo proliferation, proliferating cells and in cells 
that have recently replicated (Mathews et al 1984; Morris and Mathews 1989). 
PCNA can be detectable in some model systems up to 3 days after 
proliferation has stopped (Wijsman et al 1992). Use of PCNA immunostaining 
therefore leads to an overestimate of the population of cells actually 
undergoing proliferation at any one moment (Wijsman et al 1992). Measuring 
uptake of BrdU would have been a more sensitive technique to use.
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Number of cells per bladder in explants versus in vivo
bladders
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Figure 7.8: Explant growth in cell numbers versus in vivo bladders 
Increase in cell numbers in explants (pink) as compared to in-vivo bladders 
(blue). The in-vivo data are from 3 parallel suspensions, prepared from 
whole litters at E14 (dayO), E18 (day 4) and neonatal mouse pups (day7). 
This illustrates that although ex vivo bladders did grow in culture, the 
growth was not at a normal rate.
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Smooth muscle prorportion of bladders assessed 
by desmin expression in vivo versus ex vivo
30%
25%
0)
0  . „(/) eg 20%
1 2t <0
O g 15%
€  3  10%
a0
01 5%
0%
0 2 4 6 8
Days of organ growth (from E14)
Figure 7.9: Smooth muscle maturation of explants versus in vivo bladders. 
The proportion of bladder surface area that has differentiated into smooth 
muscle has been assessed by examining the proportion of the surface area 
of histological sections that expressed desmin. N=3 for each time-point 
(separate bladders stained at the same time). This allowed comparison to 
be made against the proportion of smooth muscle differentiation that has 
occurred in the ex vivo bladders.
In vivo 
Ex-vivo
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Growing embryonic bladders ex-vivo is obviously not a normal process. The 
bladders had no blood supply, needing to receive all their nutrients by 
diffusion from the fluid surrounding them, and exchange gases across their 
surface area, rather than at a capillary level. The diffusion distance would 
therefore have been markedly increased. That this should limit growth should 
not be a surprise. Similarly these explants were not exposed to the growth 
factors present in urine, or to the mechanical stretch by urine that occurs from 
embryonic day 16 onwards in the mouse. The role of these growth factors and 
mechanical stretch in normal bladder growth are however unknown. 
Quantitation of desmin and aSMA was assessed by measuring proportions of 
surface area on cross-sections, but not by direct measurement of protein 
levels by western blot. It would have been more robust to have measured 
PCNA and smooth muscle markers in both ways. Unfortunately samples were 
not pooled and the tiny amounts of protein extracted from individual bladders 
were too small to perform WB with.
Despite these limitations ex vivo embryonic bladder culture provides a model 
which recapitulates key steps in detrusor smooth muscle differentiation 
providing a tool for interventional studies to examine development ex-vivo, 
even though it is not per se a good model for normal growth. This model has 
been used to explore the effect of exogenous VEGF on explant bladder 
growth (Burgu et al 2006). The addition of VEGF to the explanted bladders in 
this study might have improved their growth, perhaps making a perturbing 
effect (such as the use of the anti-fibronectin antibody) more marked.
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Unfortunately the first strategy employed to block fibronectin function using a 
polyclonal antibody to fibronectin, as has been successfully described by 
Moursi et al (1997) and Sakai et al (2003) - the latter in mouse salivary gland 
explants - did not prove successful. In this explant experiment the control IgG 
appeared to have the same effect as the blocking antibody. In the adhesion 
blocking experiment (discussed below), all three IgG’s, whether control or 
function blocking, had a large effect -  reducing cell adhesion by 50% when 
added to explant growth media at 10  pg/ml (final concentration).
Is there a mechanism that can explain these somewhat surprising results? 
There are several possible explanations: 1) the blocking antibody was not 
effective, and non-specific effects of IgG swamped any specific anti- 
fibronectin action; 2 ) the outcome measures were crude, and it may have 
been with more accurate techniques, such as the use of FACS as described 
by Burgu et al (2006), that a difference between the control and blocked group 
could have been found; 3) perhaps if growth of the explants had been 
optimised by the addition of VEGF Burgu et al (2006), then the blocking effect 
of the anti-fibronectin antibody might have been detectable. 4) a speculative 
possibility is that IgG generically interacts with fibronectin (Rostagno et al 
1989; Rostagno et al 1996; Rostagno et al 2002), and has a blocking function. 
This effect has not been described in previous cell culture (Moursi et al 1996; 
Moursi et al 1997), or organ culture work (Sakai et al 2003).
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Conclusion
In order to further explore possible roles for fibronectin in the whole 
developing bladder, rather than isolated cells, an explant embryonic organ 
culture model was established in mice which recapitulated at least some of 
the differentiation features seen in vivo. This model was used to investigate 
the possible effects of presumed 'fibronectin-blocking' antibodies on 
parameters of growth and differentiation: however, no specific effects could be 
demonstrated. Time did not allow the testing of possible effects of RGD 
oligopeptides.
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Chapter 8. Fibronectin expression in normal and 
pathological development of human fetal bladders
Hypotheses
Fibronectin is expressed during normal human fetal DSMC development, 
furthermore altered fibronectin expression may be implicated in human BOO 
detrusor smooth muscle pathology.
Background
Fibronectin is upregulated in the ECM of fetal murine DSMC (Smeulders et al 
2003), which are proliferative (Smeulders et al 2002). A putative fibronectin 
receptor, integrin a 5 p i ,  is also upregulated antenatally in these DSMC 
(chapter 5). Desmin positive cells from E18 bladders adhere to fibronectin and 
express integrin a 5 p i ,  a process at least in part modulated by RGD integrins 
such as integrin a 5 p i .  Fibronectin adhesion is synergistic with serum in 
promoting proliferation (Chapter 6 ).
This leads to questions about the expression of fibronectin in human bladders; 
1) is fibronectin expressed in the basal lamina of fetal human bladders? 2 ) 
What the pattern of expression of fibronectin and the morphology of these 
bladders in obstruction? 3) How does normal development and development 
of the urinary tract (kidneys and bladder) in obstruction differ? In order to be 
able to compare the normal and obstructed kidneys and bladders a measure 
of renal dysplasia (renal dysplasia score) needs to be generated, as does a 
scoring scheme for muscle abnormality in the bladder (muscle dysmorphology
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score). The strategy would therefore be to obtain ethical committee approval 
to identify normal and abnormal human fetuses (diagnosed as having 
presumed congenital bladder outflow obstruction on post mortem) from the 
human embryo bank held at UCH by Dr R Scott. Using the information from 
the post mortem certificates, from IHC examination of the urinary tracts 
(bladders and kidneys) to answer these questions.
Aims
1) Demonstrate the normal pattern of fibronectin expression in human fetal 
bladders, and to correlate this with gestational age, and measures of cell 
turnover such as proliferation (by Ki67 expression) and apoptosis (using 
TUNEL test). 2) Describe the fibronectin expression in fetal bladders with 
presumed BOO and to compare this with normal development.
Results 
Normal development:
Muscle
At 16 weeks the human fetal bladder had three recognisable morphological 
layers on histology section: first, urothelium; second, lamina propria; and third, 
detrusor; surrounded by a serosa composed of loose areolar tissue. The 
detrusor layer (stained red by Masson’s trichrome in figure 8.1 A) had well 
defined recognised muscle bundles, but those on the medial and lateral side
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of this layer are smaller. As gestation proceeds the overall thickness of the 
detrusor layer increases, with the muscle bundles become much larger and 
more homogenous in size throughout the detrusor layer (figure 8.1 B-F).
Serial sections immunostained with mouse anti-human desmin antibody 
revealed a similar pattern of muscle distribution to that shown by the 
Masson’s trichrome stain (Figure 8.2).
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Figure 8.1: Masson’s trichrome staining of normal human fetal bladders from 14 
weeks of gestational age to 31 weeks. (A) 18 wks, (B) 20 wks, (C) 24 wks, (D) 
26 wks, (E) 28 wks, (F) 31 wks. Scale bar 400fxm.
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Figure 8.2: Desmin immunostaining of normal human fetal bladders from 14 
weeks of gestational age to 31 weeks, counter-stained with haematoxylin. (A) 
18 wks, (B) 20 wks, (C) 24 wks, (D) 26 wks, (E) 28 wks, (F) 31 wks. Scale bars 
40 i^rn.
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Collagen
Van Gieson staining stains collagen fibres red. Collagen staining was present 
persistently in the lamina propria throughout development (figure 8.3).
284
A 18 wks B 20 wks
D 26 wks
__
D
- I  U
LPi_ r
■ * • '*«  ' •  ■ ife/ i ' - 'V 'W S v ' -
F 31 wks
U
;i&£SSBbmC 24 wks
f
Figure 8.3: Van Gieson staining of normal human fetal bladders from 14 weeks 
of gestational age to 31 weeks. (A) 18 wks, (B) 20 wks, (C) 24 wks, (D) 26 wks, 
(E) 28 wks, (F) 31 wks. Scale bar 40 jim.
Wall thickness
For normal bladders the total wall thickness increased over gestation from 16 
weeks to 32 weeks (figure 8.4A). This was a statistically significant, r=0.89 
p=0.001, 2-tailed Pearson correlation. Most of this apparent growth was in 
thickness of the detrusor layer as can be seen from the scatter plot in figure 
8.4B. Growth in detrusor thickness correlated significantly with gestational 
age, r=0.74 p< 0.01 2-tailed Pearson correlation.
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Figure 8.4: Morphometry of normal human fetal bladders. Wall thickness (mm) 
as measured on sections of normal fetal bladders using ImageJ. (A) total wall 
thickness in normal bladders compared with gestational age. (B) detrusor 
thickness versus gestational age (C) lamina propria thickness compared to 
gestational age. Males are green boxes, females are red boxes.
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Fibronectin
Fibronectin, as assessed by IHC, was expressed predominantly in association 
with the fetal smooth muscle cells of the detrusor (figure 8.5). As gestation 
progressed, the thickness of the detrusor muscle increased, as did the area of 
associated fibronectin expression - assessed qualitatively by examination of 
the slides (figure 8.5). Colocalization of desmin and fibronectin examined 
using confocal microscopy revealed the close relationship between fetal 
smooth muscle cells and fibronectin in the fetal detrusor (figure 8 .6 ).
Quantification of detrusor fibronectin percentage of surface area (%) positively 
correlated with gestational age, r=0.62 p<0.05 Pearson 2-tailed test. 
Quantification of the lamina propria fibronectin area showed no significant 
change related to gestational age.
288
A 18 wks
*  *  / * *  A
LP U
M-
B 20 wks
V.
w v■ > 'lin"' - w • ' * LP U
; > • .  ? c*
# **? < ./
€ :■ i'S> ? *y-
r. %  ‘..ft '?,*
■ <■ is* *«•. ;.1M-
C 24 wks
■ f U LP
D 26 wks
LP U
. . V
• ■■■. _
D
" C :
*A**
E 28 wks U F 31 wks
T;
LP
U
X-
LP
V
V  +£_■
Figure 8.5: Fibronectin immunostaining of normal human fetal bladders from 14 
weeks of gestational age to 31 weeks. Counter-stained with haematoxylin. (A) 
18 wks, (B) 20 wks, (C) 24 wks, (D) 26 wks, (E) 28 wks, (F) 31 wks. Scale bar 
40jim. Positive and negative controls for anti-human fibronectin antibody 
(A0245, DAKO) are shown in Appendix 4: figure 4.1.
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AB
Figure 8 .6 : Desmin and fibronectin double immunostaining in normal bladders 
(18 weeks gestational age) . Green (FITC) fibronectin, red (TRITC) desmin. 
(A) x20 FITC, immunofluorescence staining of Fibronectin (green). TRITC, 
immunfluorescent staining desmin (red) and combined image, (B) x99 High 
power view of detrusor with FITC and TRITC signals superimposed.
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Cell turnover in normal bladder development
There was no significant correlation between gestational age and proliferation 
as measured by percentage of Ki67 positive nuclei in the urothelium, lamina 
propria and detrusor, data tabulated in Appendix 4: table 4.2. Similarly no 
correlation between apoptosis, as measured by TUNEL positive cells as a 
percentage of total cells in each layer, and gestational age was apparent, data 
tabulated in Appendix 4: table 4.2. The results for each layer of the bladder for 
all gestational ages were averaged (figure 8.7). Although the lamina propria 
appeared to be a more active compartment both in terms of proliferation, as 
assessed by Ki67, and apoptosis, this was not statistically significant.
However the most actively proliferating bladders were most proliferative in all 
3  compartments: urothelial proliferation correlated with lamina propria 
proliferation and detrusor proliferation (r=0.81 p=0.005, and r=0.71 p<0.05) 
and between lamina propria and detrusor proliferation (r=0.87 p<0.001). 
Detrusor fibronectin density did both correlate significantly, but inversely with 
downregulation of proliferation in the detrusor layer (r=-0.694 p=0.012).
Comparison of normal male and female fetal bladders
In none of the analyses were there any significant differences between normal 
male and female fetal bladders. All bladders were therefore analyzed as one 
group.
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Figure 8.7: Proliferation and apoptosis in normal fetal bladders. (Bars 
mean±SEM)
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Bladders from fetuses with presumed bladder outflow 
obstruction
Muscle
The amount of muscle present in the presumed congenitally obstructed 
bladders varied across a spectrum from thick walled, to intermediate muscles, 
to bladders where the muscle was attenuated (figure 8 .8 ). The thickness of 
the lamina propria also varied, but in the opposite direction: a thick detrusor 
layer was associated with a thinner lamina propria (figure 8 .8  A,B), and thin 
detrusor was associated with a thicker apparent lamina propria (figure 8 .8  
E,F). These results are plotted against gestational age and normal bladders in 
figure 8.9. Analysis was performed by comparing the presumed BOO 
bladders (all male) against age and sex matched normals (ie males only), 
against age matched controls (male and female) and also with all male and 
female normals (with similar results).
Muscle morphology
Examination of the morphology of the muscle bundles in the detrusor showed 
a spectrum of abnormality, varying form near normal (with easily recognised 
bundles with no excess connective tissue) (figure 8.10 A,B); to bladders 
where the detrusor muscle bundles were still recognisable, but with increased 
collagen (figure 8.10 C); to bladders where the amount of muscle was 
reduced, but also where the muscle bundles were no longer recognisable, 
with large amounts of connective tissue (figure 8.10 D,E,F).
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Decrease in the area density of muscle in these bladders correlated positively 
with increasing muscle dysmorphology score (r=0.49 p<0.05, 2-tailed 
Spearman non-parametric rank correlation). Only one quarter the variation in 
the dysmorphology score can be explained by differences in muscle density.
Collagen
The amount of collagen present varied in a spectrum in these bladders also: 
the thicker walled bladders had relatively little collagen, whereas the 
intermediate bladders had more, collagen between and within the muscle 
bundles of the detrusor, and the ‘disrupted/attenuated’ bladders had less 
muscle and more general connective tissue infiltration (Figure 8 .8 ).
Muscle/Collagen ratios are tabulated in Appendix 4: table 4.1, and results 
discussed in Appendix 4.
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Figure 8 .8 : Fetal bladder outflow obstruction Masson’s trichrome and van 
Gieson stains . (A,C,E) Masson’s Trichrome. (B,D,F) Van Gieson stain. (A,B) 
thicker walled bladder, (B,C) intermediate-walled bladder, (E,F) thinner-walled 
bladder with disrupted detrusor. Scale bar400^m.
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Figure 8.9: Morphometry of fetal presumed bladder outflow obstruction (A) 
Total wall thickness, (B) detrusor wall thickness and (C) lamina propria 
thickness versus gestational age for presumed obstructed (Open circles, 
BOO) and all normal bladders (Black circles, Normals).
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Figure 8.10: Muscle dysmorphology in presumed fetal bladder outlet obstruction . 
(A) Muscle dysmorphology score 2, MC ratio 0.45.(B) Muscle dysmorphology 2, 
MC ratio0.84. (C) Muscle morphology 5, MC ratio 0.77. (D) Muscle Morphology 5 
MC ratio 0.27 (E) Muscle morphology score 6, MC ratio 0.23. Scale bar 400^im. 
MC is muscle/collagen ratio, discussed in Appendix 4.
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Fibronectin
Fibronectin area in congenitally obstructed bladders was maximal on 
immunostaining the most morphologically normal bladders with intermediate 
wall thickness (figure 8.11A). These bladders also had the most normal 
muscle morphology. In the thick-walled obstructed bladders, fibronectin was 
present in the basal lamina around the detrusor smooth muscle cells, but the 
immunostaining was apparently reduced as assessed qualitatively by 
examination of the slides (figure 8.11 C). These bladders had intermediate 
muscle morphology. Double immunostaining using confocal microscopy 
showed that fibronectin was present in thick walled bladders, in the basal 
lamina of smooth muscle cells (figure 8 .1 2 ), but that this was lost in bladders 
with disruption of muscle morphology (figure 8.13). Figure 8.14 shows that the 
bladders with the most normal architecture were associated with fibronectin in 
the basal lamina, whereas disrupted architecture was associated with less 
fibronectin.
The detrusor fibronectin area inversely correlated with the muscle 
dysmorphology score (r=-0.54 p<0.05 2-tailed Spearman rank correlation) for 
all bladders both presumed BOO and normal (with no change whether males 
and females were included or not).
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Figure 8.11: Fibronectin expression compared to muscle morphology in fetal 
presumed BOO. (A.C.E) Masson’s Trichrome; (B,D,F) fibronectin 
immunostaining. (A,B) Muscle morphology minimally affected, (CD) 
moderately affected morphology (E,F) bladder disrupted detrusor. Scale bar 
400|xm.
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Figure 8 .1 2 : Fibronectin and desmin double immunostaining in thick-walled 
presumed obstructed bladder. (A) FITC immunofluoresecent staining of 
fibronectin in the detrusor layer. (B) Desmin detected using TRITC labelled 
antibodies in detrusor layer. (C) Combined FITC/TRITC (desmin/fibronectin) 
expression. (D) high power view of area in white box in C, showing desmin 
expression of DSMCs, with surrounding fibronectin in the basal lamina. 
Magnification (A-C) x2 0 . Magnification (D) x100.
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Figure 8.13: Fibronectin and desmin double immunostaining in disrupted, thin- 
walled presumed obstructed bladder. (A) FITC immunofluoresecent staining of 
fibronectin in the detrusor layer. (B) Desmin detected using TRITC labelled 
antibodies in detrusor layer. (C) Combined FITC/TRITC (desmin/fibronectin) 
expression. (D) high poer view of area in white box in C, showing desmin 
expression of DSMCs, with surrounding fibronectin in the basal lamina. 
Magnification (A-C) x20. Magnification (D) x100.
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Figure 8.14: Fibronectin and desmin double immunostaining in the 
detrusor of normal, thick walled, disrupted detrusor. Comparison of (a) 
normal detrusor fibronectin desmin colocalization; (b) thick walled, 
presumed obstructed bladder showing loss of fibronectin; (c) disrupted 
detrusor with loss of fibronectin.
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Renal dysplasia, muscle dysmorphology and fibronectin expression
The most normal bladders from presumed BOO cases, were associated with 
the most normal kidneys (figure 8.15 A,B). Moderately disrupted thick-walled 
bladders were associated with marked renal malformations (figure 8.15 C,D). 
The most abnormal muscle morphology was associated with the most 
abnormal kidneys (figure 8.15 E,F). The muscle dysmorphology positively 
score correlated with the renal dysplasia score (r=0.823 p<0.001, 2-tailed 
Spearman rank correlation).
Similarly, the same comparison was made between the fibronectin expression 
of these bladders and the degree of kidney abnormality (figure 8.16). A 
greater degree of fibronectin immunostaining was associated with more 
normal kidneys (figure 8.16 A,B); less fibronectin immunostaining was 
associated with more dysplastic appearance of the kidneys (figure 8.16 C,D); 
Absence of fibronectin in the most severely affected bladders was associated 
with severe renal dysplasia (figure 8.16 E,F). Detrusor fibronectin area (%) 
significantly negatively correlated with renal dysplasia score (r=-0.573 p<0.05, 
Spearman rank correlation coefficient). Similarly decreasing detrusor 
fibronectin area (%) correlated with an increasing muscle dysmorphology 
score, detrusor fibronectin area (%) versus muscle dysmorphology score( r=- 
0.61 p<0.05, Spearman rank correlation).
In summary greater detrusor fibronectin immunostaining was associated with 
more normal muscle morphology, more muscle and less collagen, and the
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most normal kidneys. Lower detrusor fibronectin immunostaining was 
associated with disrupted muscle morphology, loss of muscle and increased 
fibrosis, and with increased renal abnormalities.
Lamina propria fibronectin area or density showed no association with 
increasing fibrosis, or the degree of kidney malformation.
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Figure 8.15: Detrusor muscle morphology and renal dysplasia. (A,C,E) 
Masson’s Trichrome; (B,D,F) Haematoxylin and eosin staining of the fetal 
kidneys from the same fetuses. (A,) Muscle morphology minimally affected, (C) 
moderately affected morphology (E) bladder disrupted detrusor.
Scale bar 40|im.
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Figure 8.16: Detrusor fibronectin immunostaining and renal dysplasia. (A,C,E) 
Masson’s trichrome; (B,D,F) Haematoxylin and eosin staining of the fetal 
kidneys from the same fetuses. (A) Muscle morphology minimally affected, 
fibronectin expressed strongly in detrusor muscle bundles. (C) moderately 
affected morphology, with fibronectin weakly expressed in detrusor muscle 
bundles. (E) bladder with disrupted detrusor muscle bundles, no fibronectin. 
Scale bar 40pm.
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Proliferation and apoptosis in presumed obstructed fetal bladders
Averaging cell turnover for all presumed BOO bladders the urothelium 
showed similar incidence of apoptotic 3.7±2.4% (mean±SEM) and proliferative 
cells (3.5±1.2%), not significantly different to that found in the normal 
bladders. In the lamina propria, proliferation (5.3±1.5%) was not significantly 
greater than in the normals (p=0.31), but apoptosis was significantly reduced 
(0.1±0.02%), p<0.05 2-tailed t-test if all normal bladders were considered, 
however this did not reach significance if only age and sex matched controls 
were compared (p=0.17). There were no significant differences in the cell 
turnover for the detrusor.
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Proliferation in obstructed bladders
Urothelium Lamina Propria Detrusor
Apoptosis in obstructed bladders
Urothelium Lamina Propria Detrusor
Figure 8.17: Proliferation and apoptosis in presumed BOO 
bladders. Bars show mean±SEM of counts for bladders.
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Comparisons between normal fetal bladders and presumed 
obstructed fetal bladders
The presumed congenitally obstructed bladders were compared to all the 
normal bladders.
Examination of wall thickness however revealed that the presumed 
congenitally obstructed bladders had significantly greater total wall 
thicknesses (p=0 .0 0 1  2 -tailed t-test), and that this increase was mainly due 
to an apparent increase in lamina propria thickness (p=0.003) (figure 8.18 
A,B). The difference between presumed BOO and normal groups did not 
reach significance for the detrusor thickness (figure 8.18 C). A scatter-plot 
between the wall thicknesses for fetal presumed BOO versus all the normal 
bladders against gestational age is shown in figure 8.4.
Comparison between the normal group and presumed BOO group showed 
that the expression of fibronectin (fibronectin area (%)) in the detrusor was 
significantly reduced in the presumed obstructed (8.4±2.9%) versus normal 
bladders (18.4±1.9%), p<0.01 2-tailed t-test unequal variance (figure 8.19A) 
The obstructed bladders similarly had a greater muscle morphology score 
(17±1.5) versus normals (9.5±0.9), p<0.05 2-tailed t-test unequal variance 
(figure 8.19B). Renal dysplasia was higher in the presumed BOO group 
(10±1) compared to the normal fetal bladders (1 ±0.5), p<0.05 2-tailed t-test 
unequal variance. Comparisons of the muscle/collagen ratios showed a 
reduction in the presence of obstruction, but this was not significant (figure
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8.19C). Similarly the decrease of lung/weight ratios in the presence of 
oligohydramnios did not reach significance.
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Figure 8.18: Comparisons of wall thickness between fetal presumed BOO 
bladders and normal controls. (A) Total wall thickness was significantly 
bigger. (B) Lamina propria thickness was significantly greater in BOO 
bladders. (C) Detrusor thickness was not significantly larger in BOO bladders. 
*, p<0.05; **,p<0.01. Data plotted as mean±SEM.
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Figure 8.19: Comparisons between fetal presumed BOO and normal 
controls. (A) detrusor fibronectin area percentage was down-regulated. (B) 
Muscle morphology score was upregulated. (C) Muscle/Collagen ratio was 
not significantly different. *, p<0.05; **,p<0.01. Data plotted as mean±SEM.
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Discussion
Normal development of the human fetal bladder
In normal fetal bladder the wall of the bladder underwent an approximate 
doubling in thickness from 0.5 mm to 1.2 mm, from 16 to 24 weeks. Thereafter 
there was no further increase. Total wall thickness more than doubled, which 
was statistically significant. This was almost entirely due to an increase in 
thickness of the muscle layer which increased from 0.3 to 1.0 mm from 16 to 
24 weeks and thereafter plateaued. The lamina propria thickness did not 
increase. Similar results were obtained in previous studies: 15 normal male 
and female bladders in the age range 19 to 40 weeks, with a mean 
gestational age of 27 weeks had a detrusor thickness of 1 mm (Kim et al 
1991a); Workman and Kogan (1990) described 5 normal fetal bladders with a 
gestational age of 27±4 weeks (mean ± SEM) as having detrusor thickness of
0.9±0.2 mm; and Freedman et al (1997) described a normal population of fetal 
bladders <30 weeks gestational age with a detrusor thickness of 1.1 ±0.8 mm, 
and >30 weeks 1.8±0.1 mm. This again is in close agreement with the 
detrusor thickness described in our series. No data has been described for 
the thickness of the lamina propria in other series.
In normal bladders at 16 weeks, the muscle bundles were poorly developed, 
and thin, but demonstrated a progressive increase in size until mature large 
muscle bundles were present by 30 weeks (figures 8.1, 8.2). This 
morphological change has also been described by (Kim et al 1991a). The 
amount of muscle present (muscle area), but not the percentage of surface
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area of muscle present (muscle surface area (%)), significantly increased in 
our series, as was described by (Kim et al 1991a). In our series the 
muscle/collagen ratio doubled significantly during gestation (p<0.05 2-tailed 
Pearson correlation), and again, Kim et al reported a similar finding (Kim et al 
1991a). Bladder wall thickness is dependent on the state of filling of the 
bladder. In this series, only sections of the dome were fixed, so the bladders 
wall thickness is that for relaxed bladders. Sections of bladder dome were 
obtained in another series (Freedman et al 1997), and then fixed, so the wall 
was relaxed in a comparable manner to our series. In other studies, the 
bladders were fixed in distension (Workman and Kogan 1990;Kim et al 1991b, 
a).
Fibronectin expression was immunolocalised mainly to the detrusor layer and 
increased with gestational age (fibronectin area (%)), r=0.62 p<0.05, as did 
the detrusor thickness (r=0.74 p<0.01). The area of muscle correlated with 
the area of fibronectin as can be seen by comparing figures 8 .1 , 8 .2 , 8 .6 ; and 
the confocal images highlight that fibronectin appeared to be in the basal 
laminae of the DSMC. The area of muscle correlated with the area of 
fibronectin for the normal bladders, r=0.76 p<0.01 (Data appendix 4). In 
normal human fetal bladders fibronectin is immunostaining increases with 
growth of the DSMC (figure 8 .6 ). This increase in normal detrusor fibronectin 
has not previously been reported.
Cell turnover has not previously been described in the fetal human bladder. 
There was a significant inverse association between fibronectin area and 
density (%), and downregulation of proliferation in all layers of the normal
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human fetal bladder. This could mean either that fibronectin was acting as a 
maturation factor in this case, or that some other mechanism was inhibiting 
the proliferative signal from the fibronectin. This observation agreed with the 
data described by Smeulders et al where increasing fibronectin in the detrusor 
antenatally was actually associated with a progressive decrease in 
proliferation in the detrusor (Smeulders et al 2002, 2003). There was however 
a marked decrease in postnatal fibronectin expression in murine bladders, 
associated with a further decrease in proliferation of DSMC, and an increase 
in maturation, as assessed by desmin IHC and Western blot.
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Fetal bladder outlet obstruction
Comparisons were made between the presumed BOO bladders and the 
normal bladders (there was no difference in outcome if the comparisons were 
made by comparing all the normals, or age-matched, or age and sex-matched 
controls), using Students t-test e.g. for wall thickness, fibronectin expression, 
renal dysplasia score etc. Correlations were also drawn for the whole group 
for measurements that varied continuously from normality to abnormality. This 
allowed correlation between muscle morphology (dysmorphology score) and 
renal abnormality (renal dysplasia score), for example, to be made.
Comparisons between presumed BOO and normals revealed that the 
presumed BOO bladders were generally thicker walled than the normal 
bladders, averaging 70% thicker. This was significant, p<0.01 unpaired t-test. 
The absolute increase in wall thickness was also described in previous human 
fetal series (Workman and Kogan 1990;Kim et al 1991b;Freedman et al 
1997). However in these series the detrusor muscle thickness was 
significantly increased. This was not found in this series, where it was the 
doubling in width of the lamina propria in the obstructed group that resulted in 
the overall difference in total wall thickness. Comparisons between the normal 
and presumed BOO groups in this study, with regards muscle and collagen 
area and density (%) were not significant (data in appendix 4). This was 
because the obstructed group included members with a higher than ‘normal’ 
muscle area (perhaps compensated bladders), and at the other extreme 
members with a lower than normal muscle area (possible decompensated
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bladders). Similar observations applied to collagen expression. This wider 
range averaged out to similar mean values for muscle area, collagen area, 
and muscle/collagen ratio as for the normal controls (figure 8.21  and below for 
further discussion of hypothetical mechanisms of bladder dysgenesis). Again 
these results agreed with series previously described (Freedman et al 1997). 
Fibronectin expression as measured by percentage of surface area (%) in the 
presumed BOO bladders was halved in comparison to the normal male fetal 
bladders. Other differences between the groups that were significant included 
a marked increase in the dysmorphology scores and renal dysplasia scores in 
the presumed BOO bladders compared to the normals.
Comparisons within the group of obstructed bladders showed that this was a 
heterogenous group. Some bladders had thick muscular walls, some had 
almost no muscle left at all. If the muscle/collagen ratio was examined some 
were much more muscular than normal bladders, whereas some were much 
more fibrotic. Increased detrusor fibronectin was associated with more normal 
muscle morphology, more muscle and less collagen, and the most normal 
kidneys. Reduced detrusor fibronectin was associated with disrupted muscle 
morphology, loss of muscle and increased fibrosis, and with increased renal 
abnormalities. Fibronectin was lost with increasing severity of obstruction.
From this study it is not possible to quantify the degree of obstruction, but the 
most abnormal human bladders had a histological appearance similar to 
rabbit models of decompensation, and adult human decompensated bladders 
(Buttyan et al 1997).
317
Reliability of methods of quantification
It would have been much more powerful to have had descriptive 
immunohistochemistry compared with an independent measure of the amount 
of protein by Western blot, or ELISA (eg Desmin as smooth muscle marker), 
collagen and fibronectin. Unfortunately this was a retrospective study using 
tissue that had been stored in paraffin blocks. No protein samples were 
available for independent analysis by, for example, Western blot. The 
significance of the area quantifications made should not be over-interpreted, 
but simply used as supporting evidence for the immunohistochemistry.
The immunohistochemical observations in this study were backed up by 
morphometric analyses of the thickness of the bladder walls in these human 
fetal bladders. The results obtained were in agreement with previous series of 
human data. The area and area (%) of muscle, collagen and fibronectin in 
these human fetal bladders measured. This was a modification of the 
methods used by previous authors (Workman and Kogan 1990;Kim et al 
1991a, b;Freedman et al 1997). In these papers the authors measured wall 
thickness, but then at medium to high power measured the area of muscle, 
connective tissue or collagen in multiple defined small areas. This produced a 
two-dimensional density measurement used as a surrogate for ‘the amount’ 
of eg muscle present. Freedman et al called this the ‘density (%)’ (Freedman 
et al 1997). In this thesis, however the total area of, for example muscle, in a 
section has been measured, as well as the total area of the section so that not 
just a density measurement (the term percentage surface area is used as an 
alternative to area density (%) in this thesis), but also a total area 
measurement. These values have different advantages and disadvantages,
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so a consideration of both is useful. Figure 8.20 describes in cartoon form the 
relationship between the linear morphometric data, area data, and 
implications for comparison with mouse data where independent western blot 
data was available.
Area measurements will vary according to the square of the linear 
measurements. Area measurements give a guide as to how much of a 
protein, or muscle is present, but this is not the same as the mass (intuitively 
the mass would be ‘the amount present’) of a particular protein. Mass varies 
with the cube of the linear measurement. As such the area measurements are 
a guide to the mass present. Western blot data gives relative information to 
changes of a protein concentration. The limitation of this is that if one were to 
measure for example desmin in this way, if the amount of desmin per 
milligram of muscle were to be constant, then the actual total amount of 
muscle could double, or halve and the desmin concentration as it would be 
constant would not change- and neither would the western blot data. 
Concentration measurements are therefore independent of total mass 
present. In a similar way measuring the total area of for example muscle in 
these sections is a guide to the total mass present, whereas the density 
measurement is not. Density measurements however do have a built in 
advantage. There would be variations in total area due to randomness in the 
selection of fields to be photographed, boxes P,Q,R in the cartoon figure 
8.20B. Multiple fields could be averaged as a way of reducing this error. 
Alternatively the area density could be compared which gives information that 
is area independent, all be it with loss of a measurement that is related to 
absolute quantities. It is area density that is the 2-D equivalent of measuring
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relative changes in protein concentration that is western blot data. Measuring 
a ratio of area densities of 2  different materials e.g. collagen and muscle 
would be a way to arrive at a number that described the total bladder that was 
area independent. Variations in choice of fields examined would cancel out. 
The muscle/collagen ratio was therefore measured in this study for this 
reason, and was similarly measured by Freedman et al (1997), although the 
authors in this study quote collagen/muscle ratios.
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Absolute 'amount' Relative 'amount'
1 dimension Linear
measurement
Ratio lengths
2 dimensions Area
measurement
Area density 
(% surface area)
3 dimensions Volume/mass
measurement
Concentration 
(Western Blot)
Figure 8.20: What has been measured? (A) linear measurements of bladder 
wall thickness. (B) Area measurements -  positioning of region-of-interest will 
affect total area measurement. Area density is not so affected.
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Variation in the intensity of expression in the immunohistochemistry slides 
obviously occurred. However for the purpose of area measurements this 
variation in intensity was lost, simply a measure of presence or absence 
taking place. Area measurements were therefore an approximation to 
expression seen on direct examination of slides.
Absolute numbers were however measured for cell turnover and apoptosis. 
These results were given in terms of number of positive cells as a percentage 
of total cells in each compartment, where 3 fields of each fetal specimen were 
counted. This data was therefore robust.
The most subjective data were the scores for muscle morphology and renal 
dysplasia. Bias in these scores was avoided by having three independent, 
blinded observers. That there were very close correlations between scores by 
each of these observers demonstrates the reproducibility and reliability of 
these scores. What is less certain is how linear the relationship is between an 
increase in muscle morphology score and the disruption in the fetal bladders. 
Because these are relative numbers generated from an ordinal scale, and 
possibly non-linear, the analysis of the correlations of these scores with 
absolute variables has been entirely by non-parametic statistical tests 
(Spearman’s rank correlation).
What does the muscle ‘dysmorphology score’ describe? Similar changes 
documented in human obstructed adult bladders with ‘infiltration’ of smooth 
muscle bundles by connective tissue (Gosling and Dixon 1980). Similar 
findings have been reported in a rat model of partial bladder outflow 
obstruction (Hanai et al 2002) and in a fetal sheep model of bladder outflow
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obstruction (Thiruchelvam et al 2003). In decompensated obstructed bladders 
disruption and loss of smooth muscle have been reported in humans, and 
animal models (Levin et al 2000). This score therefore recapitulates this 
progression. It also correlated well with the severity of renal dysplasia, p<0.05 
Spearman rank correlation.
Is renal dysplasia a marker for severity of bladder outlet obstruction?
That there was a spectrum of mild to severely abnormal renal dysplasia in the 
fetal presumed BOO group is not in question. However there are two possible 
explanations for the dysplasia and muscle dysmorphology; either there is a 
failure of normal development that encapsulates both the bladder and kidney,
i.e. a ‘field change’ -  as has been postulated to occur with severe vesico- 
ureteric reflux and kidney dysplasia (Godley et al 2001); or the bladder is 
obstructed and back pressure on the kidney results in dysplasia. This has 
been demonstrated in animal models (Peters et al 1992a; Nyirady et al 2002), 
but has also been suggested as the pathogenesis in human fetuses (Shimada 
et al 2003).
Study groups: presumed fetal bladder outlet obstruction and normal fetuses
Presumed BOO was defined clinically in this series by the appearance at the 
time of post-mortem, in a similar manner to previous series reported in the 
literature (Workman and Kogan 1990; Kim et al 1991a, b; Freedman et al 
1997). Direct examination of the posterior urethra was limited to describing if
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the posterior urethra is dilated. No attempt to identify an intravesical 
obstruction was routinely carried out as part of the postmortem examination at 
UCH, either by histology, or by radiology. Histology was not done as the yield 
of identifying the obstruction is low because of difficulties with aligning 
sections for cutting. These specimens were identified retrospectively, and as 
the diagnosis therefore was on the appearance of secondary signs of BOO, 
these specimens have at best a presumed diagnosis of bladder outflow 
obstruction.
Presumed congenital BOO fetuses which had evidence of prune belly 
syndrome were excluded, as were isolated urethral atresias. The remaining 
group therefore most probably represented posterior urethral valves, and was 
a much more homogenous study group than in other series. In previously 
studied series PUV, urethral atresia and PBS were variously included. In 
comparison to the previously published series my pathologically obstructed 
group was on average much younger (Workman and Kogan 1990; Kim et al 
1991a, b; Freedman et al 1997).
Similarly the ‘normal’ group were all morphologically normal fetuses, as 
opposed to simply those which had normal genitourinary tracts as described 
in the published series (Workman and Kogan 1990; Kim et al 1991a, b; 
Freedman et al 1997). However normal fetuses do not die in utero or 
spontaneously abort. The control group in our series overlapped well with 
those in other series. An alternative would have been to use fetuses aborted 
for other congenital abnormalities.
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The combination of a more normal study group and a more homogenous 
obstructed group has made comparison easier between the two groups, with 
reduced variation within the groups, than in previously published series.
Implications
The obstructed bladders in this group were not just from earlier gestational 
ages but also appeared to be much more abnormal than the bladders in 
previous human series, where thick-walled bladders, due to increased 
detrusor thickness, predominated. In this series there was a spectrum of 
thicker muscle to attenuated muscle, but the ‘decompensated’ appearance as 
described by Levin et al predominated (Levin et al 2000). The appearance in 
extreme cases being similar to that described in the fetal ovine obstruction 
model, after 30 days of obstruction (Thiruchelvam et al 2003). A shorter 
duration of obstruction (9 days) appears to produce a thick-walled, 
hypertrophic bladder (Farrugia et al 2006a, b). The muscle/collagen ratio in 
the obstructed bladders straddled the normals, a similar result to that 
described by (Freedman et al 1997).
In adult rabbit bladders exposed to partial bladder outflow obstruction, an 
initial hypertrophic phase has been described, followed by a period of 
compensated function, followed by decompensation (Buttyan et al 1997). 
Similar changes appear to happen in adult men with BOO (Levin et al 2000).
It could be speculated that the bladders with presumed BOO represented a 
spectrum from compensated to decompensated bladders with loss of
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fibronectin, increased muscle dysmorphology and worsening renal dysplasia.
It is however also possible that these bladders actually were a human 
analogue of the two forms of decompensation described in the rabbit model 
by Levin et al (2000): myogenic failure with a large, compliant flaccid thin- 
walled bladder; or, myogenic failure with a thick-walled, non-compliant, small 
volume bladder. Other immunohistochemical markers for decompensation 
that might be instructive in this situation would be acetyl cholinesterase, or 
another neuronal marker such as PGP 9.5, or S100: this has been shown to 
be significantly downregulated in decompensated human bladders (Buttyan et 
al 1997), with a reduction in expression of neuronal markers also seen in the 
fetal ovine bladder outflow obstruction model described by (Nyirady et al 
2002). This could help resolve the question as whether all of these bladders 
were in fact decompensated or whether some were still compensated.
In normal human bladders the detrusor smooth muscle was closely 
associated with fibronectin. That there was reduced fibronectin in the 
presumed obstructed group was explained by this group having relative 
disruption and loss of muscle also. It can be further speculated that fetal 
DSMC and fibronectin are interdependent.
Fibronectin immunostaining was not increased in the lamina propria in 
presumed obstruction. This may be indirect evidence that activation of 
myofibroblasts as has been described in cutaneous wound healing (Serini and 
Gabbiani 1999) -  with their dependence on fibronectin -  was not taking place 
in these bladders. Or, it could be that fibrosis was taking place due to a 
different mechanism than other forms of fibrosis (Gabbiani 2003).
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In the obstructed bladders in this series the apparent lamina propria was 
thickened. There are two possible mechanisms that could explain this: either, 
obstruction inhibits myogenesis in the detrusor layer, but stimulates the 
growth of the lamina propria instead; or, the thickened lamina propria seen in 
the presumed BOO group may represent in part degenerated DSM, which has 
lost cells with the typical smooth muscle markers looked for in this study i.e. it 
is only apparent lamina propria. Thickening of the lamina propria has not 
previously been described and may become a clinically useful marker for 
severely affected obstructed bladders in the future as higher resolution 
ultrasound and MRI become available.
Hypothetical models of response of human fetal bladders to obstruction
1) Compensation/decompensation
It is possible that the pattern of compensation, followed at a variable time later 
by decompensation is a good model for the changes in the human bladder. In 
this model the initially relatively normal bladder (with a normal 
muscle/collagen ratio) compensates by hypertrophy and hyperplasia of the 
detrusor smooth muscle cells -  with increased expression of fibronectin. The 
muscle collagen ratio rises and then at a variable time later the bladder 
decompensates in one of 2 ways -  thin walled, or thick walled (figure 8.21 A).
2) Progressive bladder dysplasia -  Prune belly type
The bladders may never start as normal having always been partially 
obstructed. Some become progressively thick walled and decompensate 
(muscle/collagen ratio rises to above normal). Other bladders never undergo
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normal smooth muscle myogenesis and become progressively more fibrotic, 
with poorly developed detrusor layer (figure 8.21 B).
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Figure 8 .2 1 : Hypothetical models of bladder dysgenesis resulting from fetal 
bladder outlet obstruction : (A) Levin compensation-decompensation. (B) 
Woolf Prune belly-type dysplasia. Normal = normal muscle/collagen ratio, high 
= excess muscle vs. collagen; low = reduced muscle vs. collagen.
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The data we have simply represent snap-shots. No inference about what has 
gone before can be made, but would be a pointer towards future work.
Conclusion
With regards the hypotheses tested by this comparison of normal and fetally 
obstructed human bladders, the following conclusions can be drawn:
1) During normal human bladder development detrusor thickens and 
fibronectin is expressed proportionally to the increase in muscle tissue. 
However, the proliferative synergy between fibronectin substrate and fetal calf 
serum, seen in the mouse bladder cell suspension experiments described in 
Chapter 6 , did not appear to happen. Increasing fibronectin instead being 
associated with increased maturation, and decreased proliferation.
2) In human fetal bladders with presumed BOO, there is a spectrum of 
phenotypes: at one extreme, some of these bladders had fibronectin 
expression, muscle morphology and renal histology which resembled 
normal controls. At the other extreme, reduced detrusor fibronectin was 
associated with disrupted muscle morphology and with increased renal 
abnormalities.
3) In severely affected fetal bladder outlet obstruction, the lamina propria was 
apparently thickened.
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Chapter 9. Final discussion and future work
A hypothetical cell biology model for bladder development
The studies presented here provide further descriptive, and hence 
circumstantial, evidence that ECM/integrin interactions are important in normal 
bladder development; however, further studies are warranted to resolve the 
apparently conflicting organ and cell culture data to unravel possible 
functional roles for fibronectin and its receptors. The studies also provide the 
first evidence that fibronectin expression is abnormal in human congenital 
bladder anomalies.
First, the descriptive work on normal murine bladder development is 
consistent with the contention that integrin a5pi could mediate instructive 
signals from a fibronectin-rich matrix. Second, upregulation of integrin a7p1 
harmonised with the upregulation of laminin and DSMC maturation, 
suggesting that these molecules could modulate a muscle differentiation 
signal.
Second, the cell adhesion experiments showed that fibronectin allowed 
adherence and spreading of DSMC in the developing bladder. These fetal 
DSMC predominantly expressed integrin a5, pi and desmin. Blocking integrin 
receptors using RGD oligopeptides not only decreased desmin positive cell 
adhesion, but also reduced cell spreading. Fibronectin and serum had a 
synergistic effect on proliferation of bladder cells. Thus, integrin a5pi could
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mediate adhesion of fetal DSMC to fibronectin, and could potentially mediate 
a proliferative signal from fibronectin to these cells.
Based on the descriptive work presented in this thesis, and the results of 
previous studies (Baskin et al 1993a, b and c; Schuger et al 1997; Relan et al 
1999; Yang et al 1999; Smeulders et al 2002 and 2003), a scheme has been 
generated to explain DSMC differentiation (McCarthy et al 2003). The smooth 
muscle differentiation occurs at the periphery first. Two possible hypotheses 
can explain the pattern of DSM maturation:
1) Centripetal hypothesis This requires an initial signalling event between the 
urothelium and primitive mesenchyme, which causes the mesenchyme to 
start differentiating at the periphery of the bladder. Baskin et al (1996b) 
propose a role for the serosa, sensitising the peripheral cells to subsequent 
epithelial signals. These smooth muscle pre-cursor cells then differentiate and 
acquire the markers of the smooth muscle phenotype: (aSMA, desmin, 
myosin, vimentin) Baskin et al (1996c). These cells proliferate, the zone of 
differentiation spreading ‘centripetally’ towards the centre of the bladder. The 
bladder of figure 1 would appear with differentiated smooth muscle cells 
extending from the periphery towards the lamina propria.
2) Centrifugal hypothesis Mesenchymal/epithelial interaction induces laminin- 
1 expression in the basement membrane. This causes spreading and 
proliferation of mesenchymal cells in a similar way to myogenesis in the lung- 
bud (Schuger et al 1997). These mesenchymal ‘stem cells’ would proliferate 
producing a ‘transit amplifying’ population of smooth muscle precursor cells. 
These would be pushed ‘centrifugally’, outwards, by continued production of
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more smooth muscle precursor cells by the mesenchymal ‘stem cells’ 
underneath them. Mesenchymal-epithelial interaction therefore has acted 
locally to induce mesenchymal proliferation; cells proliferate causing 
centrifugal/outwards movement of the most mature of these, which then 
differentiate at the periphery of the bladder. It is at the periphery that smooth 
muscle markers first become detectable. These ultimately will mature into 
adult smooth muscle cells, from the periphery inwards. This fits with the 
progressive thinning of the lamina propria layer we see as maturation 
progresses. It can be speculated that the transit amplifying cells in the lamina 
propria are not exposed to the same differentiation signals as those in the 
detrusor layer and so differentiate into fibroblasts. Similarly those cells in the 
interfascicular regions, between the muscle bundles of the detrusor may 
experience different cues and become fibroblasts.
Role of Fibronectin
Whether these cells arrived by a centrifugal or centripetal pattern of growth, it 
can be hypothesized that the fetal smooth muscle cell phenotype is 
dependent on fibronectin expression. These cells are capable of further 
proliferation, particularly in response to stretch, and synthesis of more basal 
lamina components. As they mature the DSM cells change from the fetal to 
the adult phenotype with a loss of synthetic capability, become non­
proliferative, and increasingly contractile. Associated with this is a 
replacement of the basal lamina fibronectin by laminin reinforcing this
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phenotype switch to a fully differentiated form. Integrins mediate this ECM 
ligand signal to the muscle cells.
This hypothetical model for the role of extracellular matrix in bladder 
development might also shed light on the pathological changes in congenital 
bladder outflow obstruction.
In congenital bladder outflow obstruction, the bladder wall is ‘over-stretched’ 
and damaged. It can be speculated that fibronectin is deposited at the site of 
tissue damage. From the cell culture experiments described in the 
introduction this would encourage the fetal smooth muscle cells to maintain 
this phenotype: that is a synthetic, proliferative phenotype that continues to 
produce ECM components and more smooth muscle cells. The result could 
be the thick walled, fibrotic, poorly compliant, dysfunctional valve bladder that 
is commonly seen in posterior urethral valves.
This could led on to a further questions:
Is fibronectin expression increased in bladder outflow obstruction?
In the human fetal bladder outflow obstruction fetuses examined, loss of 
smooth muscle cells in the most severely abnormal bladders was associated 
with loss of the basal lamina fibronectin. It was not possible to comment on 
whether detrusor hyperplasia and hypertrophy might be associated with 
increased fibronectin expression in the basal lamina, in an initial response to 
BOO.
Are the adult smooth muscle cells capable of proliferation?
334
This could be tested by generating primary cultures of adult mouse bladders 
and characterising the phenotypes of the cells that become proliferative, when 
these cells are grown on an appropriate substrate (e.g. fibronectin) in an 
appropriate growth medium.
Normal and pathological human fetal bladder development
During normal human bladder development DSMC proliferate and 
hypertrophy in close association with fibronectin. However the proliferative 
synergy between fibronectin substrate and FCS does not appear to happen, 
the increasing fibronectin instead being associated with increased maturation.
In human fetal bladder outlet obstruction, there is a spectrum of bladder 
responses: at one extreme, increased detrusor fibronectin was associated 
with more normal muscle morphology, and the most normal kidneys. Reduced 
detrusor fibronectin was associated with disrupted muscle morphology and 
with increased renal abnormalities. In could be speculated that this spectrum 
of abnormalities may represent a progression from compensation to 
decompensation.
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Future work
The role of fibronectin in maintenance of fetal smooth muscle cell phenotype 
needs elucidating. Using the explant model of fetal bladder maturation might 
allow this to be determined using other strategies such as the use of RGD / 
RAD oligopeptides to block fibronectin receptors, and the use of RNA 
interference techniques to ‘turn off fibronectin expression -  as described by 
Sakai et al (2003), or downregulate integrin a5, or indeed a7 expression.
What happens on maturation of the detrusor post-natally? How does the 
change from a fibronectin rich basal lamina to a laminin rich milieu occur, and 
does this influence DSM maturation?
What is the biochemical pathway that leads to bladder decompensation? Is 
this a result of increasing ischaemia in the bladder wall? Perhaps the ex-vivo 
fetal bladder explants could elucidate the mechanism. Work subsequently has 
shown that vascular endothelial growth factor (upregulated in ischaemia), 
increases the smooth muscle mass of fetal murine bladders by a combination 
of increasing proliferation and inhibiting apoptosis (Burgu et al 2006).
Is the pattern of fetal bladder growth in response to presumed BOO 
compensation / decompensation or is it a progressive dysplasia? A dynamic 
fetal animal model, demonstrating if compensation followed by 
decompensation does occur in the fetal bladder, would be necessary (Nyirady 
et al 2002; Thiruchelvam et al 2003; Farrugia et al 2006b, a). This model may 
allow an evaluation of the effect of timing of a fetal intervention such as
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vesico-amniotic shunt placement -  on renal preservation and recovery, or 
otherwise of fetal bladder function
Prospective studies to identify failing bladders, is lamina propria thickness a 
marker? Use of high resolution cross-sectional imaging may in the future be 
able to use the increase in thickness of the lamina propria as a marker for 
worsening bladder state.
Conclusion
The extracellular matrix has a hierarchical structure: structural collagens link 
to the basal lamina, which in turn connects to the cell surface via integrins. 
Components of the basal lamina such as laminin and fibronectin have not just 
a supportive function but are also have an instructive role in determining 
smooth muscle differentiation in the bladder. This signal is mediated by 
integrins. ECM, growth factors and integrins are an essential part of the story, 
and epithelial mesenchymal interactions, irrespective of how they are 
mediated, are crucial to this process. In human fetal bladder outlet 
obstruction, there is a spectrum of bladder responses: at one extreme, 
increased detrusor fibronectin was associated with more normal muscle 
morphology, and the most normal kidneys. Reduced detrusor fibronectin was 
associated with disrupted muscle morphology, loss of muscle and increased 
fibrosis, and with increased renal abnormalities.
Specifically the following have been shown:
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1) Fibronectin and the candidate integrin receptor (a5p1) used in this 
study change in a coordinated manner during mouse bladder 
maturation, allowing for a possible instructive role in development.
2) Laminins, specifically laminin-1 and laminin-2/4, are upregulated in 
very similar pattern to integrin a7- subunit, the candidate muscle 
laminin receptor, during mouse bladder development.
3) Fetal mouse DSMC expressed integrin a5, pi and desmin. Blocking 
integrin receptors using RGD oligopeptides not only decreased desmin 
positive cell adhesion, but also reduced cell spreading. Fibronectin and 
serum had a synergistic effect on proliferation of bladder cells. Thus, 
integrin a5p1 could mediate adhesion of fetal DSMC to fibronectin, and 
could potentially mediate a proliferative signal from fibronectin to these 
cells.
4) Established serum free, antibiotic free defined culture conditions for ex- 
vivo fetal bladder explant differentiation.
5) During normal human bladder development DSMC are in close 
association with fibronectin.
6 ) In human fetal presumed bladder outlet obstruction, there is a 
spectrum of bladder phenotypes: at one extreme, more detrusor 
fibronectin was associated with more normal muscle morphology and 
the most normal kidneys. Less detrusor fibronectin was associated with 
disrupted muscle morphology, loss of muscle and increased fibrosis, 
and with increased renal abnormalities.
7) In fetal presumed BOO, the lamina propria is apparently 
disproportionately thickened.
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Appendix 1
Integrin a5 positive control
Positive staining of fetal skin (from mouse paw) is seen on this slide. Human 
keratinocytes have previously been shown to express integrin a5 (Adams and 
Watt 1991).
B’.‘I
%  *- <
Appendix 1: Figure 1.1 Positive control for integrin a5. (A) integrin a5  
immunostaining of positive control tissue -  skin of E18 mouse paw. (B) 
Same section of mouse paw with isotype control rabbit IgG substituted for 
integrin a 5  antibody. Scale bar 5(tym
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Appendix 1: figure 1.2 : Integrin p i positive control. (A) Skin of mouse paw- 
irrmnostainedfor irrtegin p i. (B) Pre-inrmre rabbit lg3 isotype control. Scale 
bar 50 pm
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Data from fibronectin, integrin a5 and /31 Western Blots
Appendix 1: Table 1.1: Fibronectin WB data
Time-point
E14 E16 E18 D1 6 wks
1.15 1 .0 0 0.62 1.93 0 .2 0
Fibronectin 0 .8 8 1.77 0.78 2.31 0.44
Densitometry 1.93 1.58 1.21 2.26 0.46
relative to 1.81 2.14 1.05 2.43 1.08
p-actin 1.73 1.89 1 .0 2 2.54 0.48
1.52 1.60 2 .0 2 0.44
In order to allow comparison between relative trends during development, the data 
was converted into a relative percentage of the maximum mean data point, as 
described by (Smeulders et al 2002, 2003).
Appendix 1: Table 1.2: Integrin a5 WB data
Time-point
E14 E16 E18 D1 6 wks
Integrin cx5 36.6 60.2 79.8 103.3 109.9
Densitometry 43.0 55.8 55.5 112 .1 110.9
relative to 23.2 58.8 91.4 116.9 140.7
p-actin, 39.8 63.2 60.6 127.5 73.8
expressed 63.4 60.2 53.3 76.6
as a % of 
maximum 
(6 wk mean) 73.3 70.1 6 8 .2 8 8 .2
Appendix 1: Table 1.3: Integrin pi WB data
Time-point
E14 E16 E18 D1 6wks
0 . 0 7 0 . 3 5 1 . 0 5 1 . 7 4 1 . 0 0
Integrin p i 0 . 4 8 1 . 1 5 0 . 8 9 0 . 9 7 0 . 7 2
Densitometry 0 . 6 4 1 . 1 4 1 . 0 9 0 . 9 9 0 . 8 7
relative to 0 . 5 8 1 . 2 0 1 . 8 2 1 . 7 8
p-actin 0 . 7 5 1 . 1 9 1 . 9 6 1 . 7 8
• . 1 . 8 5 2 . 0 5 1 . 8 4
Appendix 1: Table 1.4: p-actin expression was unchanged throughout murine 
bladder development
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Time-point
E14 E16 E18 D1 6wks
6242 6590 9486 5124 7816
5443 9006 9443 11879 7217
5709 6654 5932 7736 6792
6484 6754 7748 6329 6373
8766 7301 9274 6031 6012
7655 7506 5409 5814 5120
9150 9971 8809 9226 12112
16064 8406 5818 8814 14251
p-actin 11265 8630 4131 10686 15377
densitometry 10950 13464 14680 13432 17852
7565 15528 14776 12156 22082
15594 11169 18287 19299
10621 12519 7421 5830
11500 12074 8931 6643
11368 10303 6719 6854
8522 8108 7373 6747
9813 7633 7033 7628
9085 7024 6136 7544
There was no change in p-actin densitometry (measured in arbitrary units -  AU) 
during murine bladder development, so this was useful as a loading control for WB 
data interpretation.
b-actin  densitom etry during m urine bladder 
developm ent (Mean + / -  SD)
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Appendix 1: figure 1.3: Laminin a1 (laminin-1) positive control
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Appendix 1: figure 1.3 : Laminin-1 (laminin a1) positive control. (A) Skin of D1 
mouse paw - immunostained for laminin a l  (B) Isotype control. Scale bar 50 pm
Integrin a6 subunit immunohistochemistry
Integrin a 6  expression was present in the urothelium, but also in the basal 
lamina of blood vessels in the lamina propria and detrusor. It was not 
expressed by fetal or adult smooth muscle cells (Appendix 1: figure 1.5).
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Appendix 1: figure 1.4 : Integrin a6 positive control skin of E18 fetal mouse 
paw. (A) Skin of paw immunostained for integrin a6. (B) Isotype control
Appendix 1: Figure 1.5: Integrin a6 immunostaining. (A,B) E14; (C,D) E18, 
(E,F) Day1; (G,H) 6 wks. Scale bars (A,C,E,G) 400pm, (B,D,F,H) 50pm.
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Integrin a7  subunit immunohistochemistry
Integrin a7 immunostaining required optimisation of fixation technique by the 
use of acetone at -20oC, instead of 4% paraformaldehyde) (Appendix 1: figure 
1.6). Once fixation had been optimised then optimisation of the DAKO ARK kit 
was performed. Appendix 1: figure 1.7 shows the positive control for this 
antibody -  myoblasts in the developing mouse paw.
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c
r -
- 4 *
•»
Acetone, Integrin Alpha 7 Ab (3C12), 0.1% BSA
d  . *?
*  #  .  .
u ' W ,
*  >»a
v ‘
Paraformaldehyde (4%), Control IgG, 0.1% BSA Paraformaldehyde, Integrin Alpha7(3C12), 0.1% BSA
Appendix 1: figure 1.6: Optimisation of integrin a7 immunohistochemistry -  fixation 
technique. (A) and (C) isotype control mouse IgG substituted for primary antibody.
(B) and (D) Integrin a7 antibody (3C12) detected using Dako ARK. (A) and (B) are 
sections where acetone (-20’C) was used, compared to 4% paraformaldehyde in
(C) and (D). Acetone fixation was associated with a much greater availability of the 
antigen (B) than the use of paraformaldehyde (D). Scale bars 50 pm.
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Appendix 1: Figure 1.7: Integrin a7 positive control - skeletal muscle from D1 
neonatal mouse paw. (A) and (C) isotype mouse IgG. (B) and (D) integrin a7 
immunostaining using Dako ARK technique, with AB blocking kit. Scale bars (A 
and B) 400|xm, (C and D) 50(Lim.
394
Integrin a 7  subunit FACS analysis
The anti-integrin a7 antibody (3C12) was used for FACS analysis, using 
protocol as described on the data sheet. A positive control of smooth muscle 
(from the genito-urinary tract) was used as suggested by the data sheet (data 
not shown).
For each time-point, 3 parallel cell suspensions were created. Each had flow 
cytometry performed using anti-integrin a7 antibody and a control isotype IgG. 
The positive cell percentage was obtained by subtracting the isotype control 
percentage from the anti-integrin percentage.
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Appendix 1: figure 1.8 : flow cytometry dot-plots for integrin a l  in whole 
bladder suspensions from E14 (A,B); E18(C,D); D1(E,F); 6 wks (G,H). 
(A,C,E,G) are control runs using isotype control pre-immune IgG. 
(B,D,F,H) are runs using integrin a l  antibody (3C1 2).
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Appendix table 1.6: Integrin a l  FACS results
E14 E18 D1 6wks
A7 Isotype Subtracted A7 Isotype Subtracted A7 Isotype Subtracted A7 Isotype Subtracted
% Cells 0.29 0.27 0.02 5.37 0.2 5.17 9.12 3.39 5.73 12.22 1.65 10.57
detected 0.1 0.34 -0.24 6.93 1.38 5.55 9.52 3.92 5.6 10.78 1.54 9.24
by FACS 0.1 0.23 -0.13 4.31 1.38 2.93 8.18 3.38 4.8 14.36 2.03 12.33
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Appendix 2: Data for Cell adhesion experiments
Background data for cell adhesion experiments
1) Fibronectin plating concentration.
Each suspension was created from 1 litter, using approximately 10 fetal E18 
bladders. Three parallel cell suspensions were created, to produce n=3 fro 
this preliminary experiment.
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Appendix 2: Table 2.1: Initial phase contrast adhesion experiment.
Suspension
Fibronectin
cone Morphology Countl Count2 Count3 Count4 Average
1 0 R 23 16 20 8 16.75
2 0 R 22 3 12 11 12
3 0 R 17 4 22 48 22.75
1 10 R 15 13 34 24 21.5
2 10 R 20 19 15 25 19.75
3 10 R 12 13 11 11 11.75
1 20 R 21 26 17 28 23
2 20 R 27 25 29 16 24.25
3 20 R 10 13 9 9 10.25
1 40 R 33 20 20 33 26.5
2 40 R 14 25 16 22 19.25
3 40 R 20 11 8 13 13
1 0 S 18 21 7 7 13.25
2 0 S 5 14 1 0 5
3 0 S 12 0 8 13 8.25
1 10 S 35 29 52 35 37.75
2 10 S 103 122 36 79 85
3 10 S 64 66 33 32 48.75
1 20 S 61 46 32 58 49.25
2 20 S 65 81 95 100 85.25
3 20 S 47 71 47 48 53.25
1 40 S 58 58 53 70 59.75
2 40 S 70 63 63 76 68
3 40 S 63 86 39 29 54.25
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This data shows an increase in adhesion of cells (increase is in cells with a 
spread morphology), up to 10  mcg/ml of plating concentration of fibronectin. 
There was no significant increase in adhesion after this (ANOVA p<0.05, with 
Bonferroni post-hoc significance of p<0.05 for comparisons between 0 and 
20ng/ml and 0 and 40^ig/ml).
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Appendix 2: Figure 2.1: Preliminary fibronectin adhesion experiment, 
using 3 different E18 cell suspensions. Adhesion was allowed to 
proceed for 1 hour, and after rinsing, adherent cells were visualized by 
phase contrast microscopy.
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2) Immunocytochemistry 
CD31
CD31, platelet endothelial cell adhesion marker was used as a marker of 
endothelial cells. It is expressed in the developing murine bladder (Appendix 
2: figure 2.3).
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BAppendix 2: figure 2.2 : CD31 positive control E14 umbilical artery. (A) 
Umbilical artery - immunostained for CD31 (B) Isotype control
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Appendix 2: figure 2.3: Blood vessel development during bladder development. (A-D) IHC from 
E14 to 6wks showing immunostaining for CD31, Platelet endothelial cell adhesion molecule 
(PECAM), as a marker of endothelium. Dissection microscope photographs of bladders at 
E14-day1. The pattern of blood vessels is very similar in both. Scale bars 400|nm.
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Appendix 2: figure 2.4: Immunocytochemistry of CD31 cells. (A) 
CD31, positively staining cell shown in close-up. (B) Isotype control 
IgG instead of CD31 antibody, no staining seen.
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Cytokeratin 18
Cytokeratin 18 is expressed in developing murine urothelium (Baskin et al 
1996c). Appendix 2: figure 2.5 demonstrates its expression in mouse bladders 
during development.
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Appendix 2: figure 2.5: Cytokeratin-18 immunostaining throughout bladder 
development, only present in urothelium. (A,B) E14; (C,D) E16; (E.F) E18; (G,H) D1; 
(I,J) 6 wks. (A,C,E,G,I) Scale bars 400 (nm. (B,D,F,H,J) Scale bars 50|nm.
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Appendix 2: figure 2.6: Cytokeratin 18 immunocytochemistry. (A) E18 
bladder cell suspension immunostained cytokeratin 18, arrow pointing 
to positively immunostained cell. (B) Isotype control IgG used in place 
of cytokeratin antibody.
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aSMA
aSMA is a marker of smooth muscle cell differentiation, and has been used to 
demonstrate maturation of DSMC in murine bladders (Smeulders et al 2002). 
Appendix figure 2.7 demonstrates aSMA immunostaining during mouse 
bladder development E14 to 6  wks. Figure 2.8 shows aSMA  
immunocytochemistry.
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Appendix 2 : figure 2.7: aSMA immunostaining throughout bladder development. 
(A,B) E14; (C,D) E16; (E,F) E18; (G,H) D1 ; (l,J) 6 wks. (A.C.E.G.I) Scale bars 400 ^ 
m. (B.D.F.H.J) Scale bars 50nm.
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Appendix 2: figure 2.8: aSMA immunocytocemistry. (A) E18 bladder 
cell suspension immunostained aSMA, arrows highlighting positive 
cells. (B) Isotype control IgG used in place of cytokeratin antibody.
3) Fibronectin proliferation experiment
Appendix 2: Table 2.2: Fibronectin adhesion proliferation data
Time Fn
FCS
added
Sus­
pension BrdU+1 Total 1 BrdU+2 Total2 BrdU+3 Total3 BrdU+4 Total4 AvBrdU+ AvTotal %8 rdU+
1 1 0 1 0 1 0 1 2 0 13 0 26 0 13 0 16 0 %
1 1 0 1 0 2 0 70 0 61 0 62 0 83 0 69 0 %
1 1 0 1 0 3 0 45 0 34 0 18 0 28 0 31 25 0 %
1 1 0 1 0 4 0 13 0 1 0 0 17 0 8 0 1 2 0 %
1 1 0 1 0 5 0 33 0 1 0 0 29 0 19 0 22.75 0 %
1 1 0 1 0 6 1 49 0 38 0 45 0 25 0.25 39.25 1 %
1 1 0 0 1 0 37 1 26 0 23 0 33 0.25 29.75 1 %
1 1 0 0 2 0 51 0 49 0 40 0 43 0 45.75 0 %
1 1 0 0 3 0 40 2 51 0 58 0 26 0 5 43 75 1 %
1 1 0 0 4 0 18 0 16 0 13 0 8 0 13.75 0 %
1 1 0 0 5 0 24 0 29 0 31 0 33 0 2925 0 %
1 1 0 0 6 0 39 0 28 0 41 0 29 0 34 25 0 %
1 0 1 0 1 0 4 0 3 0 4 0 3 0 3.5 0 %
1 0 1 0 2 0 2 0 0 3 0 15 0 5 0 10.75 0 %
1 0 1 0 3 0 2 0 3 0 3 0 2 0 25 0 %
1 0 1 0 4 0 3 0 4 0 2 0 1 0 2.5 0 %
1 0 1 0 5 0 1 0 0 5 0 5 0 2 0 5.5 0 %
1 0 1 0 6 0 5 0 4 0 1 0 2 0 3 0 %
1 0 0 1 0 3 0 1 0 0 9 0 8 0 7.5 0 %
1 0 0 2 0 13 0 9 0 1 0 0 19 0 12.75 0 %
1 0 0 3 0 23 0 31 0 1 0 0 24 0 2 2 0 %
1 0 0 4 1 8 0 1 2 0 7 0 14 0.25 10.25 2 %
1 0 0 5 0 28 0 18 0 1 0 0 18 0 18.5 0 %
1 0 0 6 0 32 0 32 0 38 0 19 0 30.25 0 %
1 2 1 0 1 0 1 3 25 5 63 1 54 6 43 3.75 46 25 8 %
1 2 1 0 1 0 2 6 42 3 61 11 64 9 75 725 60.5 1 2 %
1 2 1 0 1 0 3 5 50 3 36 4 46 1 61 325 48.25 7%
1 2 1 0 1 0 4 1 25 2 36 1 17 3 39 1.75 29.25 6 %
1 2 1 0 1 0 5 6 8 6 3 60 5 31 5 25 4.75 50.5 9%
1 2 1 0 1 0 6 6 50 5 34 4 28 1 33 4 36.25 1 1 %
1 2 1 0 0 1 0 36 1 24 0 39 0 48 0.25 36.75 1 %
1 2 1 0 0 2 0 34 0 41 0 27 0 40 0 355 0 %
1 2 1 0 0 3 0 41 0 45 1 2 1 0 19 025 31 5 1 %
1 2 1 0 0 4 0 28 0 14 0 24 0 23 0 22.25 0 %
1 2 1 0 0 5 4 76 3 45 4 25 2 60 3 25 51.5 6 %
1 2 1 0 0 6 1 48 2 34 0 41 2 8 6 1 25 5225 2 %
1 2 0 1 0 1 0 1 2 0 19 0 2 0 0 2 2 0 1825 0 %
1 2 0 1 0 2 0 54 0 52 2 50 0 59 0.5 5375 1 %
1 2 0 1 0 3 0 51 0 64 2 46 0 76 0.5 59 25 1 %
1 2 0 1 0 4 0 15 0 4 0 14 0 5 0 9.5 0 %
1 2 0 1 0 5 0 26 0 37 0 2 0 2 64 0.5 3675 1 %
1 2 0 1 0 6 0 16 0 25 0 23 0 15 0 19.75 0 %
1 2 0 0 1 0 5 0 5 0 5 0 1 0 0 625 0 %
1 2 0 0 2 0 16 0 1 2 0 1 2 0 17 0 14.25 0 %
1 2 0 0 3 0 15 0 7 0 16 0 16 0 13.5 0 %
1 2 0 0 4 0 11 0 1 0 0 1 2 0 3 0 9 0 %
1 2 0 0 5 0 9 0 17 0 1 0 0 7 0 10.75 0 %
1 2 0 0 6 0 19 0 13 0 8 0 16 0 14 0 %
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4) RGD oligopeptides concentration
Appendix 2: Table 2.3: Preliminary RGD/RAD oligopeptides concentrations vs 
Fibronectin concentration. Percentage blockade is calculated from total cell 
numbers adherent for a cell suspension in presence of RAD (control peptide) 
minus total cell numbers adherent in presence of RGD (active blocking 
peptide), divided by RAD total and expressed as a percentage.
Suspension
Blocker
conc.
Fibronectin
conc. % Blockade
1 10 0 -11.0
2 10 0 -12.5
3 10 0 13.3
1 10 5 30.6
2 10 5 29.5
3 10 5 26.4
1 10 10 22.5
2 10 10 26.6
3 10 10 -22.1
1 10 20 -6.8
2 10 20 -6.7
3 10 20 -20.5
1 20 0 -24.4
2 20 0 16.0
3 20 0 -3.1
1 20 5 46.6
2 20 5 25.0
3 20 5 -15.6
1 20 10 20.1
2 20 10 7.1
3 20 10 23.4
1 20 20 36.0
2 20 20 18.3
3 20 20 23.8
1 40 0 37.0
2 40 0 -2.2
3 40 0 -17.3
1 40 5 -5.1
2 40 5 12.0
3 40 5 20.1
1 40 10 29.1
2 40 10 30.0
3 40 10 20.2
1 40 20 15.2
2 40 20 58.7
3 40 20 -11.5
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From appendix 2: figure 2.9 it can be seen that with low concentration of 
oligopeptide blockers, the blockade of adhesion to the fibronectin substrate is 
reduced as the fibronectin coating concentration increases. With 20 mcg/ml of 
oligopeptides, the blockade increases with increasing fibronectin coating 
concentration. With 40 ^g/ml of oligopeptide, the blockade is not as marked 
as it is with 2 0  p,g/ml of oligopeptide, raising the possibility of increasing non­
specific effects. In comparing the percentage blockade of oligopeptides at 20 
ng/ml vs 10 ng/ml on 40 i^g/ml of fibronectin, there was a significant increased 
blockade (-11% vs 26%) (students t-test p<0.05), whereas there was a 
reduced effect for 40 ng/ml oligopeptide, and no significant difference. The 
oligopeptide concentration chosen for subsequent blocking experiments was 
therefore 2 0  jag/ml.
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Appendix 2: figure 2.9: Blockade E18 cell adhesion (%) versus, 
fibronectin (coating concentration (pg/ml)) versus. RGD/RAD 
oligopeptide concentration (ng/ml). Percentage blockade calculated 
by subtracting cell counts with RGD from cell counts in presence 
RAD (control), divided by RAD cell count.
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IAppendix 2: figure 2.10: TUNEL test control. Negative control rTdT not added
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Appendix 3
Generating fetal mouse bladder explant model
Preliminary experiments were performed to optimise the growth conditions: 
the first comparison was between antibiotics and FCS, vs. FCS, vs. ITS. The 
protein estimations from bladders harvested after 3 days of explant culture are 
listed below.
Appendix 3: Table 3.1: Comparison media additives and explant growth after 
three days
Medium Protein
Abx+FCS 0.075510204
Abx+FCS 0.025820763
Abx+FCS 0.052144336
Abx+FCS 0.04208814
FCS 0.067957802
FCS 0.061029759
FCS 0.075515667
FCS 0.058510471
FCS 0.047488584
FCS 0.062289403
ITS 0.052842072
ITS 0.172823177
ITS 0.140387341
ITS 0.063234136
ITS 0.105117304
ITS 0.073941112
Anova (p<0.05), for growth medium comparing ITS to FCS, to Antibiotics and FCS.
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Appendix 3: Figure 3.1: Initial growth of E14 explant bladders in 3 
different media: 1) Antibiotics and FCS, 2) FCS, 3) ITS. Data plotted 
as mean±SEM.
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Appendix 3: figure 3.2 : PCNA positive control. - skin from paw of Dl mouse 
(A) skin from paw - immunostained for PCNA (B) Isotype control
Appendix 4
Positive controls for anti-human Fibronectin antibody and anti-human Desmin 
antibody.
420
°Appendix 4: figure 4.1: Positive control anti-human fibronectin. (A) Fibronectin 
immunostaining of stroma and undifferentiated mesoderm in human fetal 
kidney. (B) Rabbit isotype IgG control showing minimal non-specific staining 
of human fetal bladder. (C) Serial section of same human fetal bladder 
immunostained with anti-human fibronectin antibody (A0245, D AKO ).
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Appendix 4: figure 4.2: Positive control anti-human desmin. Desmin 
immunostaining of smooth muscle in human fetal GIT
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Appendix 4: Table 4.1: Tabulated results for human bladders
Fetus
Bladder
outflow
obstruction?
Gestational
age
(weeks)
Sex
Total
wall
thickness
(mm)
Thickness
lamina
propria
(mm)
Detrusor
thickness
(mm)
Muscle
area
ratio
(%)
Collagen 
area 
ratio (%)
Muscle/collagen 
ratio (%)
Fibronectin 
area (%) - 
Detrusor
Fibronectin 
area (%) - 
Lamina 
Propria
Muscle 
Dysmorphology 
score (0-6)
Renal 
dysplasia 
score (0- 
15)
Pumonary 
hypoplasia 
(Lung/total 
body wt)
Oligohydramnios
1 n 16 F 0.5 0.16 0.34 30.8% 40.0% 76.9% 8.5% 3.6% 2 4 4.1% No
2 n 16 M 0.67 0.21 0.47 18.9% 25.6% 73.7% 21.1% 3.0% 1 4 3.8% No
3 n 18 M 0.78 0.29 0.5 9.3% 35.6% 26.1% 11.8% 3.8% 2 1 3.3% No
4 n 20 F 1 0.29 0.71 15.7% 36.0% 43.6% 14.5% 2.4% 1 0 3.1% No
5 n 20 M 1.15 0.46 0.69 10.7% 25.6% 41.6% 14.2% 1.0% 2 1 3.1% No
6 n 21 M 1.1 0.25 0.85 21.7% 32.2% 67.4% 24.6% 20.1% 0 1 1.6% No
7 n 24 M 1.42 0.25 1.17 18.3% 26.9% 67.8% 14.0% 8.5% 0 0 1.8% No
8 n 26 M 1.09 0.25 0.84 18.2% 31.2% 58.4% 13.3% 4.3% 0 0 4.2% No
9 n 27 F 1.25 0.11 1.14 23.3% 27.9% 83.4% 23.2% 17.5% 0 0 2.4% No
10 n 28 F 1.08 0.31 0.77 21.9% 26.3% 83.4% 20.6% 3.9% 1 2.2% No
11 n 30 M 1.23 0.46 0.77 20.1% 23.3% 86.3% 32.3% 5.6% 2 0 1.8% No
12 n 31 F 1.63 0.53 1.09 29.0% 26.0% 111.8% 24.1% 8.5% 0 1 0.0% No
13 y 18 M 1.26 0.68 0.58 15.6% 56.7% 27.6% 1.4% 1.5% 5 15 2.4% Yes
14 y 18 M 2.22 0.21 2.01 19.5% 25.3% 77.3% 2.3% 7.1% 5 10 0.9% Yes
15 y 18 M 1.4 0.44 0.97 18.8% 41.8% 45.0% 15.5% 5.0% 2 7 2.7% No
16 y 19 M 2.05 0.41 1 65 20.5% 24.4% 84.1% 14.1% 4.3% 2 7 1.5% No
17 y 20 M 1.98 0.95 1.03 11.4% 47.8% 23.8% 1.6% 2.2% 6 11 3.3% Yes
18 y 21 M 1.22 0.69 0.53 12.3% 42.2% 29.0% 4.4% 17.7% 6 13 1.4% Yes
19 y 22 M 1.86 0.79 1.07 19.4% 38.2% 50.8% 2 1.0% Yes
20 y 24 M 0.78 11.4% 23.5% 48.4% 19.5% 5.7% 5 8 2.2% No
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Appendix 4: Table 4.2: Tabulated results for human bladders -  cell turnover
Fetus
Bladder
outflow
obstruction?
Gestational age 
(weeks) Sex
Ki67 (%) in 
urothelium
Ki67 (%) in 
lamina propria
Ki67 (%) in 
detrusor
Apoptosis 
(%) in 
urothelium
Apoptosis 
(%) in lamina 
propria
Apoptosis 
(%) in 
detrusor
1 n 16 F 5.59% 6.73% 3.89% 0.14% 0.14% 0.03%
2 n 16 M 5.17% 2.08% 0.28% 0.00% 2.57% 0.17%
3 n 18 M 3.59% 12.26% 3.25% 0.00% 0.30% 0.04%
4 n 20 F 4.09% 7.30% 1.83% 0.14% 1.50% 0.41%
5 n 20 M 0.71% 0.39% 0.52% 0.40% 0.40% 0.48%
6 n 21 M 0.09% 0.00% 0.00% 0.00% 0.46% 0.02%
7 n 24 M 0.94% 1.66% 0.53% 0.00% 0.25% 0.13%
8 n 26 M 3.52% 2.71% 0.60% 0.00% 0.07% 0.02%
9 n 27 F 0.00% 0.48% 0.06% 0.00% 0.08% 0.01%
10 n 28 F 0.00% 0.00% 0.14% 0.14% 0.02%
11 n 30 M 0.78% 0.12% 2.14% 0.42% 0.00%
12 n 31 F 1.36% 1.18% 0.86% 1.05% 0.21% 0.34%
13 y 18 M 4.05% 5.50% 4.43% 0.00% 0.05% 0.04%
14 y 18 M 2.20% 1.73% 0.00% 0.09%
15 y 18 M 3.22% 7.72% 3.03% 16.84% 0.09% 0.09%
16 y 19 M 7.38% 9.43% 1.36% 0.00% 0.08% 0.04%
17 y 20 M 2 . 2 0 % 1.59% 0.81% 0.10% 0.12% 0.17%
18 y 21 M 0.40% 2.42% 0.08% 6.87% 0.07% 0.01%
19 y 22 M 0.00% 0.01% 0.20%
20 y 24 M 0.00% 0.96%
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Appendix 4: Table 4.3: Area of fibronectin immunostaining vs. area of detrusor muscle
Fetus
Bladder outflow 
obstruction?
Gestational age 
(weeks) Sex Muscle area (AU)
Fibronectin area - 
Detrusor (A U)
1 n 16 F 0.54 0.09
2 n 16 M 0.42 0.21
3 n 18 M 0.29 0.22
4 n 20 F 0.48 0.26
5 n 20 M 0.38 0.33
6 n 21 M 0.82 0.68
7 n 24 M 0.72 0.32
8 n 26 M 0.58 0.41
9 n 27 F 0.96 0.89
10 n 28 F 0.88 0.56
11 n 30 M 0.63 0.82
12 n 31 F 1.29 0.80
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Assessment of cell tum-over In human fetal bladders 
Ki67
Ki67 immunostaining was used as the marker of proliferation in the human 
fetal bladders.
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Appendix 4: figure 4.3: Ki67 immunostaining. (A) Human tonsil positive 
control. (B) Ki67 positive cells in urothelium and lamina propria of 
human fetal bladder. Scale bars (A) 400 \im, (B) 50 ^im.
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Appendix 4: Figure 4.4: (A) Urothelium and lamina propria from human bladder 
immunostained with Ki67, counter-stained haematoxylin, (B) Lamina propria area 
measured, Ki67 positive nuclei counted, to derive Ki67 cells / area, (this was 
repeated on 3 separate photomicrographs for each specimen. Cell density was 
calculated by measuring cell density in 4 typical sections of the lamina propria from 
each slide (Black boxes). Ki67 (%) could thus be derived. (C) Ki67 positive cells 
were counted, and area measured in a similar way for the urothelium. U, urothelium; 
LP, lamina propria
428
Apoptosis
Apoptosis was assessed by the TUNEL test and counter-staining with 
propidium iodide. FITC was tagged to the ends of the cut DNA (green colour). 
Red blood cells can autofluoresce at the similar wavelengths to FITC. A 
positively apoptotic cell was therefore taken to be one in which the TUNEL 
FITC signal and propidium iodide colocalized.
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Appendix 4: Figure 4.5: Human bladder urothelium TUNEL test 
counterstained with propidium iodide. (A) TUNEL test showing apoptotic 
nucleus (hollow arrow), and autofluorescent RBCs (filled arrow), (B) PI 
staining of nuclei (closed arrow) apoptotic nucleus. (C) composite overlay of 
PI and TUNEL, apoptotic nucleus (hollow arrow), and autofluorescent RBCs 
(filled arrow).
Appendix 4: Figure 4.6: Human bladder lamina propria TUNEL test 
counterstained with propidium iodide. (A) TUNEL test showing apoptotic 
nucleus (hollow arrow), and autofluorescent RBCs (filled arrow), (B) PI 
staining of nuclei (closed arrow) apoptotic nucleus. (C) composite overlay of 
PI and TUNEL, apoptotic nucleus (hollow arrow), and autofluorescent RBCs 
(filled arrow).
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Appendix 4: Figure 4.7: Human bladder detrusor TUNEL test counterstained 
with propidium iodide (A) TUNEL test showing apoptotic nucleus (hollow 
arrow), and autofluorescent RBCs (filled arrow), (B) PI staining of nuclei 
(closed arrow) apoptotic nucleus. (C) composite overlay of PI and TUNEL, 
apoptotic nucleus (hollow arrow), and autofluorescent RBCs (filled arrow).
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Appendix 4:Figure: 4.8: Low power views of human bladder, (A) PI counter-staining, (B) 
close-up of (A); (C) TUNEL staining, low power view, (D) close-up of the same region, a, 
apototic nucleus present on both PI and TUNEL images, whereas r, red blood cell, is only 
present on TUNEL image. (E) Rapid flicking between images highlights truly apoptotic 
nuclei, whereas autofluorescence of RBCs does not coincide with a nucleus on PI 
staining.
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Muscle area, muscle percentage of surface area (%), Collagen and collagen 
percentage of surface area (%) and Muscle Collagen ratio
Measurements of muscle area (mm2) for each of the bladder sections showed 
a significant correlation with increasing gestational age, p<0.01, 2-tailed 
Pearson correlation. Muscle percentage of surface area (ie percentage of total 
cross-sectional area of section which is muscle) showed an increasing trend 
over the period samples were available, but this did not reach significance. 
(Muscle increased, but so did the wall thickness -  density remained 
approximately static therefore.)
The area of collagen in normal bladders showed a tendency to increase with 
gestational age, but this correlation was not significant. The proportion of 
collagen in the bladder walls did however show a significant decrease, p<0.05 
2-tailed Pearson correlation. This reflected the distribution of collagens being 
mainly in the lamina propria, which did not significantly increase in width 
during the period studied. Dividing percentage muscle area by percentage 
collagen area allowed a muscle collagen ratio to be derived for each bladder. 
This showed a significant increase with increasing gestational age (p<0.05 
Pearson 2-tailed test).
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